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SUMMARY
The measurement of glycated proteins, in particular, glycated 
albumin using specific antibodies offers the much-needed possibility of a
(semi) automated method fo r the diagnosis and monitoring of diabetic control.
*
Glycated proteins would appear to be poor immunogens as is evident by the 
lack o f antibodies successfully raised against them when compared against the 
number of antibodies recognising reduced-glycated proteins. This study has 
successfully overcome this problem by synthesing several d iffe rent glycated 
compounds as haptens and then using them in conjunction w ith a carrier 
protein to raise antisera in sheep. The binding of one of these antisera, w ith  a 
titre  1:100000 showed considerable displacement when incubated with diabetic 
plasma at various dilutions. Western blot analysis on human plasma confirmed 
that the antiserum specifically recognised a continuous epitope on glycated 
human serum albumin. A ff in ity  purified antibodies were used to develop both 
an indirect competitive ELISA and later a direct non-competitive ELISA for 
glycated serum albumin which does not require prior reduction of the glycated 
protein to the glucitol form . These assays have a dynamic range at 0 to 100 
pg/m l and 0 to  50yg/ml of glycated human serum albumin respectively. The 
competitive ELISA exhibited <0.15% cross reac tiv ity  w ith both sodium 
borohydride and sodium periodate treated human serum albumin. Further work 
was needed to be undertaken to develop a rugged ELISA that could 
discrim inate between diabetics and normals by routinely measuring glycated 
human serum albumin levels.
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CHAPTER!
GENERAL INTRODUCTION
1.1 DIABETES MELLITUS
1.1.1 A Historical Perspective
Diabetes mellitus can be described as a metabolic disorder caused by 
insuffic ient insulin action or available insulin present in vivo. This condition 
manifests itse lf by resulting in increased blood sugar levels, otherwise known 
as hyperglycaemia. If the hyperglycaemic stage is le ft  unchecked and blood 
sugar levels continue to rise further, then glycosuria develops. This is also 
accompanied by polyuria, a characteristic feature of this disease. Indeed, the 
presence of both glycosuria and polyuria w ith its association to diabetes has 
been documented for many years. The earliest known record is in the Papyrus 
Ebers w ritten  around 1500 BC, where prescriptions are mentioned to alleviate 
the symptoms of polyuria. Aretaeus of Cappadocia in the Second Century AD 
described this disease as 'a melting down of flesh and limbs into urine ... the 
flow  of water is incessant ...'. Aretaeus was also the firs t to use the term 
'diabetes' to describe this disease. Around this time the Chinese observed that 
'the urine tasted so sweet as to a ttrac t dogs', this was of course re ferring to 
the condition of glycosuria.
In 1674 Thomas Willis put forward the idea that the glucose firs t 
appeared in the blood before passing into the urine. Slightly la ter in 1682, 
Brunner surgically removed the pancreas to produce extreme th irs t and 
polyuria. However, i t  was not until 1788 when Thomas Cawley observed that 
glycosuria might be related to pancreatic calculi and atrophy.
During the Eighteenth and Nineteenth Centuries, various other 
c lin ica l symptoms of diabetes were documented, such as ketoacidosis (acidotic 
breathing) and cataracts. In 1889, Minkowski and Mering clearly illustra ted 
the acute onset of diabetes a fte r pancreatectomy in dogs. Slightly la ter, Opie
in the USA and Ssobolev in Petrograd found pathological changes in the 
pancreatic islets firs t discovered by Paul Langerhans in 1869 during autopsies 
on human diabetics. These pancreatic islets were la te r named the 'islets of 
Langerhans1 a fte r the ir discoverer.
By the end of the nineteenth century the concept of hormones and 
endocrine secretions was well established. It was therefore thought that the 
pancreas, or more specifically, the islets o f Langerhans, secreted a hormone 
into the blood which lowered blood glucose levels. In 1909, Jean de Mayer 
named this endocrine secretion ’insuline’. Various researchers tried  to extract 
the active hormone from healthy pancreases,but this was not successful. It 
was not until 1921 when Banting and Best successfully isolated the active 
constituent and used their extract on a pancreatectomised dog to bring it  out 
o f a diabetic coma. This in itia l extract was a crude preparation of insulin, but 
since then insulin has been purified w ith  both greater yield and purity. 
Another major advance took place at Cambridge where Fredrick Sanger in 
1953 determined the amino acid sequence of insulin and also demonstrated the 
nature of the species differences.
Although the discovery of insulin has proved of immense benefit to 
diabetics by prolonging their survival, this has allowed the development o f 
other clin ical complications. Therefore the use of insulin to trea t diabetes can 
not be regarded as a to ta l cure.
1.1.2 Classification and Aetiology
The World Health Organisation (WHO/, 1985) has recommended that 
diabetes mellitus should be defined into two major classes: clin ica l and 
sta tis tica l risk. The la tte r category refers to subjects who have apparently
normal glucose tolerance, but substantially increased risk of developing 
diabetes. The clin ica l classes can be sub-divided into four fu rther categories:
(i) Insulin-dependent diabetes mellitus (IDDM)
(ii) Non-insulin dependent diabetes mellitus (NIDDM)
(iii) M alnutrition-re lated diabetes mellitus (MRDM)
(iv) Gestational diabetes mellitus (GDM)
Of these four sub-classes, the two major forms of diabetes are IDDM 
(Type 1) and NIDDM (Type 2). The major differerences between these two 
categories of diabetes can be summarised in Table 1.1.
It can be seen from Table 1.1 that there is a strong immunological 
association w ith  Type 1 diabetes. On chromosome 6 in man; there exists a 
region called the major h istocom patib ility complex (MHC) which is involved in 
the control of the immune response. Several loci are present here, referred to 
as A, B, C and D. Pyke (1979) discovered that there was a genetic 
predisposition to the development o f Type 1 diabetes. He found that nearly a ll 
Type 1 diabetics expressed a particular HLA antigen from the D locus, e ither 
HLA-DR3 or HLA-DR4. The expression of either or both these HLA antigens 
did not indicate the development of Type 1 diabetes, but only an increased risk 
factor.
Other risk factors may also be involved in the pathogenesis of Type 1 
' ■ r 
diabetes. Yoon et al., (1979) observed that there was dramatic B-cell damage
afte r v ira l infection w ith Coxsackie B4 virus in a 10 year old boy. It has also
been noted that there is a seasonal variation in the incidence of Type 1
diabetes, being slightly higher in the autumn and w inter months. This
variation is very sim ilar to the pattern of childhood illness.
Table 1.1
A comparison of Type 1 and Type 2 diabetes
Feature
Family H istory 
of Diabetics
Age of onset
Appearance of 
symptoms
Obesity
Ketoacidosis
C irculating insulin 
levels
Islet B-cell number
Inflam m atory cells in 
islets
Antibodies to islet 
cells
HLA association
Need fo r exogenous 
insulin
Type 1 (IDDM) 
Uncommon
Juvenile
Rapid
Rare
Frequent
Low
Decreased
Present
Yes
Yes
Yes
Type 2 (NIDDM) 
Common
Mature
Slow
Common
Rare
Vary
Near Normal 
Absent
No
No
No
This table has been adapted from Montague (1983).
Whatever the pre-disposition for the development of Type 1 diabetes 
i t  has been known for many years that an ti-is le t cell antibodies are present in 
newly diagnosed Type 1 diabetics (Lefebure, 1986) and that this antibody t itre  
decreases as the disease develops. Lymphocytes from these diabetics also 
demonstrate significant cy to tox ic ity  towards islet B-cells resulting in
decreased islet B-cell number. This suggests that cell-mediated autoimmunity 
is an important component in the development of Type 1 diabetes.
Although considerable progress has been made towards an
understanding of the aetiology and pathogenesis of Type 1 diabetes, this is not 
so for the case of Type 2. Unlike Type 1 diabetes^there is no HLA association, 
v ira l involvement or autoimmune reaction present. In the m ajority o f Type 2 
diabetics, the occurrence of obesity is re la tive ly high, due to an excess calorie 
intake. This is also associated w ith near normal circulating insulin levels 
(Drury, 1979). However, there is an impairment in the in itia l release of insulin 
a fte r a pronounced and acute hyperglycaemic episode, but not so fo r the 
second and more prolonged release of insulin during the secretory response. 
Insulin resistance also appears to be prevalent in the liver as well as other 
tissues, predominantly the muscle. The molecular basis of this insulin 
resistance could be a down regulation of cell surface insulin receptors due to 
high basal insulin levels (Drury, 1979). However, this does not discount the
fact that insulin resistance may be an in tracellu lar post-receptor event.
The dysfunction in insulin secretion from the B-cell appears to be 
related to the glucose receptor, which again may be down-regulated in number 
due to the persistently high blood glucose levels. Moreover, this adaptive 
change may result in permanent damage to the secretory mechanism. 
C yclic-AM P plays a crucial role in this mechanism as a second messenger in 
the control o f insulin secretion. Therefore, a defect in the cyclic-AM P system
of the B-cell may be responsible, as became evident by the action of 
sulphonylureas. Sulphonylureas, used to treat Type 2 diabetes, are known to 
increase cyclic-AM P levels and this in turn is able to. increase insulin 
secretion. It is possible therefore that Type 2 diabetes is due to a defect in 
adenylate cyclase ac tiv ity , responsible for cyclic AMP production (Montague,
1983). This does not discount, however, the possible role of insulin resistance 
at the target tissue in Type 2 diabetes.
1.1.3 Diagnosis and Control
Classically, diabetes mellitus has presented itse lf to the clin ician in 
its severe form w ith several clin ica l manifestations. These symptoms are 
polyuria, polydipsia and weight loss, as well as ketoacidosis. However, in the 
case of Type 2 diabetes, the symptoms are less severe and in some cases may 
prove d iff ic u lt to diagnose conclusively w ithout certain biochemical tests 
being undertaken. Urinary glucose determinations may also prove misleading 
in the diagnosis, as mild cases o f diabetes may not show glycosuria i f  the blood 
glucose levels are not in excess at lOmM. There is therefore a necessity to 
perform routine blood glucose analyses, i f  only to confirm  a c lin ic ian ’s in itia l 
finding.
Random blood glucose levels can be categorised into three d istinct 
groups as put forward by the WHO, 1983. These are as follows for venous 
whole blood:
(i) < 4.4mM Normal
(ii) 4.4-10mM Diabetes (uncertain)
(iii) > lOmM Diabetes present
In Group (ii) a patient is s till diagnosed as uncertain w ith respect to 
diabetes and it  is therefore necessary to perform an oral glucose tolerance 
test (OGTT). This involves the consumption of a 75g glucose load a fte r 
overnight fasting and the subsequent measurement of blood glucose over a 2 
hour period. The presence of diabetes mellitus would be diagnosed i f  a blood 
glucose level in excess of lOmM were present a fte r the 2 hour period (Keen, 
1986). I f  blood glucose were between 7-10mM, impaired glucose tolerance 
would be assigned; less than 7mM indicating a normal glucose tolerance.
Unfortunately, however, the OGTT although a very precise test for 
diabetes at present, is costly in terms of manpower per patient as well as 
being inconvenient to the patient. In addition, day-to-day variation in 
individuals along w ith age, drugs and disease can a ffec t the test (Hall et al.,
1984). Recently, the clinician has considered the measurement of non- 
enzymatically glycosylated proteins (also known as glycated proteins) as a 
possible index for both the diagnosis and control of the diabetic state. The use 
of glycated proteins in the diagnosis of diabetes are for confirm ation of the 
clinician's in itia l finding or where the OGTT in some patients gives paradoxical 
results. This would be particularly relevant in patients suffering myocardial 
in farction or other stress-related illness, where hyperglycaemia is present 
(Gokhroo et al., 1983; Monai e t al., 1986).
However, the main application of glycated protein measurements at 
present is in the control of diabetes. Most proteins are glycated to some 
extent (Trueb, 1980; Candiano et al., 1985), depending on the ir ha lf-lives and 
the level of endogenous blood glucose. The presence of hyperglycaemia 
promoting increased glycation of these proteins. Two proteins in particu lar, 
glycated haemoglobin and glycated serum albumin, are of c lin ica l usefulness 
(Koenig e t al., 1976 and Caines et al., 1986). The measurement of glycated
serum albumin gives an insight into the glycaemic status of a diabetic over the 
previous 2-3 weeks (Kennedy et al., 1981). Therefore, the short-term  
assessment of a particular therapy/regimen can be evaluated and modified i f  
necessary. The measurement of glycated haemoglobin levels on the other 
hand, gives an indication of long-term glycaemic control over the past 6-8 
weeks due to the longer ha lf- life  o f the protein (Bunn et al., 1978).
1.2 GLYCATION
1.2.1 The Chemistry of Glycation
Glycation, or non-enzymatic glycosylation of proteins, occurs as the 
result o f a reaction between reducing sugars and available primary amino 
groups on the protein w ithout the use of enzymes (Roth, 1983). It is d istinct 
from glycosylation, which involves the use of enzymes for the transfer o f an 
oligosaccharide from doiichol phosphate to the protein w ithin the lumen of the 
rough endoplasmic reticulum . The point of attachment for the oligosaccharide 
is mainly via an N-acetylglucosamine residue onto either the nitrogen atom of 
asparagine (N-glycosylation) or the hydroxyl group of a serine or threonine 
residue (O-glycosylation). Glycation, on the other hand, can be either an 
in tra - or in tercellu lar event.
Glycation has long been known to food chemists as the in itia l stage of 
the 'browning' or Maillard reaction that occurs in foodstuffs, but recently i t  
has been shown to be of increasing importance in the fie ld of medicine, 
particularly in diabetes. It was a French chemist, Maillard in 1912, who firs t 
demonstrated that the reaction of a sugar w ith a primary amine gave rise to 
brown fluorescent pigments. In 1925, Amadori found that the same reaction 
gave rise to two d istinct compounds which he termed the labile and non-labile 
isomers, the lab ility  being determined by the change of optical ro tation in acid 
solution. Kuhn and Weygrand (1937) proposed the labile compound was a Schiff
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Figure 1.1. The glycation of an amine. Based on the work of Kuhn and 
Weygrand (1937).
base, the glucosylamine, whereas the non-labile compound was a 1 -am ino-l- 
deoxy-D-fructosamine. These workers showed that the la tte r compound was 
formed by a molecular rearrangement of the glucosylamine, which they named 
the 'Amadori Rearrangement' (Figure 1.1). The reaction sequence illustrated 
in Figure 1.1 fo r the in itia l steps of glycation was by no means complete as 
was shown by Isbell (1943), who proposed a mechanism for the Amadori 
rearrangement. This mechanism for the formation of the 1-am ino-l-deoxy-D- 
fructose-amine (fructosamine) is shown in Figure 1.2. S tric tly  speaking, this 
mechanism, if  i t  is indeed correct, cannot be referred to as a rearrangement 
as i t  does not involve the m igration of a chemical group to an electron 
deficient atom w ith in the same molecule.
The reaction mechanism shown in Figure 1.2 can essentially be sp lit 
into four d iffe rent stages as discussed by Hodge (1955). The firs t stage 
involves the form ation of the aldimine (III) via two transient intermediates (I) 
and (II) and is basically a condensation reaction involving the loss of water. 
The second stage results in the formation of an enol (IV) from  the aldimine 
(III). This reaction occurs because of a flow  of electrons towards the 
positively charged nitrogen atom, which makes carbon-1 transiently positive. 
This allows a flow  of electrons between carbon-2 to carbon-1, weakening the 
C-H bond on carbon 2, resulting in the loss of a hydrogen atom from carbon-2 
to give the enol (IV). Stage three is then a tautomeric sh ift of the enol (IV) to 
the ketoamine (V). However, the stra ight chain form of the ketoamine is 
unstable and w ill cyclise to form either the a - or 3-anomers of the pyranose or 
furanose rings. It is this cyclisation in the fourth stage which is responsible 
for driving the tautomeric sh ift in stage three towards forming the ketoamine 
(V). Neglia et al., (1985) by using C ^ -N M R  spectroscopy were able to show 
that the major anomeric form of the fructosamine was the 8-pyranose ring.
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Figure 1.2 The mechanism of formation of 1-am ino-l-deoxy-D-fructose- 
amines. Based on Isbell (1943) and Neglia et al. (1983).
Kuhn and Weygrand (1937) and then Hodge (1933) presumed that the
Amadori rearrangement was irreversible. This was particularly apparent when
the mechanism proposed by Isbell (1943) showed that the conversion of the
aldimine (III) to the enol (IV) was irreversible. Many other workers also
assumed that the Amadori rearrangement was irreversible. However,
Mortenson and Ghristoferson (1983) were able to demonstrate that the
14Amadori rearrangement was, in fact, reversible by the use o f C -tracer 
14studies. By using C -labelled glucose they glycated haemoglobin and isolated
the fructosamine product. A fte r dialysis of the glycated haemoglobin, they
14were then able to detect C -glucose in the dialysate indicating the 
revers ib ility  of the Amadori rearrangement. Acharya and Sussman (1984) were 
also able to demonstrate this revers ib ility  of the Amadori rearrangement, 
validating the earlier findings of Mortenson and Christoferson.
A ll the early work on glycation involved the use of alkyl or aryl 
amines and amino acids (Gottschalk, 1952; Abrams et al., 1955; Lowy and 
Borsook, 1956). The possibility that proteins could be glycated in vivo and in 
v itro  was firs t recognised by Dixon ? 1972. He was able to show that peptides 
could be glycated by glucose in v itro  and postulated that this should also occur
ti
in proteins. I t  was Fluckiger and W interhalter (1976) who firs t conclusively 
observed the glycation of a protein, more precisely, haemoglobin. They 
reacted ,D -(2-^H) -glucose w ith haemoglobin and were able to observe tha t 
the Amadori rearrangement took place w ith  proteins, which was evident by the 
loss of the tr itiu m  atom from the 2-carbon atom in the D-glueose molecule. 
Since 1976_,various workers have shown that many other proteins are glycated 
in vivo (Harding, 1985) and the change in the ir physiological and chemical 
properties has also been investigated (see table 1.2).
The reaction of glucose w ith a primary amine in glycation does not 
term inate w ith the form ation of fructosamine. Although the amine group 
w ithin the fructosamine is now a secondary amine, it  can s till react w ith a 
second glucose molecule by the same mechanism described previously to form  
a di-fructosamine. Anet (1959) was able to purify the di-fructosamine of 
glycine which was found to be thermolabile and decomposed back to the mono- 
fructosamine and a reactive six carbon carbonyl compound. This carbonyl 
compound was found to be a 3-deoxyosone a fte r further characterisation 
(Anet, 1960a). Anet (1960b) also proposed a possible mechanism for the 
form ation of the 3-deoxyosone involving the loss of a hydroxyl ion from the 1,2 
enolic form of the difructosamine. Around the same time, Kato (1960) 
suggested that the 3-deoxyosones could also be formed from the 
monofructosamine via the same mechanism put forward by Anet. Both 
workers suggested that the reaction between the more reactive 3-deoxyosone 
and an amine was the main cause of the browning reactions as reviewed la ter 
by Reynolds (1963 and 1965). Harding and Beswick (1988), however,
commented that 3-deoxyosones, in particular 3-deoxyglucosone, would react 
preferentia lly w ith arginine rather than lysine as was evident by the work of 
Yankeelov (1972) and Kato e t.a l. (1987). Whereas, McLaughlin et al. (1980) 
showed that both lysine and arginine reacted equally w ith  3-deoxyosones. It is 
therefore possible that the formation of 3-deoxyosones is the in itia l stage in 
the formaton of advanced glycation end products (AGE), which are believed to 
play an important role in the pathophysiological complications associated w ith  
diabetes (Brownlee, 1988). The mechanism for the formation of the 3- 
deoxyosone is summarised in Figure 1.3.
The Maillard reactions had previously been studied by Hodge (1953) 
who suggested that a series of dehydration, fission reactions and sfrekker 
degradations could lead to the formation of AGE. Finot (1982) summarised the
I \
rjiH 
CH2
I L 
0 = 0
CHOH
fructosamine
I
CH2 
1 z
c = o
CHOH
CH2
i 1
c=o
CHOH2  1 i ,w '  < 1 / 3
CH2OH CH2OH
di-fructosamine
R
©,
A mfructose L H
-deoxyglucosone
+
Amind"
N /  \
fructose QH
-m-  C—OH 
CHOH
CH,0H
0
©
R
- A
fructose
II
®CH
Advanced Glycosylation 
Endproducts
Figure 1.3 A mechanism for the production of 3-deoxyosones via the 
form ation of di-fructosamines. Based on Anet (1960a).
Fructosamine
(1,2 enolisation) (2,3 enolisation)
3 - Dehydration and 
Fission Products
Amines
MELANOIDINS
(AGE)
Figure 1.4 Possible alternative pathways fo r the form ation of AGE from 
fructosamines. Adapted from Finot (1982).
Maillard reaction by demonstrating that the fructosamine could undergo either
1,2 or 2,3 enolisation resulting in two d iffe ren t Maillard pathways, both 
pathways leading to the eventual formation of brown fluorescent compounds 
termed melanoidins, also known as AGE. Figure 1.4 illustrates the reaction 
sequences proposed by Finot (1982)^ but also incorporates the earlier work of 
Anet (1960b) who demonstrated that 1,2 enolisation of fructosamines gave rise 
to 3-deoxyosones.
The firs t AGE to be identified was found to be a fluorescent 
chromophore derived from the glycation of polypeptides w ith glucose in v itro  
(Pongor et al., 1984). By using NMR, mass spectroscopy and chemical 
derivatisation studies, the compound was assigned the structure 2-(2-furoyl)- 
4(5)-(2-furanyl)-lH -im idazole, abbreviated to FFI. Four other AGE have also 
been reported. Njoroge et al., (1987a and 1987b) isolated two pyranole-based 
molecules which they postulated were derived from 3-deoxyglucosone and 
could also lead to protein cross-linking. Using neopentylamine as a model 
amine fo r glycation, they found two major fluorescent compounds called 3-(D- 
erythro-trihydroxypropyl)-l-neopentylpyrrole-2-carboxaldehyde and 5- 
hydroXymethyl-l-neopei\b',ylpyrole-2-carbaldehyde, abbreviated to 3-ETP-NPC 
and 5-HM-NPC respectively. The remaining two AGE were isolated from  
sulphite inhibited Maillard reactions in v itro  by Farmer at al., (1988). Both 
these compounds were found to be l-a lkyl-2-form yl-3,4-d ig lycosylpyro les 
(AFGP) by using ^C -N M R  spectroscopy. The potential of these compounds to 
cross-link proteins In  vivo was postulated by all three research groups, thereby 
affecting protein structure and function along w ith their probable role in the 
pathophysiological complications of diabetes and ageing. Figure 1.5 illustra tes 
the AGE in the ir potential role as protein cross-linking agents.
Figure 1.5 Isolated AGE and their possible role as protein crosslinking 
agents: (a) 3-(D-erythro-trihydroxypropyl)-l-neopentyl pyrole-2-
carboxaldehyde; (b) and (d) l-a lkyl-2-form yl-3 ,4-d ig lycosylpyro les; (c) 5- 
hydroxymethyl-I-neopentylpyrole-2-carboxaldehyde; (e) 2-(2-furoyl)-4(5)-(2- 
fu ranyl)-lH -im idazo le.
Recently, questions have been raised as to the va lid ity of FFI as a 
genuine AGE (Njoroge et al., 1988). These authors suggested that FFI was in 
fact an a rte fact of the method employed by Pongor et al., (1984) to isolate 
this compound. Njoroge et al., (1988) were able to show that boiling 
fructosamine in 6M hydrochloric acid for 24 hours, the conditions used by 
Pongor et al. to hydrolyse the ir protein samples and thereby extract the FFI, 
would themselves result in the formation of FFI. However, Chang et al., 
(1983) had raised an antiserum against FFI which was specific and
showed that they could detect FFI-bound to in vivo and in v itro  glycated 
proteins. In this study the protein samples had been treated by either acid 
hydrolysis or enzymic digestion, the levels of FFI were noticeably higher in the 
acid hydrolysis-treated samples. Additional evidence must therefore be sought 
to discount FFI as a possible AGE.
1.2.2 Factors Affecting Glycation of Proteins
Glycation of amines in v itro  has been shown to be affected by a 
variety of factors, namely temperature, pH, glucose concentration, amine 
concentration, incubation time and the presence of certain catalysts (Hodge, 
1955). These catalysts could be either acidic, usually organic acids such as 
acetic acid, or compounds containing an active methylene group (Hodge and 
Rist, 1952). However, when considering the glycation of proteins in v ivo , two 
factors become particu larly apparent namely, glucose concentration and 
protein h a lf-life  (sim ilar to incubation tim e in v itro ). However, other 
parameters do have a role to play in a ffecting the in itia l stages of glycation 
fo r the form ation of fructosamine groups on the protein.
The mechanism fo r the in itia l stages of glycation, as shown in Figure
1.2 may be simplified to a two stage process, the re la tive ly rapid Schiff base 
formation of the aldmine from the amine groups on the protein and glucose,
followed by the slower formation of the fructosamine group via the Amadori 
rearrangement (Higgins and Bunn, 1981). By the Law of Mass Action, 
increased glucose concentration w ill result in increased aldimine formation, 
which in turn w ill help to drive the reaction towards the production of 
fructosamine. Therefore, i t  can be seen that the presence of hyperglycaemia 
in vivo w ill help 'drive1 the glycation reaction towards the form ation of the 
fructosamine (Agarwal, 1985).
Two other factors are known to a ffec t Schiff base formation, these 
are the pKa o f the protein's amino groups and the presence of phosphate. For 
Schiff base form ation to occur, the glucose molecule must be present in its 
straight chain form to allow the aldehyde to react w ith the amine which must 
be in its uncharged;dissociated state. Low pKa values have been shown to aid 
glycation as this allows the amino groups to be more, e ffective  nucleophiles at
it
physiological pH for attacking the aldehyde group in glucose (Fluckiger and 
W interhalter, 1976; Bunn et al., 1979; Watkins et al., 1985). The second 
factor, phosphate, causes the glucose to exist in its straight chain form  
thereby allowing it  to be more reactive to attack by nucleophilic amino 
groups. The factors affecting aldimine synthesis are on a macro- 
environmental scale in that they a ffec t a ll parts of the protein equally, 
whereas the factors affecting fructosamine production from the in itia l 
aldimine are on a micro-environmental scale. These micro-environmental 
factors occur w ith in the v ic in ity  of the site of glycation. Shapiro et al., (1980) 
found that there was increased glycation of lysine residues adjacent to acidic 
amino acids in haemoglobin, suggesting that carbonyl groups on either 
aspartate or glutamate residues could serve as intramolecular catalysts fo r the 
Amadori rearrangement. Watkins et al., (1985) reported sim ilar findings when 
studying the glycation of RNAase. The presence of a lysyllysine sequence in 
human serum albumin was shown to be the principle site of glycation in vivo by
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Figure 1.6 A lternative pathways affecting the form ation of AGE.
both Garlick and Mazer (1983) and Iberg and Fluckiger (1986). The presence of 
anions, such as phosphate, bicarbonate or organic phosphate,was also shown to 
have a substantial e ffect on fructosamine formation in RNAase (Watkins et 
al., 1987). They postulated that the anions would bind to nearby basic amino 
acid residues w ith in the protein and then act as an intramolecular catalyst for 
the Amadori rearrangement.
As discussed earlier in Section 1.2.1, the la tte r stages of glycation 
result in the form ation of AGE. Although not much is known about factors 
affecting the form ation of AGE in vivo, i t  is generally understood that AGE 
accumulates on long-lived proteins, that is, proteins which have a long half- 
life  in vivo^such as lens crysta llin  and collagen (Monnier et al., 1984; Pongor et 
al., 1984; Chang et al., 1985). The formation of AGE however, has been shown 
to be lim ited  in vivo by the oxidative degradation of the fructosamine. This, 
therefore, lim its  the amount of fructosamine able to accumulate and result in 
the form ation of AGE. These two oxidative pathways result in the production 
of either an N -6  -carboxymethyllysine derivative (Ahmed et al., 1986) or a 3- 
(N- £ -lys ino)-lactic  acid derivative (Ahmed et al., 1988), the two products 
being unreactive and excreted in the urine. Brownlee et al., (1986) found that 
the addition of aminoguania'ine in v itro  to  a glycated protein was able to 
inh ib it the formation of AGE by irreversibly binding to the fructosamine 
residue making i t  unreactive. These alternative pathways affecting the 
formation of AGE are illustrated in Figure 1.6.
1.2.3 Pathophysiological Complications of Glycation
Glycation of proteins in vivo occurs in all mammals due to the 
endogenous glucose levels present. However, diabetics have been shown to 
have higher levels of glycated proteins in a variety of tissues (Ney, 1985), 
these levels of glycated proteins correlating well w ith the incidence of
Table 1.2
Glycation of protein in vivo and the corresponding 
physiological functions effected
Protein
Haemoglobin
Albumin
Red blood ceil 
membrane proteins
Low density 
lipoprotein (LDL)
Fibrinogen and 
antithrombin III
Tubulin
Lens crystalin
Myelin
Glomerular basement 
membrane proteins
Collagen
Immunoglobulin
Insulin
Physiological function 
Oxygen transport
Osmotic regulation and metabolite transport 
Deform ability of red blood cells
Lipid and cholesterol transport
Plasma viscosity and clot form ation
Axonal transport 
Light transmission 
Nerve impulse conduction 
Renal f iltra tio n
Structural protein
Defense against infection
Regulation of blood glucose levels 
and metabolism.
This table is based on the following papers:
Kaneshige (1987), Karp (1985), Candiano (1985), Dolhofer (1979), Wieland (1983), 
Ney (1985) and Sampletro (1986).
diabetic complications (Vogt et al., 1982; Brownlee et al., 1984b). Table 1.2 
outlines those proteins that have been found to be glycated, alongside the 
physiological role, that js affected, which the protein plays in vivo.
Haemoglobin is probably at present the most extensively studied 
glycated protein as it  was the f irs t to be identified as a protein that could 
undergo glycation in vivo (Koenig, 1977; McDonald, 1978; Higgins, 1981). It 
was shown by D itze l et al., (1974) that glycated haemoglobin in blood taken 
from diabetic children had an increased oxygen a ffin ity . Therefore, one could 
postulate that i f  glycated haemoglobin levels were high enough this might 
impair the supply of oxygen to other tissues. Other red blood cell proteins, 
such as spectrin, are also glycated and this results in a stiffening of the red 
blood cell as spectrin is responsible for its e lastic ity  (McMillen, 1982). 
Glycated albumin was thought only to  be a good index of short-term  glycaemic 
control. However, Shaklai et al., (1984) observed that glycated albumin had 
altered ligand-binding properties and Williams et al., (1981) suggested a role 
fo r glycated albumin in diabetic microangiopathy.
Another serum protein that is glycated is apoprotein B (Schleicher et 
al., 1981) which is responsible fo r the uptake of low density lipoproteins (LDL) 
by endothelial cells expressing a receptor fo r apoprotein B. The glycation of 
this apoprotein impairs its association w ith the high a ffin ity  receptor, leading 
to an increase in plasma LDL levels (Witzum et al., 1982). In addition, Lopes- 
Virella et al., (1988) were able to demonstrate that cholesteryl ester 
synthetase a c tiv ity  in human monocyte-derived macrophages was incresed 
above normal levels in the presence of glycated LDL. Further, Lopez-Virella 
et al., (1988) stated that modified LDL, such as glycated LDL, are taken up by 
monocyte-derived macrophages via a scavenger pathway which, in turn, can 
lead to the formation of foam cells, which have a close association w ith  the
presence of atherosclerotic plaques. Therefore, poor diabetic control may 
lead to high levels of glycated LDL and hence, increased risk of developing 
atherosclerosis.
Brownlee et al., (1988) were able to show that glycation of fib rin  on 
the £-amino groups resulted in a decrease in its degradation by plasmin. The 
decrease in degradation was shown to be dependent on the extent of glycation 
of lysyl residues, as these residues were the sites for plasmin hydrolysis of the 
fib rin . Brownlee et al., (1984a) reported the glycation of another coagulation 
protein, antithrombin III, and its e ffec t in allowing the accumulation of fib rin  
from fibrinogen by not inhibiting the ac tiv ity  of thrombin. Again, this 
impairment in protein function was a result of the glycation of lysyl residues 
via the £ -amino groups, these lysyl residues being important fo r the proper 
functioning of antLthrombin III. These authors therefore postulated (Brownlee 
et al., 1984a) that the build up in glycated fib rin  could be accumulated in 
various tissues, thereby leading to a predisposition of various 
pathophysiological states, such as macrovascular disease, atherogenesis, 
retinopathy and decreased glomerular filtra tio n  rates in the kidney.
So far the protein dysfunctions discussed have been a result of the 
early products of glycation, that is, the fructosamine adduct. However, 
structural proteinsysuch as collagen and lens crystallin,are long lived proteins 
and therefore are prone to the form ation of AGE from protein glycation 
(Garlick et al., 1984). Cerami et al., (1979) proposed that protein glycation 
may have a role in the development of the diabetic cataract a fte r observing 
the development of opalescent lens crysta llin  during glycation in v itro  w ith 
glucose. Monnier and Cerami (1983) la ter showed that this opalescence may 
be due to the presence of covalently cross-linked crysta llin  proteins, the cross- 
linking agents, now known as AGE, exhibiting fluorescent yellow-brown
pigments. In streptozotocin-induced diabetic rats, Perry et al., (1987) 
observed the parallel onset of cataract development and the formation of high 
molecular weight aggregates, as well as increased levels of glycation. On 
further examination, these aggregates were found to be linked either 
covalently or non-covalently to protein disulphide bridges. Although they do 
not iden tify  fu lly  the high molecular weight aggregates, it  is possible to 
propose that they may be a cross-linked crysta llin  protein using an AGE as the 
cross-linking agent. A lternative ly, these high molecular weight aggregates 
may be a glycated crysta llin  protein containing many fructosamine residues 
altering the protein structure and function. Lewis and Harding (1988) found 
that the compound, 5-hydroxy-(l-benzyl- jj-f] indazol-3-yl oxyacetic acid) 
blocked the lysine residues on crysta llin  from glycation and also resulted in a 
delay to cataractogenesis.
Myelin is another long-lived protein and was shown to be extensively 
glycated by Vlassara et al., (1983). I t  was later found that myelin contained 
AGE, due to the long-term effects of glycation (Vlassara et al., 1984). They 
also observed that macrophages expressing specific receptors fo r AGE 
accumulated glycated nerve myelin and that this process is 3.5 times greater 
in diabetics than in normals. This could therefore lead to a progressive 
demyelination of nerve fibres w ith the resultant increase in diabetic 
neuropathy. These receptors fo r AGE are d istinct from those used by 
macrophages in the scavenger pathway fo r LDL uptake discussed earlier 
(Brownlee et al., 1988).
Finally, collagen, an important structura l protein in connective tissue 
as well as in basement membranes, has been extensively studied w ith respect 
to its glycation. As collagen contains an abundance of lysine and 
hydroxylysine residues, it  is not surprising that this long-lived protein is 
glycated. Indeed, Schnieder and Kohn (1981) demonstrated that both diabetes
mellitus and increasing age resulted in a correspondingly significant increase 
in the extent of glycation of collagen. Glycation of the £-amino groups of 
lysine residues could result in less intramolecular cross-linking between 
collagen fibres (Le Pape et al., 1984). This would a ffect the s tab ility  and 
physiochemical properties of connective tissue and extracellu lar matrices (Le 
Pape et .al., 1981), such as leaky blood vessels as seen in diabetic retinopathy. 
However, other reports have shown that glycated collagen has increased 
thermal s tab ility  and decreased susceptibility to degradation by collagenase 
and pepsin (Yue et al., 1983; Kohn et al., 1984). These properties also 
correlated well w ith  the increase in brown fluorescent pigments from  glycated 
collagen (Kohn et al., 1984; Monnier et al., 1984). Cerami et al. (1987) 
provided evidence that these fluorescent pigments were, in fac t, AGE and, in 
turn, were responsible for intramolecular cross-linking between separate 
collagen fibres. A highly significant association between these AGE-related 
cross-links in collagen and diabetic retinopathy, as well as arteria l and jo in t 
s t if f  ness,was reported by Monnier et al. (1986). Such arteria l stiffness due to 
AGE-related collagen cross-linking would account for the increase in systolic 
blood pressure, which itse lf is a known risk-facto r for diabetic retinopathy 
(Monnier et al., 1986).
Brownlee et al. (1988) put forward a possible sequence of events 
resulting in the formation of vascular thrombi (Figure 1.7). They proposed 
that long-term glycation of collagen resulting in the presence of AGE was 
responsible for precipitating the onset of atherosclerosis. These AGE would 
either cross-link w ith  plasma proteins, resulting in platelet aggregation w ith  
the concomitant release of platelet-derived growth factor (PDGF), or 
recognition by macrophages (Vlassara et al., 1988) which express receptors fo r 
the binding of AGE. This would stimulate the macrophages to secrete
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Figure 1.7 A schematic diagram illustra ting  the possible effects of AGE 
crosslinked collagen and other glycated m atrix proteins in atherogenesis. 
Based on Vlassara et al. (1988).
monokines, such as interleukin 1 and tumour necrosis facto r (TNF). This, in 
turn, would result in the pro life ra tion of smooth muscle cells, endothelial cells 
and fibroblasts in the vascular cell wall, TNF causing the endothelial cells to 
pro liferate atypically allowing increased vascular permeability to plasma 
proteins. Additionally, m atrix proteins, such as laminin and fibronectin (Tarsio 
et al., 1985), may also become glycated, preventing proteoglycans to bind to 
these m atrix proteins. This^in turn,results in increased vascular permeability. 
Together, this series of evejnts leads to the form ation of vascular thrombi 
characteristic of atherogenesis.
1.2.4 The Measurement of Glycated Proteins
At present, there are several methods available for the measurement 
of glycated proteins. These involve separation due to charge differences 
between the glycated and unglycated proteins, the specific measurement of 
the attached fructosamine moiety by co lorim etric or fluo rim e tric  analysis and 
recently the measurement by immunoassay. Table 1.3 lists those methods 
presently available fo r the measurement of glycated proteins. Unfortunately, 
however, d iffe rent methods measure d iffe ren t fructosamine moieties w ith in 
the same glycated protein. This is particu larly apparent when measuring 
glycated haemoglobin which is nowadays routinely measured in diabetic clinics 
throughout the world.
. Allen et al., (1958) separated haemoglobin (HbA) into several 
I fractions using cation exchange chromatography which they termed HbAQ, 
HbA^a, H b A ^  and HbA-^. Although Bunn et al., (1978) showed that H bA j^  
contained a fructosamine m o ie ty jit was found not to be elevated in diabetes.
Table 1.3.
Methods for the Measurement of Glycated Proteins
A. Ion-exchange chromatography
B. Electrophoresis
(i) Agar gel
(ii) Iso-electric focussing
C. A ff in ity  Chromatography
(using an m-aminophenylboronate ligand)
D. C olorim etric
(i) Thiobarbituric acid
(ii) Fructosamine test
E. F luorim etric
(i) Periodate assay
(ii) Dansyl-PBA assay
F. HPLC (determination o f furosine).
G. Immunoassay
The major glycated component (approximately 4% in non-diabetics) appeared 
to be HbA^c which contains a fructosamine residue on the a-amino term inal of 
valine in the 0-chain of the haemoglobin molecule (Holmquist and Schroeder, 
1966). Later work by Bunn et al., (1979) indicated that glycated protein was 
also present in the HbAQ fraction  and consisted of fructosamine moieties 
attached to either lysine £-amino groups irv, a> and 0-chains or the a-amino 
group on the valine residue in the a-chain of haemoglobin. When considering 
other glycated proteins,th is structural heterogeneity does not occur to the 
same extent as the fructosamine moieties are mainly attached via £-am ino 
groups of lysine residues.
1.2.4.1 Ion-Exchange Chromatography
Methods relying on the separation of glycated proteins on the basis of 
their charge involve either ion-exchange chromatography or electrophoresis. 
Ion-exchange chromatography of glycated haemoglobin relies on the slight 
difference in charge between HbAQ and HbA^c and therefore only measures 
HbAic  as a representation Qlyca ti ° n w ithin haemoglobin. The advantages 
of this technique are that i t  is cheap, both in terms of resin cost and the need 
not to have expensive additional equipment. Unfortunately, the disadvantages 
would appear to outweigh whatever advantages there are. The aldimine (or 
labile) adducts of glycated haemoglobin have been found to co-elute w ith  the 
H bA ic fraction , thereby giving falsely i elevated percentage glycated 
haemoglobin values. This was originally overcome by pre-incubating the 
erythrocytes in isotonic saline for up to 12 hours to remove the labile fraction  
(Nathan, 1981), before applying the haemoglobin sample to the column. 
However, this increases the time spent on this assay technique. Other 
drawbacks include temperature and pH sensitiv ity which must be s tr ic tly  
controlled. Variant haemoglobins such as foetal haemoglobin, can give rise to 
falsely elevated HbA^c levels (McDonald and Davis, 1979) as can samples
taken from patients who have uremia, which leads to increased carbamylation
it
of haemoglobin (Fluckiger et al., 1981).
1.2.4.2 Electrophoresis
The second technique for separating glycated proteins using 
variations in charge .involves electrophoresis. Two major forms of 
electrophoresis are used, either agar gel electrophoresis or iso-electric 
focusing. Agar gel electrophoresis relies on the separation of HbA^g, HbA-j^ 
and HbA^c (collective ly termed HbA^) from HbAQ by the presence of 
negatively charged sulphate and pyruvate groups in the agar gel. When an 
e lectric fie ld  is applied, the negatively charged groups retard the movement of 
HbAQ re lative to HbA^ thereby achieving separation of the two components 
(Menard et al., 1980). Although this system does not suffer from the effects of 
small changes in temperature and pH as does ion-exchange chromatography, i t  
s till retains several disadvantages. Again, there is the ab ility  of labile 
haemoglobin as well as foeta l haemoglobin to in terfere w ith the observed 
glycated haemoglobin levels (Nathan, 1981). Additionally, the re la tive ly  high 
cost along w ith the technical skill required to set up this technique weigh 
against its  use. However, this said, the method can separate many d iffe ren t 
haemoglobin samples w ith good resolution in under six hours i f  a pre- 
incubation step is used to remove labile haemoglobin. This possibly accounts 
fo r its widespread use in c lin ica l laboratories.
Isoelectric focusing, on the other hand, uses both a pH and voltage 
gradient to separate HbA^c from HbAQ on a polyacrylamide gel (Schoos et al., 
1978). The necessity fo r an expensive densitometer to detect the separated 
haemoglobin bands is s till present^combined w ith the need for experienced 
technical s ta ff. This technique, however, surpasses those previously described 
as it  is able to separate HbA^ into all its constitutive components (Gastagnola
et al., 1985a). Additionally, there is no interference by either the labile 
haemoglobin or foetal haemoglobin fractions which may interfere w ith the 
previous methods described (Strickland et al., 1982).
1.2.4.3 A ff in ity  Chromatography
This method relies on the ab ility  of an m-aminophenylboronic acid 
ligand immobilised on to a suitable m atrix, such as agarose gel, to selectively 
bind to glycated protein (Gould and Hall, 1987) thereby allowing non-glycated 
protein to pass through the m atrix as firs t shown by Mallia et al., (1981). The 
m-aminophenylboronic acid ligand operates by selectively binding to cis-diols 
which are present in the fructosamine moiety, this is illustrated in Figure 1.8. 
However, so as to allow the m-aminophenylboronic acid ligand to bind cis- 
diols, the correct pH environment must be present. Below pH8.0 the boronate 
ligand exists in the dihydroxyl form and is unable to interact w ith  cis-diols. 
Above pH8.0 the trihydroxyl form predominates and as a result the boronate 
atom becomes negatively charged. As the m-aminophenylboronate ligand 
contains a phenyl group as well as a negative charge in the active state, 
problems may arise due to non-specific binding of protein molecules to the 
ligand. This is because of either hydrophobic interactions between the phenyl 
ring and the molecule or charge interactions, especially i f  the molecule is 
highly positively charged. These problems may be overcome by the addition of 
chaotropic agents, such as urea, to remove the hydrophobic interactions and 
'salting out1 by the addition of sodium chloride to weaken any charge-charge 
interactions between the ligand and the protein molecules.
Elution of bound glycated protein can be achieved by either 
competition fo r binding sites w ith sorbitol (Mallia et al., 1981; Bouriotis et a l., 
1981), a sugar molecule containing an abundance of cis-diols, or by lowering 
the pH which destroys the ligand binding properties thereby eluting the bound
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Figure 1.8 Schematic representation of the binding of glycated protein to 
agarose crosslinked m-aminophenyl boronic acid .1
glycated protein. Other competing agents such as borate, which is pH 
sensitive, or compounds containing l-hydroxy-2-am ino groups are equally 
e ffective  in eluting glycated proteins.
Compared to either ion-exchange chromatography of electrophoresis, 
this method is re la tive ly straight forward and does not suffer from the 
parameters which affected the above two methods. An advantage of this 
method is that it  measures the to ta l glycated protein present and can 
discrim inate between normals and diabetics w ith good precision (Hall et al., 
1983). In the case of haemoglobin, previous methods only measured H b A ^  
whereas this a ffin ity  method measures all glycated haemoglobins (Fluckiger et 
al., 1984), including the glycated fraction  which co-elutes w ith HbA in the 
previous methods described. However, one major disadvantage is that the 
resin, as supplied by Pierce (UK) is presently very expensive, costing 
approximately £700 per 100ml. I f  1ml columns are to be used, this results in 
each column costing £7. Although each column can be used around sixteen 
times (Hall e t al., 1983), Moore et al. (1986) stated that the precision of 
measurement declined w ith continued re-use. Smaller 0.5ml columns, on the 
other hand, w ill decrease the cost per column. Another important facto r in 
assay precision which must be considered is the e ffec t of batch to batch 
variation in the a ffin ity  gel.
1.2.4.4 C olorim etric Methods
i i
The th iobarbituric acid (TBA) test orig inally reported by Fluckiger 
and W interhalter (1976) is another method, being both cheap and easy to 
perform. Essentially this method involves the hydrolysis of the fructosamine 
moiety from the glycated protein to produce 5-hydroxym ethylfurfural by 
boiling in a weak acid such as oxalic acid, fo r several hours. The protein 
fraction  is then removed by precipitation w ith  trich loroacetic acid and the
amount of 5-hydroxymethylfurfural present detected by reacting i t  w ith TBA 
to form a yellow adduct w ith an.absorbance maximum at 443nm. This method, 
also measures the to ta l glycation of a protein.
Castagnola et al., (1985b) found that the TBA test suffered from  a 
high coeffic ient of variation between samples (up to 15%) and this resided w ith  
the hydrolysis step. However, Moore et al., (1986a) la ter showed that the TBA 
test correlated well w ith other methods such as ion-exchange and a ffin ity  
chromatography; indeed, Moore et al., (1986b) were able to semi-automate the 
TBA test and achieve coefficients of variation of 6-8%. As the TBA test is 
both cheap and easy to perform^one would suppose it  would be the preferred 
method for measurement of glycated proteins, especially as i t  does measure 
to ta l glycation. However, the assay is time-consuming to perform and?in 
addition^,glucose interferes w ith the method giving falsely elevated readings. 
This makes it  necessary for a dialysis step to be included to remove glucose 
from the sample prior to analysis, or precip itate the protein from the sample 
prior to assaying the glycated protein content.
Another more recent method involves the reduction of nitroblue- 
tetrazolium  to formazan, a blue coloured adduct, due to the reducing 
properties of the fructosamine moiety on glycated proteins. The assay, 
referred to as the fructosamine test, was firs t used by Johnson et al., (1982) 
fo r the measurement of glycated plasma proteins and not glycated 
haemoglobin. The test is both cheap and lends itse lf readily to automation 
(Lloyd and Marples, 1984). Although MacDonald et al. (1987) found good 
correlation between serum fructosamine measurements and HbA^c, this was 
contradictory to the earlier results of Caines et al. (1986). Furthermore, 
Caines _et al. (1986) suggested that potential in terfering compounds in plasma 
are removed when measuring the glycation content in purified protein.
Schleicher e t al., (1988) found that non-specific reducing ac tiv ity  was present 
when measuring glycated plasma proteins. In itia l work carried out at the 
University of Surrey found that this non-specific reduction was due to the high 
molecular weight components of plasma (Gould, personal communication). 
There is also some evidence to suggest that the lipids may a ffect the assay, 
thereby necessitating an additional de-lipidation step prior to the test. 
Although this test was in it ia lly  thought to be the ideal method for 
measurement of glycated protein, i t  has not lived up to its expectations.
1.2.4.5 F luorim etric Methods
Two methods exist which rely on the measurement of glycated 
protein by fluo rim etric  analysis. The firs t method reported by Hayashi and 
Makino (1985) is specific to glycated albumin. This assay involved the use of 
dansylated phenylboronic acid in alkali pH. The boronate ligand binds to the 
cis-diols on the fructosamine adduct as in a ffin ity  chromatography. This 
binding changes the fluo rim e tric  emission spectrum on the dansyl group 
allowing quantitation of glycated albumin to be made. However, when th is 
assay was used to measure other glycated pro te ins jit proved unsuccessful and 
was therefore of very lim ited  use when trying to measure other glycated 
proteins.
In the second method, formaldehyde released from the fructosamine 
adduct by periodate is measured fluo rim e trica lly  (Gallup et al., 1981). 
Oxidation of the fructosamine adduct is carried out fo r 30 minutes at room 
temperature, followed by precipitation o f protein and excess periodate w ith  
zinc sulphate. The formaldehyde is converted to a fluo rim e tric  derivative by 
reacting i t  w ith ammonium acetate and acetyl-acetone to form 3,5-diacetyl- 
1,4-dihydrolutidine. This method oxidises both the aldimine and fructosamine 
adducts. However, by repeating the above assay procedure a fte r sodium
borohydride reduction, which converts the fructosamine adduct to a glucitol 
derivative, there is a stoichiom etric difference between the fluo rim e tric  
values obtained w ith and without sodium borohydride reduction which is only 
due to the fructosamine present. This therefore enables the to ta l amount of 
glycation to be determined fo r a protein.
1.2.4.6 High Performance Liquid Chromatography
Drexal et a l.-(198.7) reported another method fo r measuring glycated 
proteins which they claimed was both rapid and specific. Essentially, the 
method involved boiling the protein sample in 6M hydrochloric acid. This 
hydrolysed the protein and also produced furosine which is the £ -N (2- 
furoylm ethyl)-L-lysine derivative of fructosamine. Furosine was then 
separated into an individual peak by high performance liquid chromatography 
on a reverse phase C18 column and measured by UV absorbance at 280nm. 
Drexel et al. (1987), found that neither glucose nor other monosaccharides 
interfered w ith  the assay and suggested that the assay could be easily 
automated. This method only measures glycated lysine. However, as most 
proteins are mainly glycated on the £-am ino groups of lysine, this does not 
pose a serious problem. Another advantage is that this method enables one to 
obtain a result w ithin 15 to 20 minutes w ith coefficients of variation up to 
5.1%. The methodjUnfortunately^does require a large in itia l capital outlay i f  
an automated HPLC system is required.
1.2.4.7 Immunoassay
Javid et al. (1978) were the f irs t to develop an ovine antiserum that 
could detect HbA^c. This involved the purification of HbA^ ■ and its injection 
into a sheep. Antibodies that were common to all haemoglobins were 
subsequently adsorbed out of the antiserum on a column consisting of HbA 
cross-linked to an agarose m atrix. The/adsorbed antiserum in the eluent was
therefore specific fo r HbA-^. However it  was found to cross-react w ith both 
H bA ia and H bA j^. Other groups have also developed antibodies for measuring 
glycated proteins (see Table 1.4) although some do not s tr ic tly  measure the 
native glycated protein, but a sodium borohydride reduced derivative. This 
produces both glucito l and manitol compounds which are stereochemical 
isomers and are subsequently referred to as the glucitol derivative. Only one 
other group (Knowles et al., 1987) has been able to develop an antibody that 
recognises the native glycated protein. They were able to obtain a monoclonal 
antibody specific to the glycated N-term inal 8-chain of H b A ^ . Cross- 
rea c tiv ity  curves were able to demonstrate tha t the monoclonal only 
recognised H b A ^ . In itia l c lin ical studies indicated that when this antibody 
was used in a fluorescence-based immunoassay a correlation coeffic ien t of 
0.93 was observed when compared to a HPLC-based ion-exchange method fo r 
measuring HbA^c* However, no further work has been published on the 
clin ical usefulness of this monoclonal antibody for measuring HbA^c in 
diabetic and normal patients.
The remaining workers in Table 1.4 have all produced antibodies to 
the g lucito l derivative of either HbA^c or albumin whether monoclonal or 
polyclonal, except fo r Curtis and Witzum (1983) and Go e t-a l., (1987) who 
reported a monoclonal antibody and polyclonal antisera respectively, raised 
against reduced glycated LDL. This monoclonal antibody and antiserum was 
able to recognise any glycated protein provided i t  was in the reduced g lucito l 
form . One drawback, however, was that the antiserum of Go et al. (1987) 
cross-reacted with the buffer EDTA and therefore EDTA could not be used in 
of the preparation of the sample.
Many more research groups have been able to raise antibodies to the 
glucitol derivative than to the native fructosamine adduct. This may not be
Table 1.4.
Immunoassays to glycated proteins
Research Group 
Javid et al., (1978)
Curtis and Witzum (1983)
Nakayama (1986).
Zeuthen et al. (1986).
Knowles et al. (1987).
Ohe et al. (1987)
Go et al. (1987)
Glycated Protein
Polyclonal antiserum to HbA^c
Monoclonal antibody to sodium borohydride 
reduced glycated LDL.
Polyclonal antiserum to sodium borohydride 
reduced albumin
Monoclonal antibody to sodium borohydride 
reduced Hb A^c
Monoclonal antibody to Hb A^c
Monoclonal antibody to sodium borohydride 
reduced glycated albumin
Polyclonal antiserum to sodium borohydride 
reduced glycated proteins
surprising since the glucitol adduct can only exist in one form , the stra ight 
chain form , whereas the fructosamine adduct, according to Neglia et al. 
(1985), can exist in up to five d iffe rent forms. Therefore, this would make the 
fructosamine derivative less immunogenic than the glucitol form.
1.3 ENZYME IMMUNOASSAY
1.3.1. Introduction
Immunoassay is a term  used to describe the measurement of a 
specific analyte by utilis ing the property of an antibody to bind specifica lly to 
a particular antigen. Although the antibody is a protein molecule containing 
two identical antigen binding sites, the antigen may not necessarily be a 
protein such as in the case of the measurement of thyroxine ( Ekinsl960) or of 
a steroid hormone (Abraham, 1969). The principle of immunoassay was firs t 
used by Yalow and Berson (1959) in the measurement of the peptide hormone, 
insulin. So as to quantitate the amount of antibody-bound and unbound insulin, 
a radiolabelled insulin standard was used. Competition for the antibody 
binding sites between the known amount of radiolablledj hormone and the 
analyte would result. Hence, the greater the analyte concentration the less 
radiolabelled insu lin1 that would bind to antibody. This was the basic 
principle of a radioimmunoassay. Unfortunately, the use of radioisotopes as 
labels have several disadvantages: the health risk, batch-to-batch variation in 
the commercially available radioistopes, lim ited  shelf life , the use of 
expensive counting equipment fo r the ir measurement, the need for a 
separation step in the assay protocol to separate bound from unbound 
radiolabelled antigen prior to measurement and the d iff ic u lty  of automation.
The use of enzymes as alterative labels was put forward by Engvall 
and Perlmann (1971) and Van Weemen and Schuurs (1971). The advantages of 
using enzymes include s tab ility  and long shelf life , ava ilab ility , low cost,
possibility of co lorim etric  end point determinations and the reduced health 
risk. However, the use of enzymes are not w ithout their disadvantages which 
include the e ffec t of assay environment on the enzyme label in a non-specific 
manner, the need for expensive co lorim etric spectrophotometers for the 
quantitative determination of analyte and the tox ic ity  of some of the 
substrates used. The term enzyme immunoassay (EIA) is used to describe 
those immunoassays in which the a c tiv ity  of an enzyme is measured to 
determine analyte concentration. The use of enzymes in immunoassay has 
been extensively reviewed (Schuurs and Van Weemen, 1977; Voller et al., 1978; 
O'Sullivan et al., 1984 and Gould and Marks, 1988).
1.3.2. Heterogeneous and Homogeneous assays
EIAs can essentially be separated into two types of assay, termed 
either a heterogeneous or homogeneous assay. The distinction between these 
two forms of assay is based on whether a separation stage is needed to identify  
free and bound enzyme label. Heterogeneous EIA includes both classical 
competitive and non-compet'dtve immunoenzymometric assays. In both these 
situations the enzyme label is not affected by the presence of bound or 
unbound analyte and i t  is therefore necessary to separate the two phases of 
analyte so as to determine analyte concentration.
Homogeneous EIA, on the other hand, does not require a separation 
stage. This sytem relies on the principle that the enzyme a c tiv ity  is changed 
on binding of antibody to antigen and is therefore not necessary. An example 
of such a system is the enzyme m ultiplied immunoassay technique (EMIT) as 
introduced by Rubenstein et al., (1972) (figure 1.9). Since no separation stages 
are required homogeneous EIAs lend themselves readily to automation. 
However, several disadvantages have been shown to exist due to substances 
w ith in  the assay incubation m ixture stim ulating or inhibiting enzyme a c tiv ity
antibody
Ab-Ag complex
Ab-Ag complex
inactivates
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Figure 1.9 The enzyme m ultip lied immunoassay technique (EMIT). 
Hapten labelled enzyme is enzymically active, but combination w ith antibody 
forms an inactive complex. Enzyme a c tiv ity  is therefore proportional to 
hapten analyte concentration being measured.
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Figure 1.10 The prothestic group labelled immunoassay. Apoenzyme 
becomes active on binding to the prosthetic group, forming an active 
holoenzyme. Hapten concentration is therefore proportional to enzyme 
ac tiv ity .
thereby affecting assay sensitivity (Kim and Cerceos, 1976 and Ying et ah, 
1981). In addition, a potentia lly serious disadvantage of the EMIT is that 
binding of the hapten-enzyme to antibody may not produce a reversible e ffect 
on enzyme ac tiv ity . Therefore, a requirement for the hapten to be close to 
the enzyme active site is needed for a change in enzym e-activity when 
antibody binds to hapten. This may not be possible i f  suitable conjugating 
groups are not present near the active site.
To overcome this problem other molecules such as substrates, 
enzyme cofactors and inhibitors can be used fo r conjugation to hapten. The 
most successful of these, the prosthetic group-labelled-immunoassay (PGLIA) 
such as that reported by Morris et al. (1981), is illustrated in figure 1.10. 
Essentially, a prosthetic group is attached to hapten. When not combined w ith  
antibody, apoenzyme (inactive) binds to the excess hapten-labelled prosthetic 
group producing active holoenzyme which is turn can act upon substrate. 
Therefore, analyte concentration is d irectly proportional to  the amount o f 
active haloenzyme-formed. Further types of homogeneous immunoassay have 
been described by Gould and Marks (1988).
1.3.3 Competitive and Non-Gompetitive immunoassays
Both competitive and non-competitive EIA can be performed as a 
heterogeneous immunoassay, where a solid phase is used to aid separation of 
the bound and unbound antibody or antigen (analyte). In general, com petitive 
EIA is usually the method of choice for measuring haptens as they only possess 
one antigenic determinant and i t  is simpler to develop than a non-competitive 
EIA.
In the competitive EIA as illustrated in figure 1.11 competition exists 
between solid phase antigen and free antigen (analyte) fo r the lim iting  amount
/ solid—phase 
^ linked Ag
enzyme labelled Ab
Figure 1.11 A competitive heterogeneous solid phase enzyme immunoassay 
for antigen. Enzyme labelled antibody binds to solid phase antigen. As 
analyte concentration is increased less solid phase Ab-Ag complex forms. 
Therefore analyte concentration is inversly proportional to measured enzyme 
ac tiv ity .
of enzyme labelled antibody. A fte r washing the solid phase, any enzyme 
labelled antibody attached to solid phase via antigen can be measured. 
Therefore measured enzyme ac tiv ity  is inversely proportional to analyte 
concentration, unlike the EMIT or PGLIA systems described previously.
Non-competitive or immunoenzymometric assays, as the name 
implies, do not rely on competition fo r lim iting  amounts of antibody or 
antigen. Instead, these assays rely on excess reagents being present. The 
enzyme a c tiv ity  measured is therefore proportional to the amount of analyte 
being assessed. Figure 1.12 shows a schematic representation fo r the 
measurement of antigen. I t  is important to note that the antigen must possess 
at least two separate antigenic determinants. For this reason, haptens can not 
normally be measured by immunoenzymometric analysis as they usually 
contain only one antigenic determinant. This type of assay is therefore 
reserved for the measurement of macromolecules such as proteins which 
possess many epitopes. A simple variation of this method can be used fo r the 
measurement o f antibody. Essentially antigen is ' tm mobilised onto a solid 
phase then analyte containing antibody specific fo r antigen is added. Bound 
antibody-antigen complex is detected using a second enzyme labelled antibody 
specific fo r the f irs t antibody, usually via the conserved Fc portion of the 
antibody molecule (figure 1.13).
Although polyclonal antisera can be used to  construct an 
immunoenzymetric assay as outlined in figure 1.12, monoclonal antibodies can 
also be used and o f fe r . a distinct advantage. Whereas, polyclonal anti sera 
have a spectrum of antibodies with varying specific ity  and avid ity to epitopes 
on an antigen, monoclonal antibodies are specific to only one epitope on an 
antigen and therefore offer a high degree of spec ific ity  when two separate 
monoclonal antibodies are used (Soos and Siddle, 1983). In addition, one
solid-phase 
linked Ab
+
Ag (analyte)
enzyme labelled 
second Ab
Figure 1.12 An immunometric assay for antigen. A t each stage excess 
reagent may be added a fte r washing. Anaiyte concentration is therefore 
proportional to enzyme a c tiv ity .
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Figure 1.13 An immunometric assay fo r antibody. Antibody concentration 
in the sample is proportional to measured enzyme ac tiv ity .
incubation step can be elim inated and therefore these assays can be performed 
in one step prior to addition of substrate (Sevier et al., 1981).
immunoenzymometric assays because of the ir format can o ffer 
higher degrees of specific ity  fo r antigen over competitive EIA. As these non­
competitive assays re ly on an excess of reagent, antibody a ffin ity  or antisera 
avid ity is not as important, as the law of mass action w ill favour the form ation 
of antigen-antibody complex. These assays also lend themselves very readily 
to increased sensitivity. As analyte concentration is proportional to signal, 
the greater the am plification of the signal at low analyte concentrations the 
greater the sensitivity (Jackson and Ekins, 1986). This can be achieved by 
using enzyme labels w ith  very high turnover rates (Gould and Marks, 1988) or 
biotin labelled enzyme and detection antibody in a biotin-streptavidin complex 
or the use of fluorogenic substrates (Shalev et al., 1980). A lternative ly, a 
substrate cycling system can be used, such as that developed by Self (1981). 
However, one lim iting  facto r is the level of non-specific binding (NSB) which 
must be minimal i f  maximum sensitiv ity is to be achieved (Shieldsand Turner, 
1986).
In figures 1.11 to 1.13 antigen, or antibody was attached to a solid 
phase. The most commonly used solid phase at present is the plastic 
m ic ro titra tion  plate containing 96 wells. Engvall and Perlmann. (1971), 
introduced the technique of EIA using a solid phase support as a separation 
process and, coined the phrase enzyme linked immunosorbent assay (ELISA). 
The plastic m icro titre  plate permits easy washing and when blocking agents 
such as tween 20, gelatin and casein (Kenna et al., 1985) are used during the 
incubation and washing stages low NSB levels can be attained. Although the 
attachment of small antigens such as haptens to the solid phase is d if f ic u lt, 
this can be achieved by conjugation of the hapten to a suitable carrier protein
molecule and then ; allowing this protein to be absorbed onto the plastic solid 
phase by non-covalent interaction. However, i t  is important to use a d iffe ren t 
chemical link between the protein and hapten to that used for the protein 
conjugate in the immunogen. Otherwise, a phenomenon known as 'bridge 
recognition' can occur which can result in a substantial loss of sensitiv ity (Van 
Weemen and Schuurs, 1975).
1.3.4. Precision and Sensitivity of enzyme immunoassay
Absolute sensitiv ity is not of paramount concern in the development 
of an assay fo r clin ical use, but the assay should be sensitive enough to detect 
c lin ica lly  significant changes in the concentration of analyte to be measured 
(Sauer, 1986). I f  one considers the clin ical level of glycated haemoglobin and 
albumin in normal individuals, they are around lOOyM and 25yM respectively. 
Therefore for the measuremnt of glycated haemoglobin the assay must be able 
to detect a concentration of 20]iM up to 300yM. Sim ilarly fo r glycated 
albumin the assay must be sensitive enough to detect from 5yM up to 75yM 
concentrations of glycated albumin in plasma. If  an assay is too sensitive then 
the analyte must be diluted to bring i t  w ithin the workable assay range. 
However, d iluting samples has the a ffec t of introducing error due to the 
dilution process its e lf and this in turn w ill a ffec t assay precision (Wilson et. al, 
1986). Ekins (1976) therefore proposed that of fundamental concern in assay 
design should be to maximise precision of measurement through the range of 
analyte concentrations that are deemed to  be of clin ical importance. The 
concept of a precision dose profile  was introduced by Ekins (1981) and is 
essentially a relationship between the coeffic ien t of variation in the 
measurement of a specific analyte concentration thoughout a range of 
d iffe rent analyte concentrations. An assay range can then be determined, 
over which the EIA has its greatest precision, that is the lowest coeffic ien t of 
variation in the measurement of analyte.
1.4 RESEARCH OBJECTIVES
The original aims of this research project were; to synthesise novel 
glycated moCeties as haptens for the production of antisera to glycated 
proteins; to assess the various antisera produced and develop an ELISA for the 
measurement of glycated proteins; to validate this ELISA for specific ity , 
parallelism and precision and fina lly  to measure clin ical samples and correlate 
this assay w ith other established assays in use for the measurement of 
glycated proteins.
CHAPTER 2
DEVELOPMENT OF METHODS FOR THE SYNTHESIS AND 
PURIFICATION OF GLYCATED AMINES
2.1 INTRODUCTION
The reaction mechanism for glycation of an amine, as described in 
Chapter 1, can be summarised by the four major steps illustrated in Figure 2.1; 
the starting reactants, the intermediate aldimine, the fructosamine (otherwise 
known as the ketoamine) and advanced giycosylation end-products (AGE).
Many groups studying the in v itro  glycation of proteins have used 
mild glycating conditions, such as incubation with glucose at 37°C in 
phosphate buffered saline, pH7.4. The incubation period w ill determine the 
type of compounds produced. Short incubation periods of up to 7 days under 
these conditions w ill result in mainly fructosamine being present (Higgins and 
Bunn, 1981; and Acharya and Sussman, 1984). I f  AGE are required, then longer 
incubation periods of 10 days to several months are necessary (Monnier and 
Cerami, 1983;and Vlassara et al., 1984). Therefore, to make purification of 
fructosamine derivatives easier, the amount of AGE formed could be lim ited  
by using a short incubation period under m ild glycating conditions.
To purify the fructosamine derivative i t  is necessary to understand
its physical and chemical properties. In Chapter 1 i t  was shown that -amino
groups on lysine residues of proteins were the major site of glycation. 6-
Aminohexanoic acid is structura lly very sim ilar to lysine, but i t  lacks the a-
amino group lim iting  glycation to only one site. I t  was therefore used as a
representative amine for the glycation studies. Figure 2.2 illustra tes the
structura l and chemical differences between 6-aminohexanoic acid and its
fructosamine derivative. The la tte r can exist in five d iffe ren t forms; of which
the straight chain form is in equilibrium w ith the a - and 8- tautomers of the
furanose and pyranose forms. This was firs t demonstrated by Neglia et al.,
13(1985). These workers showed, using C NMR spectroscopy, that the most 
abundant form was the 8-pyranose ring. A ll forms of the fructosamine
glucose - f  amine
aldimine
fructosamine
AGE
Figure 2.1: A sim plified reaction mechanism for glycation of an amine.
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Figure 2.2: The chemical structures of 6-aminohexanoic acid and the
fructosamine derivative.
derivatives contain a cis-diol and a secondary amino group, whilst 6- 
aminohexanoic acid contains a primary amino group. Both compounds have a 
free carboxyl group. The molecular weights of 6-aminohexanoic acid and its 
fructosamine derivative are 131 and 293 daltons respectively. These 
properties can be used to purify the fructosamine derivative by gel filtra tio n , 
ion exchange or a ffin ity  chromatography.
This chapter w ill therefore describe methods of synthesis and 
purification of l-am ino-l-deoxy-D-fructose-6-am inohexanoic acid (the 
fructosamine derivative). Methods were in itia lly  developed to fo llow  the 
glycation under mild conditions, which were aimed at reducing the form ation 
of AGE. Appropriate methods were also used to analyse the complex elution 
profiles obtained during the various purifica tion procedures.
2.2 MATERIALS AND METHODS
2.2.1 Materials
O-phthaldialdehyde, Sephadex G10 and G15 were obtained from  
Sigma Chemicals (UK). A GODPAP k it (catalogue No.166391) fo r automated 
glucose analysis on a Roche Cobas Bio analyser was obtained from Boehringer- 
Mannheim. Strong anion exchange resin A103 was a g if t from Perm utit and 
Dowex 50W-X8. 200 mesh was supplied by Sigma. Glycogel B a ffin ity  resin 
was purchased from  Pierce (UK) L im ited. A ll other chemicals were of AnalaR 
grade and bought from BDH Chemicals L im ited (UK).
2.2.2 General Methodology
2.2.2.1 Determination of D-Glucose
This was carried out on a Roche Cobas Bio automated analyser using 
the glucose analysis k it supplied by Boehringer-Mannheim (Catalogue 
No.166391). The assay was based on an end-point determination. Samples of
0.1ml were transferred to the assay vials. The reagent tray was then filled  
w ith enzyme mixture (containing glucose oxidase, peroxidase, phenol and 4- 
aminophenazone) along w ith D-glucose standards. The analyser was set up 
w ith the following parameters:
1. Units mmol/1
2. Calculation fac to r 0
3. Standard 1 concentration 5
4. Standard 2 concentration 10
5. Standard 3 concentration 20
6. L im it 22
7. Temperature (degrees G) 30.0
8. Type of analysis 4
9. Wavelength (nm) 300
10. Sample volume (pi) 4
11. D iluent volume (pi) 50
12. Reagent volume (pi) 300
13. Incubation time (seconds) 0
14. S tart reagent volume (pi) 0
15. Time of f irs t reading (seconds) 10.0
.16 . Time interval (seconds) 60
17. Number of readings 2
18. Blanking mode 1
19. P rin tout mode 1
2.2.2.2 Determ ination of 6-Aminohexanoic Acid
This assay was a modification o f those reported by Roth (1971) and 
Simons (1977). A 0.1ml sample (6-aminohexanoic acid concentration must be 
less than 0.1 mg/ml) was added to 2ml methanol followed by 0.1ml 1% OPA 
solution (50mg O-phthaldialdehyde, 5ml methanol and 50pl B-mercaptoethanol, 
to be used w ith in  24h of preparation). A fte r  4 minutes a 1.0ml aliquot was 
transferred to a fluorom etric cuvette and mixed w ith a fu rther 1.0ml of
methanol. An appropriate sample blank containing no 6-aminohexanoic acid 
was taken through the above procedure. Fluorescence was measured on a 
Perkin-Elmer LS5 fluorim eter using 2.5nm excitation and emission slits w ith 
an excitation and emission wavelength of 340 and 450nm respectively.
2.2.2.3 Thiobarbituric Acid Test for the Determination of Fructosamines
This assay was based on the method of Fiuckiger and W interhalter
(1976). To 0.5ml o f 1.0M oxalic acid was added 0.3ml distilled water and 0.2ml 
of sample. This m ixture was incubated fo r 4 hours at 100°C. The tubes were 
subsequently cooled and 0.5ml of cold 40% (w/v) trich loroacetic acid added to 
precip itate any protein present, followed by centrifugation at 2000g fo r 15 
minutes. A 0.75ml aliquot was taken and 0.25ml 50mM th iobarb ituric acid 
added to it. The m ixture was then incubated at 40°C for 30 minutes. A fte r 
cooling to room temperature the absorbance at 443nm was measured. A 
sample blank consisting of 0.2ml d istilled water was taken through the above 
procedure.
2.2.2.4 The Pauly Test
This assay was based on that reported by Candiano et al., (1985). A 
0.2ml sample was mixed w ith  0.1 mi, 29mM sodium sulphite and 1.0ml, 32mM 
sulphaniiic acid in 165mM hydrochloric acid. The m ixture was then le f t  to 
incubate at 37°C fo r 1 hour, a fte r which 0.1ml, 5M sodium hydroxide was 
added and the m ixture incubated fo r a fu rthe r 45 minutes at 37°C. F ina lly the 
m ixture was cooled to room temperature and the absorbance at 492nm read.
An aliquot of 0.2ml sample buffer was used as a sample blank in the 
above procedure. This assay w ill detect the presence of phenolic and nitrogen- 
bearing compounds as well as heterocyclic compounds. I t  was therefore used
as a test to detect the presence of AGE. However, D-glucose and 
fructosamine also react in this test.
2.2.2.5 Determ ination of Advanced Glycosylation End-Products (AGE)
The presence of AGE were determined by two separate spectroscopic 
methods. The firs t method involved observing fluorescence at 450nm a fte r 
excitation at 340nm. A lOnm emission and 2.5nm excitation s lit width were 
used on a Perkin Elmer LS5 fluorim eter. The second method used u ltrav io le t 
spectroscopy at 275nm and 400nm. An absorbance reading at either of these 
wavelengths indicated the presence of AGE in the sample.
2.2.3 Time Course for the Glycation of 6-Aminohexanoic Acid
A solution of lOmg/ml 6-aminohexanoic acid was le ft to glycate w ith  
D-glucose concentrations of 750mM, 375mM and 188mM in distilled water. 
Additionally, lOmg/ml of 6-aminohexanoic acid were le ft to glycate w ith  
750mM D-glucose in 25mM sodium phosphate, pH7.4 (at 37°C in the dark). A t 
specified time intervals during glycation, 0.1ml samples were taken and then 
diluted 100-fold. The diluted samples were assayed for free primary amino 
acid groups, as outlined in section 2.2.2.2.
The glycating mixtures were also analysed fo r 'natural' fluorescence 
using the parameters detailed in section 2.2.2.5. In addition, a ll glycating 
mixtures were scanned fo r UV absorbance between 250 and 400nm on a Varian 
2200 spectrophotometer against the buffer solutions used fo r glycation.
2.2.4 Purification of 1-Amino-1-Deoxy-D-Fructose-6-Aminohexanoic Acid
2.2.4.1 By Gel Filtration and Affinity Chromatography
Three 10ml fractions of glycated material, prepared by incubating 
750mM D-glucose w ith lOmg/ml 6-aminohexanoic acid in 25mM sodium
phosphate, pH7.4, at 37°C fo r 3 days in the dark, were applied to a gel 
f iltra tio n  column containing Sephadex G15, 2.6 x 6.9cm, Vg = 408ml. 
Fractions (2.0ml) were collected on a Pharmacia Frac 100 fraction collector, 
eluting w ith 25mM form ic acid at a flow  rate of 0.77ml/min. The fractions 
were analysed fo r D-glucose, 6-aminohexanoic acid, AGE and fructosamine.
The eluted fructosamine peak was pooled, lyophilised and re-dissolved 
in 4.5ml of 25mM sodium phosphate buffer, pH9.0, prior to loading onto a pre­
equilibrated glycogel B a ffin ity  column, (1.5 x 24.5cm, Vg = 43.3ml). Unbound 
material was washed through w ith  25mM sodium phosphate buffer, pH9.0, 
followed by elution of bound m ateria l w ith 25mM form ic acid. Fractions 
(1.6ml) were collected at a flow  rate of 0.6ml/m in and assayed fo r D-glucose, 
6-aminohexanoic acid, AGE and fructosamine. The 'bound' fructosamine^peak 
upon elution w ith 25mM form ic acid was pooled, lyophilised and the resulting 
f lu ffy  white compound stored at -20°C in a sealed tube.
2.2.4.2. By Anionic exchange a n d  A ffin ity  Chromatography
100ml of three-day glycated material was prepared as described in 
section 2.2.4.1. A strong anion exchange column (DUOLITE A113) (1.8 x 
38.5cm), Vg = 115ml, was set up, charged w ith three bed volumes of 1.0M 
sodium hydroxide and then washed w ith  400ml deionised water. The glycation 
m ixture was then applied to the ion exchange column at a flow  rate of 
5m l/m in collecting 5ml fractions on a Pharmacia Frac 100 fraction  collector. 
The column was washed through with a to ta l o f 500ml deionised water and a 
linear gradient from zero to 0.2M form ic acid over 100ml used to elute any 
bound material.
Each fraction was analysed fo r 6-aminohexanoic acid, D-glucose, 
AGE and fructosamine. The fractions containing fructosamine were pooled 
and then lyophilised. This material was redissolved in 10ml of 25mM sodium 
phosphate buffer, pH9.0, and applied to a pre-equilibrated Giycogel B a ffin ity  
column (1.5 x 24.5cm, Vg = 43.3ml), fo r separation and analysis as described in 
section 2.2.4.1. The fractions containing the fructosamine peak were again 
pooled and applied to a Sephadex G15 gel filtra tio n  column (2.6 x 76.9cm, Vg = 
408ml), which had been equilibrated with distilled water at 20 - 1°C. Eluting 
w ith distilled water, 2ml fractions were collected at a flow  rate of 0.68ml/m in 
and assayed for D-glucose and fructosamine. Fractions containing 
fructosamine were pooled, lyophilised and then stored at -20°C in a sealed 
tube.
2.2.4.3 By Cationic Exchange Chromatography
50ml of 3-day glycated m ateria l was prepared as described in section 
2.2.4.1. The resultant glycated m ixture was applied to a Dowex 50W-X8 
cationic exchange colum (1 x 29cm, Vg = 23ml), pre-equilibrated to its sodium 
form. Unbound m ateria l was washed through the column w ith ten bed volumes 
of 0.2M sodium/O.lM c itra te /H C l buffer, pH3.0. Elution of bound m ateria l 
was performed w ith a linear gradient over 500ml from 0.2M sodium/O.lM 
c itra te /H C l buffer, pH3.0 to 0.3M sodium/0.1 M c itra te /H C l buffer, pH3.5. 
Fractions (4ml) were collected at a flow  rate of 2m l/m in on a Pharmacia Frac 
100 fraction  collector. Every th ird fraction was analysed fo r 6-aminohexanoic 
acid, fructosamine, AGE and by the test as described in section 2.2.2.
2.3 RESULTS
2.3.1 Measurement of 6-Aminohexanoic Acid by Fluorimetric Analysis
A standard curve for the measurement of 6-aminohexanoic acid is 
shown in Figure 2.3. The graph is linear up to O.lm g/m l w ith a linear
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Figure 2.3: A standard curve of 6-aminohexanoic acid concentration against
re la tive fluorescence (r = 0.99) expressed as a percentage.
regression coe ffic ien t of 0.99. The values on the ordinate axis are arbitrary. 
In this case they are expressed as percentage values re la tive to the maximum 
fluorescence value obtained for O .lm g/m l 6-aminohexanoic acid.
2.3.2 Studies on the Optimisation of 1-Amino-I-Deoxy-D-Fructose-
6-Aminohexanoic Acid Formation
Figures 2.4 and 2.5a show the results of several time courses for 
glycating 6-aminohexanoic acid under varying conditions. In distilled water 
(Figure 2.4) i t  is seen that increasing D-glucose concentration also increases 
the rate of glycation of 6-aminohexanoic acid. To obtain a 20% glycation of 
6-aminohexanoic acid, i t  takes 5.5, 10 and an undetermined amount of days in 
the presence of 750, 375 a n d  188mM D-glucose respectively. However, when 
750mM D-glucose is used to glycate 6-aminohexanoic acid in the presence of 
25mM sodium phosphate buffer, pH7.4, (Figure 2.5a) i t  takes only 3 days to 
achieve 20% glycation of 6-aminohexanoic acid. This suggests tha t inorganic 
phosphate may have a ca ta ly tic  e ffe c t on the glycation of 6-aminohexanoic 
acid. This w ill be discussed fu rther in Chapter 4.
Figure 2.5b shows that, as glycation of 6-aminohexanoic acid w ith 
750mM D-glucose in 25mM sodium phosphate buffer proceeds, there is an 
increase of fluorescence in the glycating m ixture at 450nm when excited at 
340nm. This graph also appears to show a lag of one day before fluorescence 
is produced and, a fte r 9 days, the increase in fluorescence appears to ta il o ff. 
However, fu rther data points a fte r this time period would confirm  whether the 
increase in fluorescence was s til l continuing and that the last two data points 
were only subject to experimental error.
U ltrav io le t scanning spectroscopy, between 250 and 350nm, indicated 
the presence of an absorption peak at 275nm which increased in intensity as
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Figure 2A : Time courses for the glycation of 6-aminohexanoic acid at 
d iffe rent glucose concentrations in d istilled water at 37 C. 6-aminohexanoic 
acid contration is proportional to re lative fluorescence on ordinate, (a) 0.19M 
D-glucose; (b) 0.38 M D-glucose; (c) 0.75 M D-glucose.
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Figure 2.5: (a) Time course for the glycation at 6-aminohexanoic acid w ith
0.75M D-glucose in the presence of 25mM sodium phosphate pH 7.4.
(b) The increase in AGE formation w ith  time as detected by fluorescence at 
450nm during glycation of 6-aminohexanoic acid w ith 0.75M D-glucose in 
25mM sodium phosphate pH 7.4.
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Figure 2.6; U ltrav io le t scanning spectroscopic profiles between 250 and 
350nm. [a) lOmg/ml 6 aminohexanoic acid and 0.75M D-glucose in water; (b) 
lOmg/ml 6 aminohexanoic acid and 0.75M D-glucose a fte r 8 days glycation in 
water at 37 C; (c) lOmg/ml 6-aminohexanoic acid and 0.75M D-glucose a fte r 4 
days glycation in 25mm sodium phosphate pH 7.4 at 37°C.
glycation of 6-aminohexanoic dcid w ith D-glucose proceeded! Figure 2.6a 
shows the profile of 6-aminohexanoic acid and D-glucose dissolved in water. 
No significant absorption peak was found using water as a blank. However, in 
Figure 2.6b, the u ltrav io le t scanning spectroscopic profile of glycating 6- 
aminohexanoic acid in water gave rise to an absorption maxima at 275nm 
which increased in intensity as glycation proceeded further. When glycation of 
6-aminohexanoic acid was repeated in 25mM sodium phosphate buffer, pH7.4, 
the increase in intensity of the absorbance maxima at 275nm developed more 
quickly, as is seen in Figure 2.6c.
2.3.3 The Purification Studies on 1 -Amino-1 -Deoxy-D-Fructose- 
6-Aminohexanoic Acid
2.3.3.1 By Gel F iltra tion  and A ff in ity  Chromatography
Figure 2.7a shows the elution pro file  fo r Sephadex G15 gel f iltra tio n  
chromatography of the applied glycation m ixture. This pro file  is typ ical o f all 
those that were run. I t  is seen that there was partia l separation of 
fructosamine, 6-aminohexanoic acid and D-glucose. The th iobarbituric acid 
test profile  measured a t 443nm shows two peaks; a small in itia l peak followed 
by a much larger second peak. Both 6-aminohexanoic acid and D-glucose 
showed characteristic elution profiles, although the tra iling  edges of the peaks 
were drawn out. This is probably a function of the amount of material applied 
to the column. I t  is also seen that the second TBA positive peak follows very 
closely that of D-glucose, which is as expected since D-glucose reacts in the 
th iobarbituric acid test. However, D-glucose is eluted a fte r 6-aminohexanoic 
acid, even though D-glucose has the higher molecular weight. This anomaly is 
probably due to a carbohydrate interaction between D-glucose and the 
polysaccharide matrix of Sephadex. Figure 2.7b, run under sim ilar conditions
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Figure 2.7: (a) and (b) Elution profiles of glycated 6 aminohexanoic acid by gel 
fitra tio n  on sephadex G 1 5 ( V  = 407 mi), (c) An elution profile  from  a
Glycogei B a ffin ity  column Cv„ = 50ml) of fructosamine isolated by gel 
f iltra tio n . A  = absorbance at 443 nm for the th iobarb ituric acid test; H  = 
fluorescence at 450nm for the 6-aminohexanoic acid analysis; £  = absorbance 
at 500nm for the D-glucose assay; 4* = absorbance at 275nm for AGE; □ = 
fluorescence at 450nm fo r AGE.
Table 2.1.
Element
Carbon
Nitrogen
Hydrogen
Micro analysis results to confirm the purification 
of the fructosamine derivative of 
6-aminohexanoic acid gel f iltra tio n  and a ffin ity  
chromatography
Theoretical %
49.15
4.78
7.84
Experimental % 
33.79 
2.31 
5.20
as used in Figure 2.7a, showed a more complex elution pro file  when 
fluorescence, UV absorbance at 275nm and th iobarbituric acid analysis were 
performed. The fluorescence pro file  consists of three peaks (V s 258, 302 and 
378ml) and the UV absorbance profile  at 275nm has only two peaks (V : 258 
and 350ml). These peaks are possibly early AGE. The impure fructosamine 
peak (V : 246ml) in Figures 2.7a and 2.7b was pooled and when loaded onto a 
GlycogelB a ffin ity  column (Figure 2.7c), D-glucose, 6-aminohexanoic acid and 
fructosamine all co-eluted in the f irs t peak, the wash fraction. The second 
peak '(V s 144ml) gave a high th iobarb ituric acid test reading, w ith very l it t le  
D-glucose, 6-aminohexanoic or AGE present on analysis. This purified 
fructosamine derivative of 6-aminohexanoic acid was lyophilised yielding 16mg 
of material. The microanalysis results of this material are given in Table 2.1.
2.3.3.2 By Anionic Exchange and A ff in ity  Chromatography
The elution pro file  from the anion exchange column (Figure 2.8a) had 
a large D-glucose peak emerging a fte r 100ml of eluant and this peak contained 
a large tra iling  edge. This would explain the high th iobarbituric acid values 
a fte r the f irs t th iobarbituric acid positive peak. The form ic acid gradient 
eluted a second, broad th iobarbituric acid positive peak, the tra iling  half of 
which contained a 6-aminohexanoic acid peak. The fractions containing 
fructosamine, Vg: 1250 to 1550ml, were pooled, lyophilised and a ff in ity  
chromatographed as described in section 2.2.4.2.
The elution profile  a fte r a f f in i ty . chromatography resembled that 
seen in Figure 2.7c. AGE, D-glucose and 6-aminohexanoic acid are again seen 
to co-elute in the wash fraction. Bound m aterial, a fte r elution w ith 25mM 
form ic acid, gave a th iobarbituric acid positive peak. The fractions containing
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Figure 2.8: (a) The elution profile  of glycated 6-aminohexanoic acid by a
strong cation exchange resin DUOLITE A113 (Vg=113ml). A 0 to 0.2M form ic 
acid linear gradient over 1000ml was used to elute bound m ateria l.
(b) An elution profile  on sephadex G13 (Vg=408 ml) o f glycated 6- 
aminohexanoic acid previously purified by anionic ion-exchange and glycogel B 
a ffin ity  chromatography. □  = absorbance at 443nm for the th iobarb itu ric  
acid test; - f  = absorbance at 300nm fo r the D-glucose assay: A  = fluorescence 
at 430nm for the 6-aminohexanoic acid analysis.
Table 2.2.
Element
Carbon
Nitrogen
Hydrogen
Micro analysis results to confirm the purification 
' of the fructosamine derivative of 
6-aminohexanoic acid by anionic exchange and a ffin ity  
chromatography
Theoretical % Experimental %
49.15 31.83
4.78 0.59
7.84 5.57
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Figure 2.9: An elution profile  of glycated 6-aminohexanoic acid applied to  a 
Dowex 50W-X8 cation exchange column (V^ = 23mi). A 0.2M sodium ion, pH 
3.0 to 0.3M sodium ion, pH 3.3 linfiar gradient over 300ml was, used to elute 
bound m ateria l. A  = absorbance at 443nm for the th iobarbituric acid test; 
□  -  absorbance at 492nm for the Pauly tes t;-f-=  fluorescence at 450nm for 
the 6-aminohexanoic acid analysis.
fructosamine were pooled and applied to a Sephadex G13 column to remove
form ic acid (Figure 2.8b). The fructosamine was eluted over Vg: 190 to 270ml
and detected using the th iobarbituric acid test. This peak contained two 
shoulders on the leading edge which appeared to coincide with a D-glucose 
positive peak. The microanalysis results of the lyophilised material in this 
pooled peak are shown in table 2.2.
2.3.3.3 By Cationic Exchange Chromatography
Figure 2.9 shows the elution profile of a glycated 6-aminohexanoic 
acid m ixture from a Dowex, 30W-X8 cationic exchange resin. No absorbance 
profile at 400nm was detected, suggesting that the yellow pigmented AGE 
were either washed through the column before gradient elution, or that they 
bound tigh tly  to the column and required stronger conditions to remove them. 
The la tte r possibility appeared to be the case, because during the 
chromatography a yellow band remained at the top of the column and was only 
removed by washing the column w ith  1M sodium hydroxide. In Figure 2.9 the 
elution profile  fo r 6-aminohexanoic acid rose sharply at Vg: 100ml and then 
gradually decreased and had not returned to baseline when elution was 
stopped. The th iobarbituric acid positive profile showed a large peak (V^: 
108ml) w ith  a shoulder on the leading edge and a long tra iling  edge. There also 
appeared to be the tra iling  edge of a th iobarbituric acid positive peak at the 
start of gradient elution. This was probably due to D-glucose s till being 
washed through the column prior to gradient elution of bound material. The 
Pauly test gave a profile  consisting of two peaks (Vg: 94 and 138ml). These 
two peaks corresponded to the shoulders on the th iobarbituric acid positive 
peak, Vg: 108ml.
2.5. DISCUSSION
The tim e course graphs for glycation of 6-aminohexanoic acid (Figure
2.4) show that as the concentration of D-glucose was increased, there was an 
increase in the rate of glycation. I t  was also seen that glycation proceeded 
approximately twice as fast in 25mM sodium phosphate buffer than in water, 
as i t  took 3 days (Figure 2.3a) as opposed to  5.5 days (Figure 2.4) to reach 20% 
glycation. Subsequent separation of the reaction mixtures showed that the 
decrease in 6-aminohexanoic acid, as measured by the fluorom etric assay in 
section 2.2.2.2, was due to the formation of glycated derivatives of 6- 
aminohexanoic acid. U ltrav io le t absorbance between 250 and 350nm was 
greater in the glycating m ixture containing 25mM sodium phosphate buffer, 
pH7.4, than in water and this showed that AGE were a m ixture of complex 
heterocyclic compounds also containing unconjugated dienes, both able to 
absorb strongly in the u travio le t region. Therefore the absorbance peak at 
275nm was probably due to AGE and absorbances at 275nm and 400nm were 
used to detect AGE in the chromatographic profiles. The increase w ith tim e 
in fluorescent compounds as shown in Figure 2.5b, rose steadily. Therefore, to 
maximise the amount of fructosamine derivative for subsequent purifica tion, 
an incubation period of 3 days in 25mM sodium phosphate buffer, pH7,4, was 
chosen so as to minimise the amount of AGE produced.
Three chromatographic procedures for the purification of the 
fructosamine derivative were examined. The firs t involved gel filtra tio n  
combined w ith Glycogel B a ffin ity  chromatography. On the basis of the 
th iobarbituric acid test,which detects fructosaminejas well as the tests fo r 6- 
aminohexanoic acid, D-glucose and AGE?a pure product of 1-am ino-l-deoxy-D- 
fructose-6-aminohexanoic acid was isolated. However, microanalysis gave an 
equivocal result that did not agree w ith the theoretical elemental percentages 
(Table 2.1).
The remaining two chromatographic procedures relied on the in itia l 
separation of molecules on the basis of their charge. Anionic exchange 
chromatography followed by a ffin ity  chromatography incorporated an 
additional fina l stage involving gel f iltra tio n . This last stage was performed so 
as to remove the form ic acid present prior to iyophilisation. I t  was thought 
that acid hydrolysis might occur during Iyophilisation because of an increase in 
the form ic acid concentration. However, upon microanalysis (Table 2.2) i t  was 
observed that the percentage nitrogen value was very low compared to the 
theoretical value. This suggested that an im purity was present in the isolated 
fructosamine.
The th ird chromatographic procedure, employing cationic exchange 
chromatography alone, appeared to isolate two d istinctly  d iffe ren t 
fructosamine derivatives as detected by the Pauly and TBA tests(Figure 
2.9). However, the separation of these two compounds would need to be 
improved fo r fu rther characterisation. Although i t  was found tha t 6- 
aminohexanoic acid started to co-elute w ith the second positive peak, no AGE 
were detected in this elution profile . Yet, w ith  the previous methods, AGE 
were detected. Therefore, as AGE formation was lim ited during the synthesis, 
those AGE that were formed appear to be easily removed by being retained on 
the column w ith  this th ird purification method.
Two c rite ria  must be considered in choosing the most e ffec tive  
purification method for fructosamine derivatives: (i) the isolation of pure 
compound, and (ii) yield. Gel filtra tio n  would lim it  the yield obtained to the 
constraints on sample volume i f  good resolution was s till to be attained. 
Anionic exchange chromatography, on the other hand, although able to
accommodate large sample volumes, did not achieve good separation of the 
various components in the reaction m ixture, except for D-glucose. However, 
cationic exchange chromatography, as well as being able to handle large 
sample volumes, appeared to isolate two separate fructosamine derivatives 
free from  any AGE. Therefore, this la tte r method would appear to be the 
most appropriate to use.
As AGE appears to be - easily removed by cationic exchange 
chromatography, then the original concept of lim iting  AGE form ation (see 
section 2.1) would now appear to be invalid. Harsher reaction conditions could 
therefore be used to utilise all 6-aminohexanoic acid during synthesis^ thus 
increasing the yield of fructosamine, even though more AGE would also be 
produced. As w ill be seen la te r in Chapters 3 and 4, this approach would be 
completely vindicated.
CHAPTER 3
THE SYNTHESIS AND PURIFICATION OF 
1-AMINO-l-DEOXY-D-FRUCTOSE-AMINE DERIVATIVES
3.1 INTRODUCTION
In Chapter 2 it  was observed that harsher methods of synthesis, other 
than those used previously for fructosamine derivatives followed by cationic 
exchange chromatography, could produce 1-amino-l-deoxy-D-fructosamines in 
high yield. However, i t  was observed that this method of purification isolated 
two fructosamine-positive derivatives. It was therefore necessary to 
characterise both compounds in order to determine which one was the 
authentic 1-am ino-l-deoxy-D-fructosam ine.
Six compounds, all possessing a primary amino group, were glycated 
for the synthesis o f fructosamine derivatives for use as haptens. The six 
compounds used were:
1. 6-aminohexanoic acid
2. 4-aminobutyric acid
3. L-valine
4. Tyramine
3. . PoIy-L-lysine
6. Lysyl lysine
The synthesis and purification of compound 6 along w ith  its 
properties are discussed in Chapter 4. Figure 3.1 shows the structure of 
compounds 1 and 4 w ith their respective glycated derivatives. The reasons fo r 
using 6-aminohexanoic acid were outlined in Chapter 2 and they also applied to 
the use of 4-aminobutyric acid. However, 4-aminobutyric acid contains two 
less carbon atoms and this property may impart d iffe ren t immunogenic 
properties towards the fructosyl residue as w ill be discussed la te r in 
Chapter 5.
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Figure 3.1 The chemical structures of four amines and the ir respective 
glycated derivatives, (a) 6-aminohexanoic acid; (b) 4-aminobutyric acid; (c) 
L-valine; (d) tyramine.
Shapiro et al., (1980) have shown by analysing enzymic digests of 
haemoglobin that the a-amino group on the N-term inal valine residue on the B 
chain of haemoglobin was glycated in vivo. Therefore, L-valine was also 
chosen as a potential hapten.
Glycated tyramine was used as a hapten because the linkage between 
the carrier protein and the fructosyl residue on the tyramine was via a fla t, 
rigid phenyl ring. This would res tric t the movement of the fructosyl residue 
and may therefore increase the immunogenicity of the fructosyl residue. In 
addition, the type of chemical linkage between the hapten and carrie r protein 
is d iffe ren t from that used w ith the other compounds, as w ill be discussed in 
Chapter 3, and could therefore be used to overcome a phenomenon called 
'bridge recognition' (Cameron et. al., 1973).
Poly-L-lysine was chosen as i t  contains a preponderance of £ -amino 
groups and only one a-amino group per polypeptide chain. A ll these amino 
groups are theoretica lly available fo r glycation and should result in a heavily 
glycated polypeptide. Due to the repetitive property o f this particular hapten, 
an increased likelihood of an immunogenic response against an individual or 
group of £-amino glycated lysine residues may occur.
Using the above-mentioned amines, the production of pure mono- 
fructosamine derivatives fo r use as haptens w ill be described in this Chapter. 
Harsher conditions of synthesis and cation exchange chromatography w ill be 
used fo r their purification. In addition, a new alternative method for 
specifically detecting fructosamines, other than those methods described in 
Chapter 2, w ill be described.
3.2 MATERIALS AND METHODS
3.2.1 Materials
Dowex 30W-X2; 200 mesh cation exchange resin, poly-L-lysine Mr 
4000, tyramine (free base), a-valine, 4-amino-butyric acid, 6-aminohexanoic 
acid and gum ghatti were purchased from Sigma Chemicals (UK). A ll other 
chemicals were obtained from BDH Chemicals (UK) and were of AnalaR 
Grade. For column chromatography a Pharmacia ■ perista ltic  PI pump and 
FRAC 100 fraction collector were used. Lyophilisation was carried out on an 
Edwards Modulyo freeze-dryer. TLC plates; 20 x 20cm, 0.2mm thickness, 
plastic backed silica gel 60F 234 (No.5735 Merck, Darmstadt) were obtained 
through Sigma Chemicals (UK).
3.2.2 General Methodology
3.2.2.1 The Fructosamine Assay
The procedure was based on the methods of Folin and Malmros (1929) 
and Borsook et al., (1935).
Preparation of a 0.1% (w/v) Ferric Sulphate Solution:
The fe rric  sulphate solution was prepared as follows: 20g o f soluble 
gum ghatti was tied up in a muslin bag which was then suspended in 1 lit re  of 
d istilled water and le ft overnight (18 hours). The resulting solution was 
strained through a double layer of muslin. To this was added 5g o f anhydrous 
fe rric  sulphate in 75ml of 85% (v/v) phosphoric acid and 100ml o f d istilled 
water. Any reducing agents derived from the solubilised gum ghatti were
oxidised by dropwise addition of a 1% (w/v) potassium permanganate solution
until the stirred solution just began to go pink. The solution was also tested 
fo r reducing agents by mixing i t  w ith an equal volume of 0.1% (w/v) potassium 
ferricyanide solution. If no blue colour was formed, then no more potassium
permanganate solution was required and the resulting fe rric  sulphate solution 
was kept at 20°C in a dark bottle.
To 0.1ml of sample were added 0.1ml 1M sodium hydroxide and 1ml 
0.1% (w/v) potassium ferricyanide solution. This mixture was le ft to react for 
5 minutes then 1ml of the fe rric  sulphate solution was added and the reaction 
continued for a fu rther 5 minutes. Finally, 5ml of d istilled water wane added 
and the absorbance at 690nm read. A sample blank, replacing the volume of 
sample w ith buffer was taken through all the stages of the above procedure.
3.2.2.2 Determination o f Free Primary Amines
A solution of ninhydrin was prepared by dissolving 0.1% (w/v) 
ninhydrin and 5% (v/v) glacial acetic acid in 30ml ethanol.
A 0.1ml sample was added to 1.0ml of the acidified ninhydrin solution 
and then heated fo r 5 minutes in a water bath at 80°C. The tubes were cooled 
and the absorbance at 580nm measured.
3.2.2.3 Determ ination of 5-Hydroxymethyl Furfural
This assay is based on the second half o f the th iobarb ituric acid test
ii
(Fluckiger and W interhalter, 1976). 0.25ml o f sample was added to 0.75,*!of
50mM th iobarbituric acid solution and le ft to incubate fo r 30 minutes at 40°C 
in a water bath. The solution was cooled and the absorbance at 443nm was 
read.
3.2.3 Analytica l Methodology
3.2.3.1 TLC Analysis
A butanol/acetic acid/water (4:1:1) solvent system on silica gel plates 
was used. Sample aliquots were spotted onto the TLC plate; the spots being 
made as small as possible. The plates were developed and the Rf values 
calculated for each detected spot.
The following sprays were used fo r the detection of spots on the TLC
plates:
(i) Detection of Amines: 0.1% (w/v) ninhydrin dissolved in methanol 
containing 10% (v/v) glacial acetic acid.
(ii) Detection of Fructosamines: The ferricyanide test was used to 
detect fructosamines. The plate was firs t sprayed w ith 0.1% (w/v) 
potassium ferricyanide and le ft for 3 minutes before spraying w ith  
fe rric  sulphate solution (as described in Section 3.2.2.1) and le ft fo r a 
fu rther 5 minutes. Any fructosamine present develops as blue spots 
on a clear background.
(iii) Detection o f Sugars: 0.1% (w/v) potassium permanganate in 0.1M 
sodium hydroxide was used as the spray. Yellow spots on a purple 
background indicate the presence of sugar alcohols, reducing and non- 
reducing sugars. Methyl and acetyl sugars are not detected (Dawson, 
E llio t et al., 1969).
3.2.3.2 NMR Analysis
This was performed by the University's Department of Chemistry on 
a 95MHz proton NMR spectral analyser. A ll samples were dissolved in 
deuterated methanol prior to analysis.
3.2.3.3 Microchemical Analysis
This was also performed by the Department of Chemistry on 1- 
amino-l-deoxy-D-fructose-6-aminohexanoic acid only.
3.2.4 Synthesis and Purifica tion o f 1-Am ino-l-Deoxy-D-Fructosam ine 
Derivatives
3.2.4.1 Cation Exchange Chromatography: Buffer Compositions
Buffer A: 0.2M sodium hydroxide 
0.1M c itr ic  acid 
10% (v/v) propan-l-o l 
Adjust to pH2.0 w ith  concentrated HCl
Buffer B: Same as Buffer A, except adjusted to pH3.0
Buffer C: 0.4M sodium hydroxide 
0.1M c itr ic  acid 
10% (v/v) propan-l-o l 
Adjust to pH5.0 w ith  concentrated HCl
Buffer D: 0.1M sodium hydroxide 
0.1M c itr ic  acid 
10% (v/v) propan-l-o l 
Adjust to pH2.0 w ith  concentrated HCl
Buffer E: Same as Buffer D but using 0.3M sodium hydroxide and adjusting
the solution to pH4.0
Buffer F: 0.4M potassium hydroxide
0.1M c itr ic  acid 
10% (v/v) propan-l-o l 
Adjust to pH5.0 w ith  concentrated HCl
Buffer G: Same as Buffer F except that 0.6M potassium hydroxide was used 
and the solution was adjusted to pH7.0
3.2.4.2 l-Am ino-l-Deoxy-D-Fructose-6-Am inohexanoic Acid
In 50ml of methanol, 0.5g (3.82 mmoles) of 6-aminohexanoic acid 
and 3.41g (18.9 mmoles) D-glucose were refluxed for up to 3.5 hours at 80°C. 
The resulting brown solution was concentrated to a syrup by rotary 
evaporation. The syrup was re-dissolved in Buffer A in as small a volume as 
possible and applied to a Dowex 50W-X2 cation exchange column (1.6 x 54cm) 
pre-equilibrated to its sodium form, at a flow rate of 4m l/m in. The column 
was washed w ith  3.5 bed volumes of Buffer B. 10ml fractions were collected 
over a linear gradient of 1000ml of increasing Buffer C concentration. The 
fractions were analysed by both the th iobarbituric acid test (Section 2.2.2.3) 
and the ferricyanide test (Section 2.2.2.1). In addition, the elution of 5- 
hydroxymethyl fu rfu ra l was followed. D-glucose and free amino groups were 
detected using the ninhydrin tests previously described (Section 3.2.3.1). The 
appropriate ferricyanide positive peaks were pooled and concentrated by 
rotary evaporation. The resulting syrup was redissolved in 25mM sodium 
phosphate and the pH adjusted to pH9.0. The m ateria l was fu rther purified by 
Glycogel B a ffin ity  chromatography. 2ml fractions were collected at a flow 
rate of lm l/m in . The. a ffin ity  column (2 x 15.9cm) had been pre-equilibrated 
w ith 25mM sodium phosphate buffer, pH9.0, and the sample washed through 
w ith 100ml of 25mM sodium phosphate, pH9.0, before eluting glycated 
material w ith 25mM form ic acid.
Fructosamine was located in the fractions by the ferricyanide test 
(Section 3.2.2.1), the second fructosamine positive peak was pooled and 
lyophilised. The yields of the two purified fructosamine materials were noted. 
The two purified materials were then analysed by:
(i) NMR spectral analysis
(ii) TLC analysis
(iii) M icrochemical analysis of the l-am ino-l-deoxy-D -fructose-6-
aminohexanoic acid only
3.2.4.3 l-Am ino-l-D eoxy-D -Fructose-4-Am inobutyric Acid
To 23ml methanol were added 0.5g (4.8mmoles) 4-aminobutyric 
acid, 0.79g (4.4mmoles) D-glucose and 5ml acetophenone. This solution was 
refluxed at 80°C for 60 minutes until the solution was a golden yellow colour. 
When the cooled solution was poured into dry ether, a d irty  white m icro- 
crystalline precipitate was formed which turned to a sticky yellow gum i f  
moisture was present. The solvent was poured o ff and the precip itate re- 
dissolved in methanol. More dry ether was added and again, a d irty  white 
precip itate resulted. The solvent was fina lly  decanted o ff. The white 
precipitate was re-dissolved in a l it t le  water and shaken with ether to remove 
any acetophenone present. The ether was removed and the process repeated 
w ith fresh ether. The remaining aqueous phase was removed by ro ta ry 
evaporation and the resulting solid re-dissolved in Buffer B. This was applied 
to a Dowex 30W-X2 cation exchange column (2 x 6.3cm) and elution was 
performed as described in Section 3.2.4.2, except that 2ml fractions were 
collected at lm l/m in . Fractions were analysed fo r D-glucose, prim ary amine 
(using the ninhydrin test) and fructosamine w ith  the fructosamine test. The 
fructosamine positive peaks were pooled and applied to a Glycogel B a ffin ity  
column. The remaining methodology was as described in Section 3.2.4.2.
3.2.4.4 1-Am ino-l-Deoxy-D-Fructose-L-Valine
To 30ml of methanol were added 0.3g (4.3 mmoles) L-valine and 
0.83g (4.7 mmoles) D-glucose. The solution was refluxed for 3 hours at 80°C.
The remaining protocol was as described in Section 3.2.4.2, except that the 
• cation exchange column was pre-equilibrated and the applied m ateria l 
dissolved in Buffer D. Linear gradient elution was carried out using Buffer D 
w ith an increasing Buffer E concentration. No microchemical analysis was 
performed and fractions were only assayed for fructosamine.
3.2.4.5 1-Am ino-I-Deoxy-D-Fructose-Tyr amine
0.5g (3 mmoles) tyramine and 0.6g (3.31 mmoles) D-glucose were 
dissolved in 23ml methanol to which 5ml of acetophenone was added and then 
refluxed fo r 2.5 hours at 80°C. The resultant yellow m ixture was poured into 
300ml ether and le f t  to stand overnight at 0°C. A d irty  white m icrocrystalline 
powder precipitated. The solvent was decanted and the precipitate washed 
w ith  dry ether tw ice. The precipitate was then redissolved in a small volume 
of water and shaken w ith ether and the ether layer removed. This was 
repeated w ith  fresh ether. The water was fina lly  removed and the solid re- 
dissolved in 25mM sodium phosphate buffer and the pH adjusted to 9.0. The 
m aterial was applied to the Glycogel B a ff in ity  chromatography column as 
described in 3.2.4.2. A fte r lyophilisation of the pooled fructosamine-positive 
m aterial in elution buffer the yield was noted. TLC analysis was also 
performed on this product.
lOOmg of the yellow solid were further purified. It was in it ia lly  
dissolved in Buffer B prior to application to a Dowex 50W-X2 cation exchange 
column (2 x 6.3cm) pre-equilibrated w ith  Buffer B. The column was washed 
through w ith three bed volumes of Buffer B, followed by elution w ith  a 200ml 
linear gradient of Buffer F to Buffer G, collecting 2ml fractions at lm l/m in . 
The fructosamine-positive material was pooled and solvent removed by rotary 
evaporation and the solid re-dissolved in 25mM sodium phosphate, pH9.0, and 
applied to a Glycogel B a ffin ity  column as previously described. The m ateria l
eluted w ith  25mM form ic acid was lyophilised and analysed by both TLC And 
NMR. Eluted fractions were assayed fo r fructosamine only.
3.2.4.6 1-Am ino-l-Deoxy-D-Fructose-Poly-L-Lysine
To 25ml methanol and 5ml of acetophenone were added 80mg (20 
ymoles) poly-L-lysine and 1.5g (8.3 ymoles) D-glycose. This solution was 
refluxed fo r 2 hours at 80°C then concentrated by rotary evaporation and 
reconstituted in 5ml of 25mM sodium phosphate, pH9.0, i f  necessary w ith 
molar sodium hydroxide. The material was then applied to a pre-equilibrated 
Glycogel B column (2 x 15.9cm) and washed through w ith  100ml of 25mM 
sodium phosphate, pH9.0, at lm l/m in . Glycated m aterial was eluted w ith  
25mM form ic acid into 4ml fractions at a flow -ra te  of lm l/m in .
The eluted fructosamine-positive fractions were again 
concentrated by ro tary evaporation to remove water and form ic acid, before 
being re-dissolved in 25mM sodium phosphate, pH9.0, and the a ffin ity  
chromatography step repeated as described above. The resulting eluted 
fructosamine positive peak was pooled and lyophilised producing a hygroscopic 
f lu ffy  yellow solid.
3.3 RESULTS
3.3.1 The Properties of 1-Amino-1-Deoxy-D-Fructosamine Derivatives
3.3.1.1 l-Am ino-l-Deoxy-D-Fructose-6-Am inohexanoic Acid
Figure 3.2a shows the elution profile  from a Dowex 50W-X2 cation 
exchange resin w ith  linear (sodium salt and pH) gradient elution. Two peaks 
were resolved which give a positive fructosamine test (Section 3.2.2.1). The 
th iobarbituric acid test profile  also indicated the presence of two peaks, 
although the second peak had a lower intensity and was present as a broad 
shoulder.
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Figure 3.2 Elution profiles for the purifica tion of glycated 6- 
aminohexanoic acid, (a) from a Dowex 50W-X2 cation exchange resin using 
lin ia r gradient elution over 1000ml from 0.2M sodium, pH 3.0 to 0.4M sodium, 
pH 5.0; (b) compound A applied to a Glycogel B column; (c) compound B 
applied to a Glycogel 8 a ffin ity  column. A .  = alkaline ferricyanide test;
□  = th iobarb ituric acid test; A  = 5-hydroxymethyl fu rfu ra l test p rofile .
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Figure 3.3 Silica gel t.l.c . profiles for the identifica tion of glycated 6- 
aminohexanoic acid using a 4:1:1 butanol: glacial acetic acid: water mobile 
phase. Plate (a) = Ninhydrin spray; Plate (b) = alkaline ferricyanide spray; 
Plate (c) = alkaline potassium permanganate spray. B = compound B; A = 
compound A; 6 = 6-aminohexanoic acid; G = D-glucose.
ppm
ppm
Figure 3.4 P ro ton  NMR profiles for glycated 6-aminohexanoic acid, (a) 
compound A; (b) = compound B.
Table 3.1
NMR data and structura l assignments for compound A
ppm M u ltip lic ity Proton Intensity 
(arb itrary units)
Assigned Chemical 
Group
1.2-2.2 Broad,
unidentified
61 Three methylenes of 
GAHA 
i.e. -C H 2-CH2-CH2-
2.25 Trip let 20 Methylene adjacent 
to carboxyl 
i.e.-CH2-COOH
2.9-3.2 Broad, Trip let 20 Methylene adjacent to 
nitrogen in GAHA 
i.e. -C H 2 -N R 2
3.58 Singlet 35 Methylene of carbon 1 
in fructosyl group 
i.e. -CO-CH2-NR2
3.6-4.2 Broad,
unidentified
85 Fructosyl protons
A strong singlet at 8.6ppm exists. This is probably due to a slow exchanging 
proton on the nitrogen atoms of aminohexanoic acid.
The ratio  of proton intensity readings for the six hydrogen atoms in the 
three methylene groups of GAHA to the five hydrogen atoms in the 
frustosyl ring of the purified compound A, indicated that a m ixture of 
mono- and d i-fructosyl derivatives of glycated 6-aminohexanoic acid had 
been isolated.
Table 3.2
NMR data and structural assignments for compound B
ppm M u ltip lic ity Proton Intensity 
(arb itrary units)
Assigned Chemical 
Group
1.2-2.2 Broad,
unidentified
78 Three methylenes of 
GAHA 
i.e. -C H 2-C H 2-CH2-
2.25 Triplet 25 Methylene adjacent 
to carboxyl 
i.e.-CH2-COOH
2.9-3.2 Broad, Trip let 28 Methylene adjacent to 
• nitrogen in GAHA 
i.e. -C H 2~NR2
3.58 Broad (Weak) 13 Methylene of carbon 1 
in fructosyl group 
i.e. -CO-CH2-NR2
3.6-4.2 Broad,
unidentified
70 Fructosyl protons
As in table 3.1, a strong singlet is observed at 8.6 ppm. This is due to a 
slow exchanging proton on the nitrogen atom.
The ra tio  of proton intensity readings for the six hydrogen atoms in the 
three methylene groups of GAHA to the five hyrogen atoms in the 
fructosyl ring of the purified compound B indicated that a mono-fructosyl 
derivative of glycated 6-aminohexanoic acid had been purified.
Table 3.3
Element
Carbon
Nitrogen
Hydrogen
M icro analysis results for the 
purified monofructosyl derivative 
of 6-aminohexanoic acid 
(compound B)
Theoretical % 
49.15 
4.78 
7.84
Experimental % 
32.12 
2.28
5.06
Figures 3.2b and 3.2c show the elution profiles for the firs t and 
second fructosamine-positive peaks respectively. Both figures 3.2b and 3.2c 
show that the columns were overloaded since ferricyanide positive peaks were 
detected when the columns were washed to elute unbound material.
Purified materials A and B (see Figures 3.2b and 3.2c) were 
analysed by TLC. Figure 3.3 shows typical results obtained w ith the three 
types of spray used to develop the chromatogram. Compound B gave one spot, 
R f 0.26, that reacted w ith all three sprays. Compound A gave two spots which 
reacted w ith  all three sprays (Rf 0.15 and 0.26) and one spot which only 
reacted w ith  alkaline potassium permanganate (R f 0.42). None of these spots 
corresponded w ith  D-glucose or 6-aminohexanoic acid.
Figures 3.4a and 3.4b are the proton NMR spectra for compounds A 
and B respectively. Although both spectra appear to be sim ilar, differences 
exist in the proton intensities for each assigned chemical group. Tables 3.1 
and 3.2 present the spectra in tabular form by listing the ppm value, proton 
intensity and assigned chemical group fo r each set of peaks. The ratio  of 
proton intensities between the methylene groups in the 6-aminohexanoic acid 
and fructosyl parts of the fructosamine w ill identify  the number of fructosyl 
groups per amine molecule. Compound B is therefore the monofructosamine 
derivative, whereas compound A is the difructosamine derivative which also 
contains some impurities as shown by the TLC data.
Microchemical analysis of the monofructosamine derivative of 6- 
aminohexanoic acid gave results that did not agree w ith the theoretical values 
expected (Table 3.3). This suggested that the monofructosamine derivative 
was impure, contrary to the TLC evidence, an issue that w ill be c larified  la ter 
in the Discussion of this Chapter (Section 3.4).
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Figure 3.5. Elution profiles for the purification of glycated 4- 
aminobutyric acid, (a) from a Dowex 50W-X2 cation exchange resin w ith 
linear gradient elution over 200ml from 0.2M sodium, pH 3.0 to 0.4M sodium , 
pH 3.0. (b) Ion exchange purified glycated 4-aminobutyric acid applied to a 
Glycogel B-resin eluting w ith 23mm form ic acid. A  = alkaline ferricyanide 
test profile .
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Figure 3.6 Silica gel t.l.c . profiles for the identifica tion of glycated U- 
a m in o b u ty r ic a c id  using a 4:1:1 butanol: glacial acetic acid; water mobile 
phase. Plates (a) Ninhydrin spray; Plate (b) alkaline ferricyanide spray; Plate 
(c) alkaline potassium permanganate spray. F = purified glycated 4- 
aminobutyric acid; B = 4-amino butyric acid; G = D-glucose.
Figure 3.7 Proton NMR pro file  for glycated 4-aminobutyric acid.
Table 3.4
NMR data and structura l assignments for the glycated 
derivative of 4-ami no butyric acid
ppm M u ltip lic ity Proton Intensity 
(arb itrary units)
Assigned Chemical 
Group
1.85 Trip let 20 Methylene protons 
adjacent to 
carboxyl group 
in aminobutyric acid 
ie . R-CH2-COOHHR2
2.4 Trip let 20 Methylene protons 
adjacent to 
amino group in 
aminobutyric acid 
ie. R-CH2NHR
3.08 Triplet 20 Methylene protons 
adjacent to an ether 
group in the fructosyl 
residue 
ie. R -0-C H 2~R
3.18 Singlet 15 Methylene protons 
of the fructosyl 
residue adjacent 
to a nitrogen atom 
ie. fructosyl-C H 2NHR
3.4-4.2 Broad
Undefined
47 fructosyl protons
I The ra tio  of proton intensity readings for two hydrogen atoms in a 
methylene group of 4-aminobutyric acid to the five hydrogen atoms in the 
j fructosyl ring of the purified glycated derivative, indicated that the mono- 
fructosyl derivative of glycated 4-aminobutyric acid had been isolated.
3.3.1.2 l-Am ino-l-D eoxy-D -Fructose-4-Am inobutyric Acid
The cation exchange elution profile is shown in Figure 3.5a along 
w ith the Glycogel B elution profile in 3.5b. Unlike the profiles for glycated 6- 
aminohexanoic acid, there was only one fructosamine positive peak. Neither 
of the starting materials, D-glucose or 4-aminobutyric acid were detected in 
the elution profile .
In Figure 3.6 the TLC profile  fo r glycated 4-aminobutyric acid is
seen. One spot reacted w ith a ll three detection sprays used (Rf 0.17). This
spot did not coincide fo r those of either D-glucose or 4-aminobutyric acid. 
The TLC analysis therefore suggested a pure fructosyl derivative had been 
isolated. NMR analysis (Figure 3.7) and the spectral assignments in Table 3.4 
confirm  that this was the monofructosyl derivative of 4-aminobutyric acid.
3.3.1.3 1-Am ino-l-Deoxy-D-Fructose-L-Valine
Figures 3.8a and 3.8b are the cation exchange and Glycogel B 
elution profiles respectively fo r the fructosyl derivative of L-valine. Again, as 
was seen in Figure 3.5a fo r 4-aminobutyric acid, there was only one peak 
detected in the cation exchange profile  and no L-valine or D-glucose. 
However, to obtain this elution profile^ a lower starting pH and sodium 
concentration was necessary fo r gradient elution. The TLC analysis, as shown 
in Figure 3.9, along w ith the R f values indicated that a pure glycated product 
(Rf = 0.13) had been isolated. The NMR analysis, Figure 3.10^ and the spectral 
assignments in Table 3.5, gave further evidence that the monofructosyl
derivative of L-valine had been produced and isolated.
3.3.1.4 1-Am ino-l-Deoxy-D-Fructose-Tyram ine
For the purification of mono-fructosyl-tyram ine (1 -A m ino -l-
Deoxy-D-Fructose-Tyramine) Figure 3.11 shows the elution profiles fo r both
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Figure 3.8 Elution profiles fo r the purifica tion  of glycated L-valine (a) 
from a Dowex 50W-X2 cation exchange resin using linfear gradient elution 
over 200ml from 0.2M sodium, pH 3.0 to 0.4M sodium, pH 5.0. (b) Ion
exchange-purified glycated L-valine applied to a Glycogel B column with 
elution by 2 5 m f o r m i c  acid a fter 100ml. ^  = alkaline fericyanide test
profile .
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Figure 5.9 Silica gel t.l.c . profiles for the identifica tion of glycated L- 
valine using a 4:1:1 butanol: glacialacetic acid: water mobile phase. Plate (a) 
ninhydrin spray; Plate (b) alkaline ferricyanide spray; Plate (c) alkaline 
potassium permanganate spray. F = purified glycated L-valine, V = L-valine, 
G = D-glucose.
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Figure 3.10 Proton NMR pro file  fo r glycated L-valine.
Table 3.5
NMR data and structura l assignments the 
glycated derivative of L-valine
ppm M u ltip lic ity Proton Intensity 
(arb itrary units)
Assigned Chemical 
Group
1.1 Overlapping 
doublet w ith 
additional 
hyperfine sp litting
60 Methyl protons 
of valine 
ie. CH3-CHR2
2.25 Broad 9 Methine proton 
of valine 
ie. CH3-CHR-CH3
3.18 Singlet 16 Methylene protons 
of fructosyl group 
adjacent to 
nitrogen atom 
ie. fructosyl-C H -2NHR
3.25 Doublet 11 Methine proton 
adjacent to 
amino group in 
valine 
ie. HOOC-CHR-NH2
3.4-4.2 Broad
undefined
57 Fructosyl
protons
The ra tio  of proton intensity readings for a methine proton adjacent to the 
amino group in L-valine to the five hydrogen atoms in the fructosyl ring of 
the purified glycated derivative, indicated that a mono-frustosyl derivative 
of glycated L-valine had been isolated.
ion exchange and Glycogel B a ff in ity  chromatography. The ion exchange 
chromatography separated two compounds both able to reduce ferricyanide. 
The second compound 120 to 220 appeared to be in greater abundance 
(assuming that both compounds had equal reducing power). The firs t 
fructosamine positive peak was most like ly  the difructosyl form of tyramine. 
This assumption was based on the purification profile obtained with glycated 
6-aminohexanoic acid (see Section 3.3.1.1). The second fructosamine positive 
peak was therefore pooled and applied to a Glycogel B a ffin ity  
chromatography column as this was assumed to be the monofructosyl form.
Figure 3.12 shows the TLC analysis for glycated tyramine a fte r 
Glycogel B a ffin ity  chromatography prior to further purification by ion 
exchange and a ffin ity  chromatography. The TLC profile  a fte r fu rther 
purification of glycated tyramine is also shown. Only one spot was present for 
glycated tyramine, indicating a pure compound. NMR analysis as shown in 
Figure 3.13 and Table 3.6 confirmed that the isolated compound was the 
monofructosamine derivative of glycated tyramine.
3.3.1.5 1-Am ino-l-Deoxy-D-Fructose-Poly-L-Lysine
The fructosamine derivative of glycated poly-L-lysine was purified 
by Glycogel B a ff in ity  chromatography. Figure 3.14 shows the elution profile  
using the fructosamine test (Section 3.2.2.1) to detect fructosyl-poly-L-lysine 
of a Glycogel B a ff in ity  column. Only one fructosamine positive peak was 
seen on elution w ith elution buffer which had a slight shoulder on the leading 
edge. A f lu ffy  yellow solid was produced a fte r lyophilisation which differed 
from  the other purified compounds which were white in appearance. No NMR 
or TLC analysis was performed due to AGE also being present on the peptide 
chain, as shown by the purified yellow product.
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Figure 3.11 Elution profiles for the purification of glycated tyram ine (a) 
from a Dowex 50W-X2 cation exchange resin using a 200ml lin ia r gradient 
elution from 0.4M potassium, pH 5.0 to 0.6M potassium, pH 7.0. (b) Ion
exchange purified glycated tyramine, peak X, applied to a Glycogel B a ffin ity- 
column w ith 25mM form ic acid elution. = alkiline ferricyanide test 
profile .
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Figure 3.12 Silica gel t.l.c . pro file  for the identifica tion  of glycated 
tyramine using a 4:1:1 butanol: glacial acetic acid: water mobile phase,Plate 
(a) = Ninhydrin spray; Plate (b) = Alkaline ferricyanide spray; Plate (c) 
alkaline potassium permangate spray; M = glyated tyramine m ixture prior to 
ion exchange purification: F = purified glycated tyram ine T = tyram ine. G = 
D-glucose
Figure 3.13 Proton NMR profile  fo r glycated tyramine.
Table 3.6
NMR data-and structura l assignments for the 
glycated derivatives of tyramine
ppm M u ltip lic ity Proton Intensity 
(arb itrary units)
Assigned Chemical 
Group
3.0 Doublet 14 Methlene of 
fructosyl group 
adjacent to 
nitrogen atom 
ie. fructosyl-CH^-NHR
3.3 Diffuse
T rip le t
27 Two methylenes 
o f tyramine 
ie. phenyl-CH^-NHR
3.5-4 .2 Broad
Unidentified
38 Fructosyl
protons
6.9 Doublet 14 Phenyl protons 
ortho to hydroxyl 
group on tryram ine
7.2 Doublet 14 Phenyl protons 
ortho to alkyl 
group on tyram ine
The ra tio  of proton intensity readings for four hydrogen atoms in the two 
methylene groups of tyramine to the five hydrogen atoms in the fructosyl 
ring of the purified glycated derivative, indicated that a mono-fructosyl 
derivative of glycated tyramine had been isolated.
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Figure 3.14 Giycogel B elution profile fo r the purification of glycated 
poly-L-lysine using 25mM form ic acid fo r elution. = alkaline ferricyanide 
test profile .
3.4 DISCUSSION
Earlier workers who studied the chemistry of fructosamines, such 
as Lowry and Borsook (1956), Heynes et ah, (1959) and Finot and Mauron (1969) 
had also used cation exchange chromatography fo r the purification of these 
sugar-bearing amine derivatives. The elution conditions they used varied from 
one w ith a single concentration of eluting buffer (Heynes et al., 1959) to one 
w ith gradient elution w ith a pyridine-based buffer system (Finot and Mauron, 
1969). Unfortunately, these elution conditions were fe lt  to be inappropriate on 
the grounds of in fle x ib ility  for the form er and safety for the la tte r. In order to 
separate amino acids by cation exchange chromatography , a 
c itra te /hydrochloric acid buffer system can be used, using changes in cation 
concentration and pH to elute specific amino acids (Devenyi and Gergely, 
1974). This buffer system was therefore adapted for the elution of the 
fructosamine derivatives and found to be very effective .
In Chapter 2, a Dowex 50W-X8 cation exchange resin was used to 
obtain partia l separation of the fructosamine derivatives of 6-aminohexanoic 
acid. This separation between the mono- and difructosamine forms was 
improved by using a Dowex 50W-X2 resin. The buffer system used fo r the 
cation exchange chromatography was not volatile  and contained a lo t of salts 
which had to be removed a fte r isolation of the monofructosamine derivative. 
This was achieved using Giycogel B a ffin ity  chromatography* A new method 
for detecting fructosamines (Section 3.2.2.1) w ith  a shorter assay tim e than 
the th iobarbituric acid test, was also used and found to be specific fo r 
fructosamine as in itia lly  shown by Lowry and Borsook (1956).
The purification of glycated poly-L-lysine did not use cation 
exchange chromatography but only Giycogel B a ffin ity  chromatography. On
each glycated poly-L-lysine peptide chain, monofructosyl as well as difructosyl 
residues and AGE may be present. Glycated poly-L-lysine was therefore only 
purified from unreacted D-glucose and poly-L-lysine by Giycogel B a ffin ity  
chromatography.
NMR was used to determine the structure of the purified 
fructosamine derivatives and confirm  that the monofructosyl derivative had 
been isolated. This was particu larly  necessary in the cases of 6-aminohexanoic 
acid and tyramine where the d ifructosyl derivatives were also present.
TLC and microchemical analysis are both able to indicate purity; 
the la tte r technique being more sensitive. TLC on the other hand, can 
indicate the number of impurities that are present, provided an appropriate 
detection system is used. Microchemical analysis data for monofructosyl-6- 
aminohexanoic acid (Section 3.3.1.1) was found to disagree w ith  the 
theoretical value. However, i t  did agree w ith the microchemical analysis data 
obtained in Section 2.3.3.1 for fructosyl-6-aminohexanoic acid purified by a 
d iffe rent method. This discrepancy between the experimental and theoretical 
results is probably due to the presence of water as the material was found to 
be highly hygroscopic. It was therefore decided that microchemical analysis 
was not appropriate to determine the purity of the other fructosamine 
derivatives.
To conclude, seven fructosamine derivatives had been purified. 
However, only four compounds were monofructosamine derivatives. A f if th  
compound, glycated poly-L-lysine, could not be purified as a pure 
monofructosamine derivative due to the complexity of the chemical reaction 
constraints imposed. The other two compounds were the difructosyl
derivatives of 6-aminohexanoic and tyramine. As shown by Anet (1957), the 
difructosyl derivative of glycine degraded easily to the monofructosyl form 
and a 6-carbon sugar molecule. This could explain the th ird TLC spot (R f 0.42) 
that reacted only w ith alkaline potassium permanganage in Figure 3.3, which 
suggested that it  may be some form of sugar molecule.
CHAPTER 4
SYNTHESIS, PURIFICATION AND SOME PROPERTIES 
OF C-AMINO GLYCATED LYSYLLYSINE
4.1 INTRODUCTION
In section 1.2 it was noted that in both haemoglobin and human serum 
albumin, one of the preferentia l sites o f glycation in vivo was a lysyllysine 
peptide sequence (Shapiro et al., 1980; Iberg and Fluckiger, 1986). It has also 
been shown in v itro  that the glycation o f one of the §,-amino groups o f a lysyl 
lysine peptide, as opposed to the glycation of the £-amino group on a single 
lysine residue is greater for lysyllysine. Moreover, it  was also found that this 
glycation was phosphate-dependent (Kirkham et al., 1988). It was therefore 
decided that an £-am ino glycated lysyllysine dipeptide might be a suitable 
hapten fo r production of antibodies against in vivo glycated proteins.
To synthesise an £,-amino glycated dipeptide it is necessary to block 
the a-amino group prior to glycation and to remove the protecting groups 
afterwards. It was firs t necessary to synthesise the a-amino protected lysyl 
lysine dipeptide, since it  was not available commercially. There are two major 
forms o f peptide synthesis; liquid and solid phase. In solid phase synthesis, as 
firs t described by M errifie ld  (1964), the peptide is constructed sequentially 
whilst immobilised on a solid phase. Whereas in liquid phase synthesis^the 
peptide is constructed in solution w ithout immobilisation. Solid phase 
synthesis is mainly used when long peptide sequences are required. However, 
fo r d i- or tri-peptides liquid phase synthesis is simpler allowing peptides to be 
obtained in high yield at low cost.
The work described here discusses the liquid phase synthesis o f the 
dipeptide N-a-Boc lyslys the subsequent glycation of the£-am ino  groups and 
purifica tion of the glycated dipeptide. In addition some properties o f Boc- 
lyslys are investigated.
4.2 MATERIALS AND METHODS
4.2.1 Materials
Except solvents, all chemicals used specifically .for peptide synthesis 
were bought from Fluka Chemicals (UK). The remaining chemicals were 
purchased as described in Section 3.2.1.
4.2.2 Synthesis of N-a-tertbutoxycarbonyl-lysyllysine
Boc-lys (Z)-DCA, 3.04g (5.41 mmoles),was dissolved in ethyl acetate 
to give a 10% (w/v) solution in a separating funnel. An equal volume of 10% 
(w/v) c itr ic  acid was added and shaken. The aqueous phase was drained o ff and 
retained, the organic phase being transferred to a conical flask. The aqueous 
phase was back washed tw ice w ith small volumes o f ethyl acetate and a ll the 
organic phase washings pooled. The pooled organic phase was then washed 
w ith  75ml o f d istilled water, followed by 20ml saturated sodium chloride 
solution. The organic phase was collected and 2g dry magnesium sulphate 
added. A fte r 1 hour of in te rm itten t shaking,the magnesium sulphate was 
removed by vacuum filtra tio n  and the ethyl acetate was removed by rotary 
evaporation. The yield o f Boc-lys (Z)-OH was noted. Samples of the aqueous 
and organic phase washing were examined by TLC using 9:1 
chloroform/methanol solvent system on plastic backed, UV254nm sensitive 
silica gel TLC plates (Merck).
1-Hydroxy-benzotriazole 0.83g (5.41mmoles) was added to the
prepared Boc-lys (Z)-OH syrup, the m ixture was dissolved in the minimum
volume of dimethyl formamide and the solution cooled in an ice bath to 0 °C . 
Dicyclohexylcarbodimide 1.12g (5.41mmoles) was dissolved in the minimum 
volume of dimethyl formamide and added to the Boc-lys (Z)-OH solution and 
stirred fo r 1 hour at 0°C , followed by a further 1 hour at room temperature. 
The preparation of activated Boc-lys (Z)-OH was checked using TLC w ith  a 9:1 
chloroform/methanol solvent solution as previously described.
Lys(Z)-OBzl.HCl 2g (4.92mmoles) was dissolved in dimethyl 
formamide w ith  gentle stirring. Then 0.85ml (4.92mmoles) of 
diisopropylethylamine was added. The pH was checked and i f  it  was not pH9.5 
a few more drops of diisopropylethylamine were added. A TLC spot of the 
m ixture was examined by TLC.
The diisopropylethylaminerdimethyiformamide m ixture was slowly 
added in a dropwise fashion w ith gentle stirring to the activated Boc-lys (Z)- 
OH solution and the m ixture le ft fo r approximately 1 hour at room 
temperature. Another TLC spot was taken and the spots were run on the same 
mobile and solid phases mentioned above. The TLC plate was studied under 
UV light and then developed w ith  ninhydrin. If the m ixture had not a ll 
reacted, another 1.12g dicyclohexylcarbodimide was added and the mixture 
was le ft to react at 4°C overnight. The TLC assessment was repeated un til a ll 
the lys (Z)-O Bzl had reacted.
Dicyclohexylurea was filte red  o ff under vacuum and washed w ith  a 
l it t le  dimethylformamide. The filtra te  was then rotary evaporated at 35°C to 
remove the dimethylformamide. The residual syrup was dissolved in ethyl 
acetate and transferred to a separating funnel. The organic phase was washed 
in the following sequence: 5% (w/v) sodium bicarbonate solution (tw ice) and 
the aqueous phase back washed tw ice w ith ethylacetate. The pooled organic 
phase was continued through the washing cycle w ith water, saturated sodium 
chloride, 10% (w/v) c itr ic  acid, water and fina lly  saturated sodium chloride. 
A ll the aqueous washings were pooled, except the c itr ic  acid washings. The 
organic phase was dried w ith  2g dry magnesium sulphate and le ft fo r 1 hour. 
The magnesium sulphate was removed as before and the ethyl acetate removed 
by rotary evaporation. TLC spots o f the two aqueous washing phases and the 
organic phase were run as described previously.
The remaining residue was dissolved in acetone and le ft overnight at 
4°C to precip itate any remaining dicyclohexylurea. Any precipitate was 
filte red  o ff and the acetone removed by rotary evaporation. The residue was 
dissolved in a small amount of ethylacetate and then the Boc-lys (Z) lys (Z)-0 
Bzl was precipitated with petroleum ether (60-80°C). The final ra tio  of ethyl 
acetate:petroleum ether was about 30:70. A fte r leaving for two days, the 
precipitate was filte red  o ff under vacuum and then washed three times w ith 
30:70 ethylacetate:petroleum ether. The precipitate was weighed and the 
percentage yield calculated.
Boc-lys (Z) lys (Z)-0 Bzl lg  (1.37 mmoles) was transferred to a 50ml 
round bottomed flask and dissolved in a small volume o f glacial acetic acid, 
before being made 75% (v/v) w ith distilled water. Nitrogen was bubbled 
through the m ixture to  remove any oxygen. Then lOOmg of palladium catalyst 
(10%) on activated charcoal was added and mixed thoroughly while more 
nitrogen was passed through. Hydrogen gas was very gently bubbled through 
the m ixture at room temperature overnight w ith magnetic stirring.
On disconnecting the apparatus, nitrogen was bubbled through the 
m ixture fo r 10 minutes to remove any residual hydrogen. The m ixture was 
filte red  into a clean 50ml round bottomed flask through two f i l te r  papers 
presoaked in 25% (v/v) acetic acid to remove the catalyst. The f i l te r  papers 
were washed twice w ith  25% (v/v) acetic acid. Acetic acid was then removed 
from the filtra te  by rotary evaporation fo r 2 hours at 25°C. A TLC spot of 
the filtra te  was taken and run against Boc-lys (Z) lys (Z)-0 Bzl in the solvent 
system mentioned previously.
Approximately 20ml of ether were added to the oily residue and le ft 
fo r 1.5 hours w ith  in te rm itten t gentle shaking. The ether was poured o f f  and
fresh ether (approximately 20ml) added, a fte r which the m ixture was 
tritu ra ted  to precipitate the product. Again the ether was poured o ff, 
replaced w ith fresh ether and the tritu ra tio n  continued. The ether was fina lly  
removed and the product Boc-lyslys, dried in a descdcator over potassium 
hydroxide pellets for about two days. The yield of product was noted. I f  any 
acetic acid s till remained, the product was dissolved in a small volume of 
water and lyophilised.
4.2.3 Synthesis and Purification of £ -Amino Glycated Lysyllysine
The tim e course o f glycation of Boc-lyslys was studied to maximise 
the yield o f fructosyl lysyllysine. 50mg (0.14 mmoles) of Boc-lys\ys were 
refluxed w ith  126mg (0.70 mmoles) D-glucose in 25ml methanol at 70°C in a 
water bath. A t specified times, 50yl samples were taken out and assayed for 
fructosamine by the ferricyanide test. In addition, samples were also spotted 
onto a 20 x 20cm silica gel TLC plate and the plate run in a butanol/glacial 
acetic acid/water (4:1:1) solvent system.
A fte r glycation, the solution was ro tary evaporated to remove 
methanol. The resulting residue was dissolved in buffer A (see Section 3.2.4.1) 
and applied to a small Dowex 50W-X2 cationic exchange column (1 x 21cm). 
The column was then washed w ith  70ml o f buffer B (see section 3.2.4.1) before 
elution with a linear gradient of increasing buffer C (see Section 3.2.4.1) over 
200ml at a flow  rate o f 0.7ml/min. 2ml fractions were collected and assayed 
for fructosyl Boc-lyslys by the ferricyanide test (see Section 3.2.2.1). In 
addition, TLC analysis on 20 x 20cm silica gel plates for the eluted 
fructosamine peaks was carried out. The detection sprays used were 
ninhydrin, alkaline ferricyanide and alkaline potassium permanganate.
The identified fructosamine derivatives o f Boc-lyslys were separately 
pooled and concentrated by rotary evaporation at 40°C until a thick residue 
remained. Trifluoroacetic acid (approximately 5ml) was added to the residue 
and le ft fo r 15 minutes w ith gentle stirring to remove the tertbutoxycarbonyl 
protecting group on the a-term ina l amino group of lysyllysine. The 
trifluo roace tic  acid was removed by rotary evaporation and the residue re- 
dissolved in 25mM sodium phosphate buffer, pH9.0. The pH was checked and 
adjusted to pH9.0 w ith a few drops of 5M sodium hydroxide. This solution was 
then applied to a boronate a ffin ity  column (V^ = 50ml, 1.8 x 25cm), pre­
equilibrated w ith  25mM sodium phosphate buffer, pH9.0. Fractions (2ml) were 
collected at a flow rate of 0.8ml/m in. A fte r the sample had been applied, the 
column was washed w ith  100ml 25mM sodium phosphate pH9.0 before elution 
of bound glycated material w ith 25mM form ic acid. The fractions containing glycated 
lysyllysine were identified using the ferricyanide test, pooled and lyophilised.
TLC analysis and NMR were used to characterise the purified m aterial (see 
Section 3.2.4).
4.2.4. The rates of glycation of N-oC-tertbutoxycarbonyllysyllysine and N-a-tertbutoxy 
carbonyllysine in the presence of inorganic and organic phosphate
4.2.4.1 The fructosamine assay for the measurement of glycated peptide
The assay was automated on a Roche Cobas Bio. N itroblue 
tetrazoline (NBT) reagent was prepared as follows. To 0.1 M sodium carbonate 
buffer pH 10.35, nitroblue tetrazolium  solid was added (0.2% w/v), the reagent 
being stored at 4°C in a dark bottle when not in use. Three standards were 
prepared consisting of 0, 0.5 and 2mM l-am ino-l-deoxy-D -fructose-6- 
fructose-aminohexanoic acid in distilled water. The analyser was then 
programmed w ith the follow ing parameters:-
1 . Units mMol/1
2 Calculation factor 0
3 Standard 1 conc. 0
4 Standard 2 conc. 0.5
3 Standard 3 conc. 2
6 L im it 2
7 Temperature (Deg c) 37.0
8 Type of analysis 5
9 Wavelength (nm) 530
10 Sample volume (yl) 20
11 Diluent volume (yil) 50
12 Reagent volume (yl) 200
13 Incubation tim e (sec) 0
14 Start reagent volume (yil) 0
15 Time of f irs t reading(sec) 600.0
16 Time intervals (sec) 300
17 Number of readings 02
18 Blanking mode 1
19 Printout mode 1
A prin tout of sample concentration in mmol/1 was obtained when the 
assay was finished.
4.2.4.2. Rate of glycation w ith inorganic phosphate
A series of reaction mixtures were set up containing 400ymoles of D- 
glucose and either 40ymoles of Boc-lyslys or Boc-lysine in 5ml of 10,100 and 
200 mM sodium phosphate buffer at pH 7.4. In addition, a reaction m ixture 
containing 40 ymoles of Boc-lyslys and 400 pmoles D-glucose in 200 mM 
TAPSO at pH 7.4 was included. The reaction mixtures were maintained at 
75°C in a water bath. A t specific time intervals o f 0, 30, 60, 90, 120, 180, 
240, 300 and 360 minutes during glycation, 0.2 ml samples were removed and 
the amount o f fructosamine was determined by using the ferricyam ide assay 
outlined in section 3.2.2.1. The experiment was repeated three times and the 
mean values of fructosamine present plotted against time. The rate of 
glycation was determined from the slope of the graph once the reaction had 
reached a steady state. Linear regression analysis was used to calculate the 
slope along w ith the standard error of the slope. These results were then 
analysed by the Student t-test.
4.2.4.3. Rate of glycation with organic phosphate
The following reaction mixtures were set up and le ft to glycate at
73°C in a water bath. Into capped bottles, 5ml of lOOmM TAPSO pH 7.4 was
added containing 400ymoles D-glucose and either 40ymoles Boc-lysine or Boc- 
lyslys. In addition 0, 5, 10 or 25 mM 2,3 diphosphoglycerate was present in the 
glycating m ixture. At specified time intervals outlined in section 4.2.4.2. 
0.1ml samples were taken and assayed by the fructosamine assay (see section 
4.2.4.1.) to determine fructosamine content. The experiment was repeated 
three times and the mean values o f fructosamine present were plotted against 
time. The rates o f glycation were determined by linear regresssion analysis to 
calculate the slope and the standard error o f the slope. These results were 
then analysed by Student t- te s t fo r significance.
4.3 RESULTS
4.3.1 TLC Data Analysis for the Synthesis of N-a-tertbutoxycarbonyl
Lysyllysine
Figure 4.1 shows the results of four separate TLC plates, all run in a
9:1 chloroform/methanol solvent system. Plate I contains two tracks, the
aqueous phase, Track A and the organic phase, Track B. Track A contains no 
detected spots whereas Track B has a ninhydrin positive spot at R f 0.52.
Three tracks are present in Plate II. . Tracks A, B and C,
corresponding to the lys (Z)-0 Bzl, the activated Boc Lys (Z)-OH and the
dipeptide m ixture respectively. Track A has only one ninhydrin positive spot 
at R f 0.57 and a UV positive spot also at R f 0.57 identifying this spot as lys(Z)- 
O Bzl. Track B, on the other hand, has two spots both of which are UV 
positive at R f 0.26 and 0.75 and one ninhydrin positive spot at R f 0.75. The 
spot at Rf 0.75 belongs to the activated Boc lys (Z)-OH and the other spot at 
R f 0.26 belonging to dicyclohexylcarbodiimide. In Track C, two spots are
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Figure 4.1 Silica gel t.l.c . profiles fo r the preparation of N -a- 
tertbutoxycarbonyl lysyllysine using a 9.1 chloroform: methanol solvent 
system. Plate I: A = aqueous phase, B = organic phase; Plate II, A = 
lys(Z)0Bzl m ixture, B = activate Boc lys(z) -OH, C = Dipeptide reaction 
m ixture; Plate III, A = c itra te  washings, B = water washings, C = organic 
phase; Plate IV, A = before hydrogenation, B = A fte r 'dehydroqenation. @  = 
Ninhydrin and UV254nm positive, = Ninhydrin positive, (|p = UV254nm 
sensitive.
again present. Both spots are UV positive at Rf 0.21 and 0.69 and one spot is 
ninhydrin positive at Rf 0.21. The spot at R f 0.21 corresponds to 
dicyclohexylurea whereas the other spot at Rf 0.69 is the blocked dipeptide, 
Boc-lys (Z) lys (Z)-0 Bzl.
Plate III also contains three tracks, A, B and C, corresponding to the 
c itr ic  acid, aqueous phase and organic phase washings during the working up of 
the dipeptide. Track A contains no spots, whereas Tracks B and C contain one 
spot each at R f 0.08 and 0.68 respectively. Both spots are UV and ninhydrin 
positive. The spot in Track B was identified as dicyclohexylurea and the spot 
in Track C as the blocked dipeptide.
Finally, Plate IV contains TLC tracks before and a fte r hydrogenation 
o f the blocked dipeptide being assigned as Tracks A and B respectively. Both 
tracks contain only one spot. However, Track A has both a UV and ninhydrin 
positive
R f 0.4 corresponding to the unblocked dipeptide, N -a- 
tertbutoxycarbonyllysylysine.
4.3.2 Time Course of Glycation of Lysyllysine
Figure 4.2 shows a time course for the glycation of Boc-lyslys. The 
production of fructosamine is seen to be linear up to about 100 minutes when 
it  starts to level out, and maximum yield appears to be obtained a fte r 180 
minutes. The methanolic reaction m ixture was seen to go brown a fte r 100 
minutes, -but no further deepening in colour intensity was observed. TLC 
(Figure 4.3) of the reaction m ixture at specified time intervals showed that a ll 
Boc-lyslys had reacted a fte r 180 minutes, as indicated by a negative ninhydrin 
positive stain. In addition, TLC showed that the amount of fructosamine 
produced increased w ith time, but i t  could not separate adequately the 
d iffe rent glycated adducts.
indicative of blocked peptide 
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Figure 4.2 Time course for the glycation of Boc lyslys w ith D-glucose. 
Fructosamine content was analysed by the alkaline ferricyanide test.
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Figure 4.3 Silica gel t.l.c . profiles of sample aliquots during the glycation 
of Boc lyslys. Plate (a) = Ferricyanide spray; Plate (b), ninhydrin spray,
^  = alkaline potassium permanganate spray.
4.3.3 P urifica tion  o f Glycated Lysyllysine
A fte r refiuxing fo r 180 minutes, the glycated mixture was separated 
on a small Dowex 50W-X2 cationic exchange column (1 x 21cm). This gave a 
complicated elution profile  (Figure 4.4a). There is a central main peak at 
approximately 145mi a fte r commencement o f gradient elution. On either side 
of this peak are shoulders, one at 110-135ml and the other at 160-200ml. This 
suggests the presence o f three types o f glycated adduct for Boc-lyslys.
TLC was carried out on each of these possible glycated adducts at 
elution volumes: 114, 120, 126, 138, 144, 130, 160, 166 and 172ml so as to try  
and determine what each glycated adduct might be. Figure 4.3 shows this TLC 
profile . Except for the last two samples, Vg 166 and 172ml, a ll the other 
samples gave two spots of R f 0.1 and 0.27 when sprayed w ith alkaline 
ferricyanide for fructosamine. Samples Vg 166 and 172ml gave only one spot 
at R f 0.27. When sprayed w ith ninhydrin, only samples Vg 138 and 172ml 
reacted. Samples Vg 138 and 166ml were positive w ith ninhydrin in increasing 
intensity at R f 0.1 and 0.27 more so for the spot w ith R f 0.1. Again, Vg 166 
and 172ml gave only one spot at R f 0.27. These results indicate that the f irs t 
shoulder (corresponding to samples Vg 114, 120 and 126ml on TLC) was a 
completely glycated Boc-lyslys compound w ithout free £ -amino groups 
present. The main peak (samples Vg 138, 144, 150 on TLC) could be mainly a 
d ifructosyl derivative on an £-amino group along w ith  contaminants from  both 
shoulders. Samples Vg 160, 166 and 172ml on TLC corresponding to the second 
shoulder could be the monofructosyl derivative o f glycated Boc-lyslys.
As was seen with glycated 6-aminohexanoic acid (section 3.3.1.1) the 
monofructosyl derivative eluted last on the ion exchange column. It  was 
therefore decided to pool Vg 144 to 200ml. The pooled m aterial was 
concentrated by rotary evaporation at 40°C. The heating process served an
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Figure 4.4. Elution profiles for the purification of glycated lysyl lysine, 
(a) from a Dowex 50W-X2 cation exchange resin using linear graient elution 
from 0.2M sodium, pH 3.0 to 0.4M sodium, pH 3.0 over 200ml, (b) from  a 
Giycogel B column using elution with 23mm form ic acid. A  = alkaline 
ferricyanide test.
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Figure 4.5 Silica gel t.l.c . profiles fo r the identifica tion  of fructosyl-Boc 
lysiys aliquots purified by ion-exchange chromatography on Dowex 50W-X2 
cation exchange resin. Plate (a) = alkine ferricyanide spray. Plate (b), ^  = 
alkaline potassium permanganate spray, ( ^  = ninhydrin spray. F = D- 
fructose, B = Boclysiys, G = D-glucose.
additional purpose besides speeding up the evaporation of solvent. As the 
d ifructosyl derivative may not be stable above 37°C and some might be 
present, then the heat may degrade this back to the monofructosyl form as 
proposed by Anet (1959) w ith difructosyl glycine. This should increase the 
yield o f the monofructosamine form isolated and reduce the contamination. 
Figure 4.4b shows the elution profile  of this pooled material from a Giycogel B 
a ffin ity  column. The elution was only monitored w ith the ferricyanide test. 
A fte r elution of bound material w ith  25mM form ic acid, two peaks can be 
seen. The firs t peak, compound C, is large in intensity and the second, 
compound D, very weak. Both peaks were pooled separately. To try  and 
further characterise these two peaks, NMR analysis was carried out. Tables
4.1 and 4.2 correspond to the NMR spectra of Figures 4.6a and 4.6b for 
compounds C and D respectively.
From the ratio of proton intensities shown in the data in Table 4.1 
this suggests compound C contained 2.6 fructosyl residues per lysyllysine 
molecule. It is therefore postulated that this compound could be a t r i -  
fructosyl derivative of glycated lysyllysine w ith some difructosyl derivative 
present. It was also noted that this material had a d istinct yellow colour 
suggesting the presence o f impurities, but not in su ffic ien t quantity to be 
detected by NMR.
In Table 4.2, fo r compound D the data indicated that there were two 
fructosyl groups per lysyllysine molecule, that is, the difructosyl derivative of 
glycated lysyllysine. In addition, the material appeared white in colour.
(a)
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Figure 4.6 Proton NMR spectra fo r (a) compound C and (b) compound D.
Table 4.1.
NMR data and structural assignments for compound C
ppm M u ltip lic ity Proton Intensity 
(arb itrary units)
Assigned Chemical 
Group
1.2-2.2 Broad,
unidentified
41 Three methylenes of 
of lysine 
i.e. -CH2-CH2-CH2-
2.9-3.2 Broad,
undefined
14 Methylene adjacent 
to nitrogen in lysine 
i.e. Rf-CH2-N R2
3.3 Singlet 10 Methylene of 
fructosyl group 
on carbon 1 
i.e. fructosyl -C H 2>NR2
3.5-4.2 Broad 113 Fructosyl protons
i) There should be a tr ip le t at 3.7 and 4.8 ppm. However, the solvent peak and 
fructosyl peak both mask these trip le ts . In addition, both trip le ts  would be 
very weak as only one proton is involved. This has been taken into account 
when determining proton intensities for the fructosyl group.
ii) Another peak was visible at 8.5 ppm downfield. This is probably due to a 
slow exchanging proton from one of the nitrogen atoms.
The ratio  of proton intensity readings for the twelve hydrgen atoms of the 
methylene groups of lysyllysine to the two hydrogen atoms of the 
methylene in the fructosyl group of the purified compound C, indicated 
that a m ixture of di- and tri-fructosy l derivatives of glycated lysyllysine 
had been isolated.
Table 4.2
NMR data and structura l assignments for compound D
ppm M u ltip lic ity Proton Intensity 
(arb itrary units)
Assigned Chemical 
Group
1.2-2.2 Broad
unidentified
75 Three methylenes of 
of lysine 
i.e. -C H 2-C H 2-C H 2-
2.9-3.2 Broad,
undefined
27 Methylene adjacent 
to nitrogen in lysine 
i.e. R '-CH2-NR2
3.3 Singlet 20 Methylene of 
fructosyl group 
on carbon 1 
i.e. fructosyl -C H 2-NR2
3.6-4.2 Broad 70 Fructosyl protons
i) . There should be a tr ip le t at 3.7 and 4.8 ppm. However, the solvent peak and
fructosyl peak both mask these trip le ts. In addition, both trip le ts  would be 
very weak as only one proton is involved. This has been taken into account 
when determining proton intensities fo r the fructosyl group.
ii) Another peak was visible at 8.3 ppm downfield. This is probably due to a 
slow exchanging proton from  one of the nitrogen atoms.
The ra tio  of proton intensity readings for the twelve hydrogen atoms of the 
methylene groups of lysyllysine to the five hydrogen atoms in the fructosyl 
ring of the purified compound D, indicated that a di-fructosyl derivative of 
glycated lysyllysine had been isolated.
4.3.4. The effect of phosphate and2,3 diphosphoqlycerate on the rates 
of glycation of N-a-tertbutoxycarbonyllysine and Na -tertbutoxycarbonyllysyllysine
4.3.4.1 The determination of the extinction coe ffic ien t for the ferricyanide test 
From a series of known concentration DMF standards(0, 0.2, 0.4, 0.6,
0.8 and l.Omg/ml) 0.1 ml duplicate samples were assayed by the ferricyanide 
assay (see section 3.2.2.1). A graph of DMF concentration against absorbance 
at 690nm was then plotted so as to determine the extinction coe ffic ien t fo r 
this assay (figure 4.7). The extinction coeffic ien t was therefore found to be 
2.571 x 10^ M~^ cm’ ^.
4.3.4.2 With inorganic phosphate
Figures 4.8a, b and c show the increase in fructosamine (nmoles)
against tim e as glycation proceeded. The extinction coeffic ient determined in
-Vo
section 4.3.4.1. was usedjcalculate the amount fructosamine present at each 
tim e intervals from the absorbance values at 690 nm. For 10, 100 and 200 mM 
phosphate the rates of glycation of Boc-lysine were 154 + 8, 234 + 8 and 332 +
10 pmol/min respectively. In 200mM TAPSO the rate o f glycation of Boc- 
lyslys was 42 + 8 pmol/min. The rate results for Boc-lysine at each phosphate 
concentration were significantly d iffe rent from each other (P<0.01 w ith  6 
degrees of freedom). A sim ilar case was also present fo r the rate results for 
Boc-lyslys.
4.3.4.3. With 2,3-diphosphoglycerate
Figures 4.9a and 4.9b showed the increase in fructosamine against
time when Boc-lysine and Boc-lyslys were glycated respectively in 200mM
TAPSO buffer w ith varying concentrations of'2,3-diphoshoglycerate. For Boc-
lysine, the rates of glycation (mean of slopes + standard error) in lOOmM
2,3-DPG
TAPSO and w ith the addition of 5, 10 and 25 mMlwere 68 + 3, 94 + 3, 229 + 7
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Figure 4.7. Standard curve for dimorpholino D-fructose concentration 
against absorbance at 690nm for the fructosamine assay.
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Figure 4.8 (a) The e ffect of phosphate on the glycation of Boc lysine; (b)
the e ffect of phosphate on the glycation of Boc lyslys; (c) the glycation of 
Boc lyslys in water, and 20GmM TAPSO buffer pH 7.4 (n = 3 w ith  SEM bars). 
Error bars are only shown i f  greater than the point markers. For graphs 
(a)and (b); A  = 10mM, □ = lOOmM, •  = 200mM phosphate. For graph (c);
A  = 200mM TAPSO buffer pH 7.4, □  = water.
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Figure 4.9 The e ffec t of DPG concentration on the rate of g lycation of
(a) Boc lysine and (b) Boc lyslys (n = 3 w ith  SEM bars).
Error bars are only shown i f  greater than the point markers.
A = 3mM, □ = lOmM, + = 23mM 2,3-DPG
and 708 + 24 pm oles/m inute respective ly.
Additionally, fo r Boc-lyslys the corresponding 
rates o f glycation were 86 + 3, 202 + 6, 334 + 3 and 843 + 35 pmol/min. For 
Boc-lysine, the results for the rate of glycation at d iffe rent 1,3- 
diphosphoglycerate concentrations were significantly d iffe rent from each 
other (P<0.01 w ith 6 degrees of freedom). Similar levels o f significance were 
also found for the rate result using Boc-lyslys.
4.4 DISCUSSION
Figure 4.2, showed that the production of fructosyl-lysyllysine bega n 
to level o ff at 180 minutes reaction time. This time period of glycation was 
therefore chosen fo r the synthesis of glycated lysyllysine. However, this time 
period gave a complicated elution profile  from  cation exchange . 
chromatography. The profile  (figure 4.4a) indicated the presence of possibly 
four d iffe ren t fructosamine derivatives (ie. mono di-, tr i- ,  and te tra  
fructosamine) o f lysyllysine. The isolated fractions were further purified by 
a ffin ity  chromatography on Glycogel B. The result indicated, from NMR 
analysis, that there was a difructosamine and trifructosam ine derivative 
present. However, i t  was not possible to te ll whether the difructosamine 
derivative of glycated lysyllysine contained only one fructosamine adduct on 
the £,-amino group o f each lysine. It may be that the original synthesis 
conditions were biased too heavily in favour o f fructosamine production and 
possibly a 1:1.1 molar ratio  of Boc-lyslys to D-glucose should have to be used 
in the glycation process, as opposed to the 1:5 molar ra tio  actually used. This 
suggested set o f reaction conditions asumes that the primary amine is more 
reactive than the secondary amine for the production of fructosamine 
derivatives, hence leading to an increased yield in the amount of 
monofructosamine derivative.
As only a small amount of Boc-lyslys was available it was decided not 
to repeat the process, but use the purified d ifructosyl derivative of lysyllysine 
as the hapten for the production of antibodies to glycated proteins. Indeed, as 
a population of antibodies w ith varying degress of specific ity  and avid ity w ill 
be produced against the hapten, it  may be possible to isolate a particular 
population of antibodies that recognise the monofructosyl derivative of a 
glycated t -amino group of lysine. This could be accomplished by absorbing out 
the required antibodies on an a ffin ity  column using immobilised fructosyl-6- 
aminohexanoic acid as the a ffin ity  ligand.
Another problem which was not foreseen in itia lly , was that the 
method of synthesis o f glycated lysyllysine was too simple because both lysyl 
side chains could be glycated on the ir E-amino groups. In vivo, only one lysine 
residue is glycated in the lysyllysine peptide sequence (Shapiro et al., 1980, 
Garlick and Mazer, 1983; and Iberg and Fluckiger, 1986). To overcome th is 
problem, i t  would be necessary to synthesise a lysyllysine dipeptide w ith  the 
£  -amino group and the a-amino group on the N-term inal lysine residue 
blocked w ith a tertbutoxycarbonyl group. This new dipeptide could then be 
glycated and the monofructosyl derivative purified before removing the 
tertbutoxycarbonyl protecting groups.
Although, the rate of glycation of e ither Boc-lysine or Boc-lyslys are 
s ignificantly d iffe ren t at the 1% level when comparing the rates of glycation 
of either amine as inorganic phosphate or2,3-diphophoglycerate concentration 
increases, this is not the case when comparing the rates o f glycation of Boc- 
lysine to Boc-lyslys at varying inorganic or organic phosphate concentrations. 
A t 100 and 200 mM phosphate concentrations the rates o f glycation of Boc- 
lysine and Boc-lyslys are s ignificantly different (P<0.01 w ith  6 degrees of 
freedom). However, w ith lOmM phosphate
the corresponding rates of glycation between Boc-lysine and Boc- 
lyslys were only significantly d iffe rent at the 10% level (P<0.1 w ith  6 degrees 
of freedom).
Watkins et al., (1987) postulated that phosphate may have a ca ta lytic  
e ffect on the glycation of proteins both in vivo and in v itro . This catalysis was 
believed to be brought about by the binding of the anion (such as phosphate) to 
a cationic microenvironment on the protein surface which was in close 
proxim ity to the site of glycation. This cationic microenvironment could be 
the zw itte rion  form o f the £-amino group of an adjacent lysine residue to tha t 
lysine residue which is preferentia lly  glycated in proteins (Shapiro et al., 1980 
and Garlick and Mazer, 1983). The in v itro  data presented here for the 
glycation of a lysine residue and a lysyllysine peptide clearly showed that 
as the inorganic phosphate concentration was increased there was a marked 
increase in the rate of glycation of lysyllysine as opposed to lysine, although 
the rate o f glycation of lysine was also increased as the inorganic phosphate 
concentration was increased. A probable mechanism for the catalysis o f this 
glycation reaction is illustrated in figure 4.10. B riefly, the phosphate 
interacts w ith  the protonated E-amino group of one lysine and the charged 
imino group o f the Schiff base in the adjacent lysyl residue. The resultant close 
proxim ity of the phosphate to the aldimine form o f the glycated lysyl residue 
allows the phosphate to catalyse the rearrangement of the aldimine to the 
ketosamine derivative. This intramolecular catalysis is apparently more 
e ffective  than intermolecular catalysis that could occur between two 
molecules o f Boc-lysine. By using computer graphics it  was possible to ve rify  
that phosphate bound to the E-amino group of one lysyl residue was indeed 
close enough to allow molecular interaction w ith the aldimine on the adjacent 
lysyl residue in the dipeptide Boc-lyslys (figure 4.11).
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Figure 4.10 A possible mechanism fo r the e ffec t of phosphate on the 
giycation o f Boc lysyllysine.
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Figure 4.11 A computer graphics diagram of the interaction of phosphate 
with the aldimine form of glycated Boc lysyllysine.
The e ffec t of 2,3-diphophoglycerate on the rates o f glycation of Boc- 
lysine and Boc-lyslys was sim ilar to the e ffec t that phosphate had. However, 
there was one difference in that the increase in the rate of glycation of Boc- 
lysine appeared to be very sim ilar to that for Boc-lyslys as 
diphosphoglycerate concentration was increased. Although, this increase in 
the rate of glycation was found to be sign ificantly higher (P<0.02 w ith  6 
degrees of freedom) by 19% for Boc-lyslys over Boc-lysine at a 25mM 2.,3- 
diphosphoglycerate concentration. This increase was not as pronounced as 
that fo r 200 mM or lOOmM phosphate. Moreover, the increase in the rate of 
glycation of Boc-lysine asQ.,3-diphosphoglycerate concentration increased was 
greater than that when phosphate was used. However, no true correlation can 
be made between the two sets of data for the e ffec t of phosphate and Q.,3- 
diphosphoglycerate as no correlation analysis was performed between the two 
types of assay used to measure glycation. Therefore, the data can not be 
considered as a whole. The results for the e ffec t o f 2,3-diphosphoglycerate, 
however, do give some evidence that the mechanism proposed fo r the action of 
phosphate on Boc-lysine and Boc-lyslys may s till hold true when 3.,3- 
diphosphoglycerate was used.
CHAPTER 5
THE PREPARATION OF HAPTEN-PROTEIN CONJUGATES 
AND GLYCATED PROTEINS
5.1 INTRODUCTION
An immunogen is a substance that when administered to a vertebrate 
hostjw ill result in an immune response against it .  Proteins and large complex 
polysaccharides are good immunogens. However, small peptides, around 3000 
daltons in molecular weight, are themselves only weakly immunogenic. 
Molecules o f less than 2000 daltons are not immunogenic; these molecules are 
referred to as 'haptens'.
Haptenic molecules, as well as the small peptides, can become 
immunogenic by covalent attachment to a larger protein molecule. This 
process is called conjugation and the protein molecule is referred to as the 
'carrier protein'. When conjugating a hapten to a carrie r protein, the resultant 
antibody specific ity to the hapten a fte r immunisation with the conjugate w ill 
depend on how the hapten was conjugated. This is illustrated by 'LandsteinerV 
Principle' (1945) which stated that antibody specific ity  is directed against tha t 
part o f the hapten furthest from the site o f conjugation to the carrier protein. 
However, it  is known that antibody specific ity  can also recognise the chemical 
link used to covalently attach the hapten to the carrie r protein. This is 
termed 'bridge recognition' (Gilby and Jeffcoate, 1973).
To decide on which conjugation method to use it is necessary to take 
into account two factors:
(i) Landsteiners Principle - which part of the hapten is antibody
specific ity to be directed against.
(ii) Which functional group(s) should be used for conjugation. I f
necessary, an analogue o f the hapten can be used which contains an
appropriate reactive group at that part o f the hapten structure to be
conjugated to the carrier protein.
Table 5.1
Conjugation methods for the crosslinkinq of 
various organic functional groups
Method Functional groups 
involved
Reference
(i) Carbodiimide R-COOH + NH2-R’ Goodfriend et al 
(1964)
( ii)  Mixed Anhydride R-COOH + NH2-R' Erl anger et al 
(1957)
( ii i)  • Glutaraldehyde r -n h 2 + NH2-R' Reichlin et al 
(1968)
(iv) Di'azotisation r - n h 2 + H O -^ R ' Kawashima et al 
(1979)
(v) Periodate
OH OH 
I i
R-NH2 + R'- CH CH-R' Wilson and 
Nakane (1978)
(v i) Mannich Reaction R-NH2/R 2NH
+ ’Active'nydrogen
Ranadive and 
and Sehon (1967)
(v ii) Disuccinimidyl
carbonate method
R-COOH + NH2-R' Sauer and Morris 
(1987)
Several conjugation methods are available for covalently linking two 
functional groups to each other (see Table 5.1). Methods (i) and (ii) result in 
the formation of a peptide (or amide) bond between the hapten and carrier 
protein. The major difference between these two methods is the specific ity  
of reaction. With the carbodiimide method any primary amino group and any 
carboxyl group w ill react to form a peptide bond. Therefore, as well as 
conjugating hapten to carrier protein, the carrier protein molecules 
themselves may also cross-react resulting in a large polymerised protein mass. 
Figure 5.1 shows the possible reaction mechanism for the carbodiimide method 
o f conjugation. Method (ii), however, is a two stage process, beginning w ith  
the formation of the mixed anhydride derivative of the carboxyl group which is 
then hydrolysed to form  a reactive intermediate. This then condenses w ith  the 
amino groups on the carrier protein (Figure 5.2). Method (ii), however, only 
results in peptide bond formation between the hapten and carrier protein and 
therefore does not result in a , ' /weakly immunogenic, insoluble protein
mass as in method (i).
The glutaraldehyde method, Table 5.1 method (iii), relies on 
covalently linking two primary amine groups together via a five-carbon spacer 
group (figure 5.3). This reaction has a number o f disadvantages: (i) the 
reaction is reversible and therefore the product can revert back to the starting 
reactants in acid conditions, (ii) the reaction lacks specific ity and hapten 
dimers as well as protein dimers and polymers are produced along w ith  the 
hapten-protein conjugate.
The diazotisation method of conjugation, Table 5.1 method (iv), needs 
a free primary amino group on the hapten. This method specifically attaches 
hapten to protein because the method is a two-step procedure consisting
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Figure 3.1 The carbodiimide reaction. Based on the mechanism of 
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Figure 5.3 The mechanfrn fo r the glutaraldehyde reaction.
firs tly  o f activation o f hapten then attachment to carrie r protein. Due to the 
nature of this reaction, the hapten is not d irectly  linked to protein but through 
a nitrogen spacer atom which forms the diazo bridge between hapten and 
protein (figure 5.4).
In the periodate method, Table 5.1 method (v), a covalent link is 
formed between a free primary amino group and an activated sugar residue. 
Sodium periodate is used to split open the carbon ring of the sugar molecule 
between two vicinal hydroxyl groups, resulting in the formation o f two 
aldehyde groups on the hapten. These can then react w ith the amine on the 
carrie r protein forming a Schiff base which is then stabilised by reduction w ith 
sodium borohydride (figure 5.5). This method can lead to self-coupling which 
can be minimised by the addition of amino blocking agents I f  periodate 
oxidation is carried out in alkali pH (Wilson and Nakane, 1978). A more 
e ffective  approach is to perform the periodate oxidation at acidic pH so 
preventing Schiff base formation (Wilson and Nakane, 1978).
The Mannich reaction, Table 5.1 method (vi), results in the covalent 
coupling of a primary or secondary amine to a carbon atom possessing an 
'active hydrogen atom!. This is best illustrated in Figure 5.6. However, in the 
reaction described by Ranadive and Sehon (1967) a nitrogen atom possessed the 
active hydrogen. Therefore, on the basis o f the specific ity  o f the resultant 
antibodies, the coupling occurred between the nitrogen atom of the indole ring 
in serotonin and the amino group on the carrie r protein. This is because the 
carbon atom, at position 3 w ithin the indole ring, which is the preferentia l site 
o f coupling no longer possessed an active hydrogen but an alkyl group instead. 
Therefore the carbon atom ceases to be reactive and has conferred the site of 
attack to the nitrogen atom at position 1 (Sundberg, 1970). Therefore, i f
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Figure 5.4 The diazotisation reaction
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Figure 5.6 The mechanism for the Mannich reaction .
a hapten possesses an active hydrogen, its position must be known in order to 
couple the hapten in the desired stereochemical position.
The disuccinimidyl carbonate (DSC) method in Table 5.1 (method vii) 
involves the formation of a peptide bond between a carboxyl group on the 
hapten and an amino group on the carrier protein through the use of an active 
ester intermediate. Sim ilarly, like the mixed anhydride method, this 
procedure is a two stage method resulting in the formation of a specific 
peptide bond between the hapten and carrie r protein. Figure 5.7 shows the 
reaction mechanism involved. The firs t stage uses N, N 'disuccinim idyi 
carbonate to form an active ester w ith  the available carboxyl group. This then 
reacts w ith the free primary amino group in the second stage to form the 
peptide bond.
The advantages and disadvantages o f the most useful conjugation 
methods have been described; however, other factors that may influence the 
immunogenicity o f conjugates need to be considered:
(a) Some condensation methods can res tric t the degree of movement of 
hapten coupled to protein. This may have a beneficial e ffe c t in 
allowing the immune system to recognise the hapten more 
consistently and so e lic it an immune response against it. The MBS 
method of Kitagawa and Aikawa (1976) or the glutaraldehyde method 
of Reichlin et aL (1968) allows a higher degree of movement fo r the 
hapten which may lead to an in fe rio r immune response.
(b) The e ffec t of the degree of derivatisation on immunogenicity does 
not appear to be so clear cut. Kantor et al., (1963) and Taylor and 
Iverson (1971) suggest that a low molar ra tio  o f hapten:protein is
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Figure 5.7 The mechanism for the disuccinim idyl carbonate reaction. 
Based on Sauer and Morris (198*?).
beneficial, whereas Spector (1973) and Hurn (1974) suggest the 
opposite. The concensus at the University of Surrey, however, is that 
an approximate ratio of 20:1 haptens per bovine serum albumin 
molecule is optimal. However, as each hapten is d iffe rent, this value 
may be dependent on the hapten used.
Robinson et al., (1974) have shown that a four-carbon spacer group 
between hapten and carrie r protein gave the most improved immune 
response of a number of d iffe ren t spacer molecules studied. This 
indicates that the more accesible the hapten to the T helper cells, 
the more like ly a stronger immune response w ill result.
The physical form of the conjugate can also a ffec t the immune 
response. An insoluble immunogen w ill remain in the animal longer 
and therefore exert a longer immunogenic e ffec t than a soluble 
immunogen.
Finally, the choice of carrier protein and the animal into which the 
conjugate w ill be administered is important. Carrier proteins vary in 
their ab ility  to e lic it an immune response against the coupled hapten 
as shown by Siskind et al., (1966). However, i f  a carrie r protein is 
itse lf strongly immunogenic, this can result in antigenic com petition 
between the epitopes on the carrie r protein and those o f the hapten 
in favour o f those on the carrier protein itse lf. Therefore, the choice 
of carrier protein must be carefully considered. Fronstin et al., 
(1967) showed that the more phylogenetically removed the carrie r 
protein from the host animal, the stronger the immune response 
towards the hapten. This necessitates that care should be taken over 
the choice of animal species for immunisation.
This chapter w ill discuss the preparation of conjugates for 
immunisation as well as for use as immunological reagents. Additionally, the 
purification of in vivo glycated haemoglobulin and human serum albumin w ill 
also be described.
5.2 MATERIALS AND METHODS
5.2.1 Materials
Iso-butylchlorocarbonate, N,N'-disuccinimidyl carbonate, l-e th y l-3 -(3 - 
dimethyl-aminopropyl) carbodiimide hydrochloride and glutaraldehyde were 
purchased from Sigma Chemicals (UK). A ll other reagents were of AnalaR 
grade and obtained from BDH Chemicals L im ited (UK).
5.2.2 Preparation o f Hapten-Protein Conjugates
5.2.2.1 Conjugation of l-Am ino-l-Deoxy-D-Fructose-6-Am inohexanoic Acid
to Ovalbumin by the mixed anhydride method
The mixed anhydride method of Erlanger et al., (1957) was used. In a 
dry, glass-stoppered test tube 18.1 ymoles l-am ino-l-deoxy-D -fructose-6- 
aminohexanoic acid vver© dissolved in 2.0ml dimethylsulphoxide w ith  slight 
heating and gentle sonication. 1.5ml o f dioxane followed by 209 ymoles tr i-n -  
butylamine were added and the m ixture cooled to 10°C. Iso- 
butylchlorocarbonate (104.8 ymoles) was added beneath the mixture surface, 
mixed and then le ft fo r 30 minutes at 10°C.
Ovalbumin (0.91 ymoles) dissolved in 0.8ml distilled water was added 
to a 10ml glass bottle. The solution was cooled to 4°C and 41.4 ymoles sodium 
hydroxide added, followed by the slow, dropwise addition of 0.8ml dioxane w ith 
continuous magnetic stirring. The activated l-am ino-l-deoxy-D -fructose-6- 
aminohexanoic acid m ixture was added dropwise and the resultant m ixture was 
then le ft fo r 5 hours at 4°C w ith  gentle stirring.
The conjugate reaction m ixture was then dialysed for 48 hours at 4°C 
against two changes of d istilled water and fina lly  lyophilised. A portion was 
assayed by the th iobarbituric acid test (see Section 2.2.2.3.) to determine the 
fructosamine content and hence the degree of derivatisation. The conjugate 
was stored at -80°C in a sealed glass container.
5.2.2.2 Conjugation o f 1-Am ino-l-Deoxy-D-Fructose-L-Valine 
to Ovalbumin
The procedure described in Section 5.2.2.1 was repeated using 18.2 
ymoles 1-am ino-l-deoxy-D-fructose-L-valine and 0.91 ymoles ovalbumin.
3.2.2.3 Conjugation of l-Am ino-l-Deoxy-D-Fructose-6-Am inohexanoic Acid 
to Bovine Serum Albumin (BSA)
The procedure was performed as described in Section 5.2.2.1 but 
using 34.8 ymoles o f l-am ino-l-deoxy-D-fructose-6-am inohexanoic acid and 
1.75 ymoles BSA. The amounts of a ll other reagents were scaled up 
proportionally on a molar basis.
5.2.2.4 Conjugation of l-Am ino-l-Deoxy-D-Fructose-6-Am inohexanoic Acid 
to Keyhole Limpet Haemocyanin (KLH)
The mixed anhydride procedure as described in Section 5.2.2.1 was 
carried out w ith the following modifications. 35.5 ymoles o f 1 -am ino -l- 
deoxy-D-fructose-6-aminohexanoic acid was used along w ith  418 ymoles tr i-n - 
butylamine and 209.6 ymoles iso-butylchlorocarbonate.
6.0 nmoles KLH were dissolved in 1.6ml distilled water and 0.4ml 
DMSO. Sonication and slight heating were required to dissolve the KLH. A 
few drops o f 1M sodium hydroxide were added followed by 0.4ml dioxane 
dropwise w ith stirring. A clear solution resulted, to which the activated 
hapten was added.
5.2.2.5 Conjugation of 1-Am ino-l-Deoxy-D-Fructose-Lysyl lysine to Keyhole
Limpet Haemocyanin
The procedure as outlined in Section 5.2.2.1. was performed using 8.0 
.nmoles KLH. 14.2 ymoles of glycated lysyilysine was dissolved in 3.0ml 
dimethyl sulphoxide and 1.0ml methanol. Other reagents were scaled down on 
a molar basis compared w ith  the amount o f KLH used in section 3.2.2.4..
5.2.2.6 Conjugation of l-Am ino-l-Deoxy-D-Fructose-6-Am inohexanoic 
Acid to Chicken-^-Globulin using the DSC method 
This method is based on that developed by Sauer and Morris (1987). 
To 6 ymoles o f l-am ino-l-deoxy-D-fructose-6-am inohexanoic acid dissolved in 
150yl methanol and 150yl acetonitrile  were added 6.6 ymoles N,N'- 
disuccinimidyl carbonate and 6.6 ymoles pyridine each dissolved in 150yl 
acetonitrile . This m ixture was le ft to react fo r one hour at room temperature 
a fte r which 3 ymoles acetic acid in 150yl acetonitrole were added and the 
m ixture le ft fo r a fu rther 30 minutes at room temperature.
This mixture was then added slowly dropwise w ith stirring to 133 
nmoles chicken-$-globulin dissolved in 3.0ml o f d istilled water. The resultant 
m ixture was le ft for two hours at room temperature w ith stirring. The 
mixture was then dialysed for 48 hours against three changes o f  d istilled 
water. The resultant protein conjugate solution lyophilised. A small sample 
was taken and analysed by the th iobarbituric acid test to determine the degree 
o f derivatisation. The remaining conjugate was stored in a sealed glass 
container a t-8 0 °C .
3.2.2.7 Conjugation of l-A m in o -l-D eoxy-D -F ruc tose -4 -A m inob u ty ric  Acid
to Chicken-^-Globulin
The same procedure as described in Section 5.2.2.6 was used, except 
that 6 ymoles l-am ino-l-deoxy-D -fructose-4-am inobutyric acid replaced the 
corresponding 6-aminohexanoic acid derivative.
5.2.2.8 Conjugation of 1-Am ino-l-Deoxy-D-Fructose-Lysyl Lysine 
to Chicken-fl'-Globulin
The method was as described in Section 5.2.2.6 w ith 6 ymoles 1- 
am ino-l-deoxy-D-fructose-lysyllysine replacing the 6-aminohexanoic acid 
derivative! used previously,
5.2.2.9 Conjugation of 1-Am ino-l-Deoxy-D-Fructose-Tyram ine to 
Qvalbumen by the Mannich Reaction
This method is based on that used by Ranadive and Sehon (1967). 
Ovalbumen (1.1 ymoles) was dissolved in 1.0ml of d istilled water to which 
500yl o f 3M sodium acetate were added slowly w ith  stirring. 500yl o f 7.5% 
(v/v) formaldehyde were added, and stirring  was continued for 10 minutes at 
room temperature. Then 20 ymoles of 1-am ino-l-deoxy-D-fructose-tyram ine, 
dissolved in 500yl o f d istilled water were added dropwise to the ovalbumin 
solution. The stirred mixture was allowed to react fo r 18 hours at room 
temperature and then dialysed fo r 48 hours against three changes o f d istilled 
water. The conjugate was lyophilised and stored in a sealed glass container a t 
-80°C. A small sample was taken fo r analysis by the th iobarbituric acid test.
5.2.2.10 Conjugation of 1-Am ino-l-Deoxy-D-Fructose-Tyram ine to Bovine
Serum Albumin
The method used was as described in Section 5.2.2.9 except tha t 735 
nmoles of bovine serum albumin were used in place o f the ovalbumin.
5.2.2.11 The Conjugation o f l-A m in o -l-D eoxy-D -F ruc tose -4 -A m inob u ty ric
Acid to Ovalbumin using the Carbodiimide Method 
This method was based on that used by Goodfriend et al., (1964). In 
1.0ml of d istilled water 18.9 ymoles l-am ino-l-deoxy-D -fructose-4- 
aminobutyric acid was dissolved together w ith  0.9 ymoles ovalbumin. Then 
373 ymoles of l-ethyl-3-(3-dim ethyl-am inopropyl) carbodiimide hydrochloride 
(EDC) was added and the mixture le ft to react fo r 30 minutes w ith  stirring at 
room temperature. ~ T.he m ixture was extensively dialysed fo r 48
hours and fina lly  lyophilised. A small sample of conjugate was taken for 
analysis by the th iobarbituric acid test and the remaining conjugate stored at 
-80°C  in a sealed glass container.
5.2.2.12 The Conjugation of Glycated Poly-L-Lysine to Ovalbumin using the 
Glutaraldehyde Method
This method was carried out according to the method reported by 
Reichlin et al., (1968) and was only done just prior to immunisation. Glycated 
poly-L-lysine (2.7 ymoles) was dissolved in 1.0ml o f sterile d istilled water 
containing 133 nmoles ovalbumin. Then 200yl o f Bacillus Calmette-Guerin 
vaccine was added followed by 200yl of 1% (v/v) glutaraldehyde solution. The 
m ixture was mixed and le ft for 10 minutes w ith  intermittent mixing. The 
m ixture was fina lly  emulsified w ith 4.8ml o f non-ulcerative Freund's 
adjuvant.
5.2.3 The Determination of the Molar Extinction Coefficient 
for the Thiobarbituric Acid Test
The method used was as described in Section 2.2. Varying amounts o f 
l-am ino-l-deoxy-D-fructose-6-am inohexanoic acid in 0.2ml were used as 
standards to determine the molar extinction coeffic ient.
5.2.4. The purification of in vivo glycated proteins and non-qlycated protein
standards
5.2.4.1 Glycated human haemoglobin
Human blood was collected in lith ium  heparin coated tubes and then 
spun at 2000g for 10 minutes. The clear plasma along w ith the pale f lu ffy  
white blood cell layer was decanted o ff. The remaining red blood cells were 
washed twice in isotonic saline (0.16M sodium chloride) and spun at 2000g for 
10 minutes. The red blood cell were then lysed w ith 20ml o f d istilled water 
and spun at 30000g for 30 minutes to remove cell membranes. The resulting 
supernatant was decanted o ff into a measuring cylinder.
A Clycogel B a ffin ity  column (V|3=50ml) was pre-equilibrated w ith  
wash buffer pH 8.5 containing 250mM ammonium acetate, 50mM magnesium 
chloride and 3mM sodium azide. A sample o f haemolysate, equivalent to 1ml 
of neat red blood cells, was diluted 1:1 w ith wash bu ffe r and -the pH corrected 
to 8.5 before applying to the a ffin ity  column. The sample was washed through 
the a ffin ity  column with wash buffer pH 8.5 at a flow rate of lm l/m in  fo r 
150ml. Bound glycated haemoglobin was then eluted w ith  elution bu ffe r pH
8.5 containing 200mM sorbitol, 100 mM Tris, 50mM EDTA and 3mM sodium 
azide at a flow  rate o f lm l/m in  collecting 2ml fractions. The fractions were 
assayed for haemoglobin by measuring absorbance at 414 nm. Those fractions 
containing haemoglobin were pooled and then u ltra filtra te d  four times w ith  
distilled water to remove elution buffer. The resulting glycated haemoglobin 
solution was lyophilised and stored at -20°C.
The (Jlycogel B a ffin ity  column was fina lly  washed w ith 5% (v/v) 
glacial acetic acid, approximately 250ml, before reuse.
5.2.4.2. Glycated human serum albumin
Glycated human serum albumin was isolated from 4% (w/v) human 
plasma protein for transfusion (Lister), which contains at least 95% HSA. This 
H5A solution, 400 ml was extensively washed with distilled water to remove 
salts and other small molecule present and then concentrated to a 20% (w/v) 
protein solution by u ltra filtra tio n  using an Amicon f i lte r  membrane w ith a 
molecular weight cut o ff o f 10000 daltons. A 50ml sample o f the 20% (w/v) 
HSA solution was diluted 1:1 w ith Glycogel B wash buffer (see section 5.2.4.1), 
the pH corrected to pH 8.5 and loaded onto a pre-equilbrated Glycogel B 
a ffin ity  coJum (Vg=50ml) as described in section 5.2.4.1. The remaining 
protocol is as described in section 5.2.4.1. except that fractions were analysed 
for absorbance at 280 nm to locate the glycated HSA. A fte r u ltra filtra tio n  of 
the pooled glycated HSA, the m aterial was assayed fo r protein content by 
using the absorbance at 280nm for lOmg/ml solution of HSA is 5.31 (Olufemi, 
et al., 1987). The extent at glycation was then analysed by the fructosamine 
assay as described in section 4.2.4.1.
5.2.4.3. Sodium borohydride treated HSA.
A 25ml sample of 4% (w/v) HSA solution, as described in section 
5.2.4.2., was taken and dissolved in 25ml o f 0„1M sodium bicarbonate pH 9.5 to 
which 378mg (lOmmoles) of sodium borohydride were added. The m ixture was 
le ft overnight at room temperature and then u ltra filtra te d  to remove 
unwanted salts and any remaining sodium borohydride. Protein concentration 
and fructosamine analysis were performed as described section 5.2.4.2.
5.2.4.4. Sodium peroidate treated HSA
To 25ml 4% (w/v) HSA were added 15ml o f 0.1M sodium peroidate 
solution made up in distilled water and the resulting m ixture le ft fo r 30 
minutes at room temperature. The reaction was stopped by the addition of
0.56ml (lOmmoles) ethane diol and then u ltra filtra ted  with 0.1M sodium 
bicarbonate solution pH 9.5. To this periodate treated HSA 751 mg glycine (10 
mmoles) were added and le ft to incubate for 2 hours at room temperature, 
followed by the addition of 378 mg (lOmmoles) sodium borohydride. A fte r a 
further incubation for 1 hour at room temperature the HSA solution was 
fina lly u ltra filtra ted  and protein and fructosamine analysis performed as 
described in section 5.2.4.2.
5.3 RESULTS
5.3.1 The Extinction C oeffic ien t fo r the Thiobarbituric Acid Test
A standard curve for l-am ino-l-deoxy-D-fructose-6-am inohexanoic 
acid concentration against absorbance at 443nm was obtained and is shown in 
Figure 5.8. Linear regression analysis gave a straight line (r = 0.998) passing 
through the origin w ith a gradient of 617 - 17 M-^. The ligh t cell path length 
was 1cm. Therefore, the molar extinction coeffic ient, £  , for the
 ^ 2 j
th iobarbituric acid test was 617 - 17 cm mole- .
5.3.2 Derivatisation Results fo r Prepared Conjugates
The results are shown in Table 5.2 for the degree o f derivatisation for 
each conjugate. The calculations were based on the extinction coeffic ien t 
determined for the th iobarbituric acid test. Only one conjugation, involving 
fructosyl-4-am inobutyric acid chicken-^-globulin, appears to have been 
unsuccessful.
The mixed anhydride method of conjugation gave the highest coupling 
e ffic iency o f approximately 60 to 70%. However, the carbodiimide method 
only had a coupling effic iency of 12% . The DSC method which also forms a 
peptide bond gave varying coupling efficiencies depending on the hapten used. 
Finally the Mannich reaction gave coupling efficiencies of around 25%.
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Figure 5.8 Beer's law plot for l-am ino-l-deoxy-D -fructose-6- 
aminohexanoic acid concentration against absorbance at 443 nm for the 
th iobarb ituric acid test.
Table 5.2
Results for the degree of derivitisation 
of conjugates
Conjugate Method Used A443nm/mg Molar ra tio  of 
hapten: protein
Fructosyl-6-aminohexanoic
acid-ovalbumin
mixed
anhydride
0.079 11.5 : 1
Fructosyl-4-am inobutyric 
acid ovalbumin
carbodiimide 0.018 2.6 : 1
Fructosyl-L-valine-
ovalbi;min
mixed
anhydride
0.100 14.6 : 1
Fructosyl-tyram ine
ovalbumin
Mannich 0.032 4.6 : 1
Fructosyl-lysyllysine
-KLH
mixed
anhydride
0.133 1000 : 1 ++
Fructosyl-6-aminohexanoic 
acid - KLH
Mannich 0.250 approx. 4000:1
Fructosyl-6-aminohexanoic 
acid - BSA
Disuccinimidyl
carbonate
0.026 5.7 : 1
Fructosyl-6-aminohexanoic 
acid-chicken-^-globulin
Disuccinim idyl 
| carbonate
0.014 6.8 : 1
Fructosyl-4-am inobutyric
acid-chicken-ft'-globulin
Disuccinim idyl 
; carbonate
0 -
Fructosyl-lysyllysine
chicken-2f-globulin
Dissuccinimidyi
carbonate
0.098 23.8 : 1 ++
V
This assumes that there are two fructosyl residues per lysyllysine 
molecule.
Table 5.3
Results fo r the purification of glycated 
and non-qlycated proteins
Protein Samples Fructosamine 
concentration (yM)
Molar ra tio  
of fructosamine 
to protein
Glycated Haemoglobin 7300 2 2 .6 :1
Glycated HSA 120 2.7 : 1
Sodium borohydride 
treated HSA
70 0.1 : 1
Sodium periodate 
treated HSA. . ..
90 0.2 : 1
5.3.3. The purification of in vivo glycated proteins
Table 5.3 shows the results for the purification or synthesis of 
glycated and non-glycated proteins respectively. It can be noticed that sodium 
borohydride or sodium periodate treatment of" HSA has been successful in 
lowering or removing the fructosamine content in this protein. In addition 
glycated haemoglobin also appears to have been successfully purified and 
contains 22.6 moles fructosamine/mole haemoglobin compared to HSA which 
contains 2.7 moles fructosamine/mole HSA. This value for haemoglobin is 
very high and cannot be regarded as accurate, because there are not that 
number o f available lysine residues fo r glycation in haemoglobin.
5.4 DISCUSSION
It would appear from the results that the best method of conjugation 
was the mixed anhydride method as this gave the highest molar ratios of 
hapten to carrier protein incorporation. The low molar ratio  obtained w ith 
fructosyl-4-am ino-butyric acid is not unexpected. This is because the 
carbodimide method, which was used for conjugation, is not specific as 
outlined in Section 5.1 and therefore protein-protein cross-linking can occur. 
This results in less carbodiimide reagent fo r the coupling of hapten to carrie r 
protein. When the DSC method was used to conjugate fructosyl-4- 
aminobutyric acid to chicken-^-globulin it  was not successful. However, the 
DSC method only proved successful when either fructosyl-lysyllysine or 
fructosyl-6-aminohexanoic acid were used as haptens (see table 5.2).
The purification o f glycated protein standard by Glycogel B a ff in ity  
chromatography was performed w ithout d iff ic u lty  resulting in an enriched 
glycated protein standard as is seen by the results shown in table 5.3. 
Treatment w ith sodium borohydride which converts the furanose or pyranose 
forms at the fructosyl residue into the straight chain g lucito l derivative also
appear to have been successful as In evident by the results seen in table 5.3 
showing a very low molar ra tio  of moles fructosamine/mole protein. S im ilarly, 
sodium periodate treatm ent, which chemically destroys the sugar residue, also 
proved successful.
To conclude^ Hi.ne d iffe ren t conjugates have been synthesised 
successfully w ith varying degrees at derivatisation, depending on the method 
used. In addition, both glycated haemoglobin and HSA as well as two types of 
non-glycated HSA have also successfully been prepared, although the 
fructosamine assay for haemoglobin would appear to give higher values of 
fructosamine content than one would expect on a quantitative basis.
CHAPTER 6
THE DETECTION AND CHARACTERISATION OF ANTISERA 
TO GLYCATED PROTEINS
6.1. INTRODUCTION
Morris (1985) has advocated the use of sheep for producing antisera 
for immunoassay use, especially when dealing with haptens conjugated to 
carrier proteins, as it  has been shown that they produce antibodies of greater 
titre  and a ffin ity  to haptenic molecules compared to other animals, such as 
rabbits and mice. Another advantage includes the possibility of being able to 
produce ovine monoclonal antibodies, using heterohybridoma technology, 
usually of higher a ffin ity  than would be seen i f  mouse monoclonals were 
developed (Morris, 1988).
Antibodies to glycated amines w ill essentially be screened fo r by
using an indirect ELISA for antibody, as outlined in section 1.3. The system
which was chosen involved absorbing antigen on to a solid phase, this being the
m icro titra tion  plate. Antibody recognising adsorbed,. Im m obilised antigen
would then be detected using enzyme-labelled anti-ovine IgG antibody.
Antiserum titre , avid ity and specific ity could also assessed using this EIA
system. By successively serially diluting the antiserum and then assaying for
antibody using EIA, an antiserum dilution curve can be obtained. The
reciprocal o f that value of antiserum dilu tion that binds 50% of a ll available
antigen binding sites is termed the antiserum titre . The avid ity o f an
antiserum as defined as the strength of binding of the antiserum to a
particular antigen and this can also be assessed ind irectly in the above system.
By preincubating the antiserum dilutions w ith a competing 'free' antigen and
indirectly
then assaying for antibody w ith  the above EIA the avid ity can be fo u n d ry  the 
degree of displacement of the original antiserum dilution curve to the le ft at 
the 50% of the maximum binding value. The greater the displacement, the 
greater the avid ity of the antiserum to that particular competing antigen. The 
degree of displacement by various competing antigens can give an idea as to
the specifity of an antiserum to a particular antigen. A highly specific 
antiserum is one in which only that competing! Ag can give rise to an 
antiserum displacement curve w ith respect to the original antiserum dilution.
An antiserum consists of a population of antibodies w ith varying 
a ffin ities  to a particular epitope on an antigen. The immunisation protocol 
used for an antigen can a ffec t the relative distribution of the high and low 
a ffin ity  antibodies and hence the avid ity of an antiserum to a particular 
epitope on the antigen.
Once primary immunisation has occured, T-heiper cells w ill stimulate 
the low a ffin ity  antibody producing B cells to d iffe rentia te  and commence 
secreting antibody to antigen. As the immune response continues, antigen w ill 
be removed from the immunisation depots as well as the blood stream and 
degraded at the same time that T suppressor cells pro liferate to control the 
immune response by in ita lly  inhibiting the secretion of low a ffin ity  antibodies. 
The lower antigen concentration has the e ffec t of stim ulating higher a ffin ity  
antibody-producing B cells and combined w ith the in itia l suppression of low 
a ffin ity  antibody-producing B cells, this results in a general rise in the avid ity 
o f an antiserum w ith  time, even a fte r maximum antiserum t itre  has been 
attained. Boosting of the animal w ith fu rther immunogen must therefore be 
delayed un til the immune response has settled back to near pre-immune levels 
so that the T suppressor cell population has returned to a quiescent state a fte r 
the in itia l immunological stimulus. Boosting of the animal w ill then result in a 
strong immunological response, mainly consisting o f the high a ffin ity  antibody- 
produced cells i f  a small quantity of immunogen is used.
This chapter describes the immunisation with those immunogens 
prepared in chapter 5 and the screening for antibodies produced against 
glycated amines. The antisera w ill also be assessed for titre , avid ity and 
specific ity  to various glycated components, including glycated haemoglobin as 
well as serum albumin.
6.2 MATERIALS AND METHODS
6.2.1. Materials
Bromophenol blue, Commassie blue R250, bovine serum albumin, 
casein, ortho phenyl enediamine (OPD), polyoxyethylenesorbitan-monolaurate 
(Tween 20), Triton X100, diaminobenzidine and tris(hydroxymethyl) 
aminomethane were purchased from Sigma Chemicals (UK). Soft 
polyvinylchloride, f la t bottomed m ic ro titra tion  plates (cat. no. 001-010-2801) 
were obtained from Dynatech. Nitrocellulose paper made by Schleicher and 
Schuell (ref. no. 401-191) was bought from Anderman and Co. Ltd. (Surrey, 
UK). Non-ulcerative Freund's adjuvant (Morris), horseradish peroxidase 
labelled donkey anti-sheep IgG, normal sheep serum, normal sheep serum IgG 
and peroxidase-labelled sheep anti-peroxidase IgG were obtained from  
Guildhay Antisera, Guildford, UK. A ll other reagents and chemicals were 
purchased from BDH Chemical (Poole, Dorset) and were of AnalaR grade.
6.2.2. Preparation o f Reagents
6.2.2.1. Phosphate-buffered Saline, gelatin, Tween 20 Solution, pH 7.4 
The solution contained:-
0.2g potassium dihydrogen phosphate 
0.2g potassium chloride
2.9g disodium hydrogen phosphate dodecahydrate 
8.0g sodium chloride
0.5ml Tween 20 
lg  gelatin
A ll constituents were dissolved in approximately 980ml of d istilled 
water, the solution was adjusted to pH 7.4 and the volume made up to one 
l it re .
6.2.2.2. i orthophenylenediamine substrate solution
This was made up fresh immediately before use. 100ml o f the OPD 
solution were prepared by adding 24.3ml of 0.1M c itr ic  acid solution and 
25.7ml of 0.2M disodium hydrogen phosphate to 50ml of distilled water. To 
this was added 40mg of i  orthophenylenediamine solid (OPD) and 40jil o f 30% 
(v/v) hydrogen peroxide solution.
6.2.2.3 Preparation of SDS-PAGE buffer
(i) Lower gel buffer was prepared by dissolving 400mg sodium 
docedyl sulphate (SDS) in 100ml of 1.5M Tris, adjusting the 
pH to 8.8 w ith hydrochloric acid.
(ii) Upper gel buffer was made by s im ilarly dissolving 400mg 
SDS in 100ml 0.5M Tris and adjusting the pH to 6.8.
( iii)  Sample buffer: This was made by incorporating into 50ml
of 62.5mM Tris, 15 %(v/v) glycerol, 5%(v/v) 2-
mercaptoethanol, 2.3%(w/v) SDS and 0.001% (w/v)
bromophenol blue, the pH being adjusted to pH6.8.
(iv) Electrode buffer: Into 2 litres of d istilled water were
dissolved 6.06g of Tris and 28.8g o f glycine along w ith  4g 
of SDS, the pH being adjusted to pH 8.3 w ith hydrochloric 
acid.
6.2.2.4. SDS-PAGE protein staining solutions
i) Staining solution: To 650ml o f d istilled water were added 
250m l. isopropanol, 100ml glacial acetic acid and 0.5g 
Commassie blue R250.
ii) Destaining solution: Into 800ml of distilled water were
added 100ml each of isopropanol and glacial acetic acid.
6.2.2.5. Preparation of Western blot buffers
i) Transfer buffer: Into 3 litres  of d istilled water were
dissolved 33.78g glycine and 7.26g Tris.
ii) Phosphate buffered saline (PBS): This was made as
outlined in section 6.2.2.1. except that no Tween 20 or 
gelatin was added to the solution.
iii)  Blocking buffer: This was made by adding 0.2% (v/v)
Triton X100 and 1% (w/v) casein to PBS.
6.2.3. Antibody Production and Screening
6.2.3.1. Immunisation of Sheep and Blood Collection
The immunogen was prepared for innoculation into a sheep as follows: 
6mg of hapten-protein conjugate were dissolved in 1.0ml o f Corynebacterium 
parvum solution (Wellcome), then 0.2ml BCG vaccine for Intradermal injection 
(Evans) added. A fte r mild ultrasonic dispersion, the resultant suspension was 
emulsified w ith  2.5ml non-ulcerative Freund's adjuvant (Morris) using a tw in 
hubbed connector until a stable emulsion was obtained that did not disperse on 
contact w ith water.
The preparation of the glycated poly-L-lysine-ovalbumin immunogen 
differed slightly. 6mg of ovalbumin and lOmg glycated poly-L-lysine were 
dissolved in 1.0ml of sterile water. 200yl o f BCG vaccine were added followed
by 200yl o f 1% glutaraldehyde. The resulting solution was mixed for 10 
minutes before emulsifying with 2.4ml non-ulcerative Freund's adjuvant as 
described above.
Prior to immunisation, a pre-immune blood sample, 40ml,was taken 
from the jugular vein of the animal to be injected. The sheep was then 
immunised intra-muscularly at 7 sites, 0.5ml persite. One site in each fore leg 
and two sites on each hind leg, the remaining site being subcutaneous on the 
back of the neck over the pectoral girdle.
Test bleeds (20ml) were taken at fo rtn igh tly  intervals commencing 
five weeks a fte r the primary injection to monitor the antibody response. The 
blood was collected into dry sterile Vacutaines (Becton Dickinson) and allowed 
to clot overnight at room temperature (in the dark). The following morning, 
the c lot was carefully removed, taking care to avoid haemolysis o f the residual 
serum. A fte r centrifugation at 1600rpm fo r 20 min at 4°C (Beckman J6), the 
clear serum was decanted o ff into a sterile glass universal bo ttle  and 
preserved by the addition o f 10% sodium azide (10yl per 1ml serum). The 
serum was stored at 4°C until required.
Animals were only boosted when antiserum titre  levels, a fte r the 
previous immunisation, had fallen to a low level. The booster injecton 
consisted of lm g  of the original conjugate, used fo r immunisation,dissolved in 
0.1ml sterile water and then emulsified w ith 2ml of non-ulcerative Freund's 
adjuvant as described previously. Innoculation was intramuscularly at 6 sites, 
0.5ml per site, again as described previously.
6.23.2 . Assessment of antiserum titre .
M ic ro titra tion  plates (96 well) were firs t washed with 40mM sodium 
bicarbonate buffer pH 9.6, then coated w ith the appropriate hapten-protein 
conjugate (coating Ag). From a coating Ag solution of 2yg/m l in 40mM sodium 
bicarbonate buffer pH 9.6, 200yl aliquots were added to each well and le ft to 
incubate at 4°C overnight in a humid environment in a closed box. The 
following morning, the plates were washed four times w ith  PB5GT. Aliquots 
of serially diluted antiserum 200yl were pipetted into the wells in duplicated 
and the plates le ft to incubate 37°C fo r 3 hours in a humid environment. 
Pre-immune serum, and la te r normal sheep serum, was used as a blank so as to 
monitor the levels of background non-specific binding (NSB). The plates were 
washed a further four times w ith  PBSGT prior to the addition of the enzyme- 
labelled second antibody, horseradish peroxidase-labelled donkey anti-sheep 
IgG. (HRP-DAS IgG). This was diluted 20,000 fold w ith  PBSGT and 200yl 
aliquots added to a ll the wells. The plates were le ft to incubate for a fu rther 
2 hours at 37°C in a humid environment, and fina lly  washed four times w ith 
PBSQT. OPD substrate 150yl per well, was added and the plates incubated fo r 
30 minutes at 37°C in a dark humid environment. The enzyme reaction was 
stopped by the addition of 50yl per well o f 2.5M sulphuric acid. The 
absorbances at 490nm in each well were measured on a Flow Laboratories 
T itertek Multiscan Plus auto reader. A graph of absorbance at 490nm against 
antiserum dilution was constructed. The titre  was determined as the 
reciprocal o f the antiserum dilution which gave 50% of maximum binding (ie. 
maximum absorbance).
6.2.3.3. Assessment o f antiserum avidity and specific ity
The avid ity o f each antiserum was ind irectly assessed by running an 
antiserum displacement curve at the same time as the antiserum dilu tion
curve Iq * determine titre . Serial dilutions of antiserum and pre-immune 
antiserum (or NSS) were prepared to which a constant amount of displacing Ag 
was added (see results in Section 6.3) to each dilution. These serial dilutions 
were then incubated overnight at 4°C before pipetting 200yl aliquots of the 
incubate into the wells o f the m icro titra tion  plate, which had already been 
pre-coated w ith  Ag as described in section 6.2.3.2. The remaining steps were 
as described in the protocol (section 6.2.3.2.).
From the plot o f absorbance at 490nm against antiserum dilu tion, the 
avid ity of the antiserum for a particular displacing Ag was ind irectly assessed 
by measuringthe amount o f horizontal displacement o f the displacement curve 
relative to the standard antiserum dilution curve. This was determined at the 
50% of maximum absorbance, at 490nm, level on the antiserum dilution curve.
Specificity of the antiserum for a particular Ag was also ind irectly 
assessed by using antiserum displacement curves. Essentially, the smaller the 
displacement by a particular cross reacting Ag re lative to an antiserum 
dilution curve, the greater the specific ity  o f the antiserum for the specific Ag.
6.2.4. The synthesis of carboxy derivatives of l-amino-l-deoxy-D-fructose-6
- aminohexanoic acid as competing antigens in EIA
6.2.4.1. The synthesis of l-am ino-l-deoxy-D -fructose-6-am ino-l-m ethylhexanoate
A 2mg/ml solution of l-am ino-l-deoxy-D-fructose-6-am inohexanoic 
acid in 10ml dry methanol was prepared. The solution was then cooled to 0°C 
in a w ater/ice slurry and dry hydrogen chloride gas bubbled through the 
solution for 30 minutes at 0°C, the waste hydrogen chloride gas being 
collected in a water trap. Excess hydrogen chloride gas was then blown o ff 
w ith nitrogen gas and the resulting m ixture concentrated by ro tary 
evaporation.
Successful esterification was monitored by infra-red analysis. The 
orginal compound l-am ino-l-deoxy-D-fructose-6-am inohexanoic acid has two 
strong absorption : peaks at 1610-1550cm"^ indicating a dissociated carboxyl 
group. The ester product is confirmed by the disappearance of the two 
absorption peaks and the appearance of an absorption peak at 1740-1715 c m " \  
due to carbonyl stretching vibrations in the ester.
6.2.4.2. The Synthesis o f l-am ino-l-deoxy-D -fructose-6 -am ino-l- 
methylhexanamide
l-am ino-l-deoxy-D-fructose-6-am inohexanoic acid (lOmg) was 
dissolved in 1.0ml d istilled water. To this solution, 152]_tl methylamine were 
added, followed by 130mg l-ethyl-3-(3-dim ethyl-am inopropyl) carbodiimide 
hydrochloride, resulting in a final molar ratio  o f 1:20:20 fo r 1-am ino-l-deoxy- 
D-fructose-6-aminohexanoic acid: methylamine : propyl carbodiimide
hydrochloride. The m ixture was le ft for 30 minutes at room temperature w ith 
gentle stirring.
The m ixture was then applied to a pre-equilibrated column of 
Glycogel B (Pierce) (Vg = 3ml), using 25mM di-sodium hydrogen phosphate 
buffer, pH 9.0, and the column washed through w ith 15ml of 25mM di-sodium 
hydrogen phosphate pH 9.0. Bound m aterial was then eluted w ith  25ml 25mM 
form ic acid. The product, l-am ino-l-deoxy-D -fructose-6-am ino-l-m ethyl- 
hexanamide, was eluted in 5 to 7ml elution buffer, the product being located 
by detecting absorbance at 214nm due to the presence of the amide bond. The 
amide was then lyophilised and stored at -80°C until use.
6.2.5. Antiserum displacement curves with normal and sodium borohydride- 
reduced, in vivo, glycated proteins.
The methodology, was essentially that described in section 6.2.3.2. 
a fte r plating out the antiserum dilutions on the m ic ro titra tion  plates.
However, prior to plating out, certain procedures were followed in 
constructing the antiserum dilutions.
500yl serial dilutions of antiserum in PBSGT were set up in 2ml 
plastic tubes. Each set o f serial dilutions contained pooled diabetic human 
plasma at a 10 or 4-fold d ilution, w ith or w ithout sodium borohydride at a 
lOmg/ml concentration. Similar serial dilutions were also set up using 10 or 4- 
fold dilutions o f 150mg/ml haemolysate from a pool o f blood from diabetic 
patients. The samples were then le ft fo r 30 minutes at room temperature.
Meanwhile, lm l G15 Sephadex columns were set up in PBSGT and 
allowed to drip dry. Each 500ul antiserum dilution was then loaded on to a 
separate column and the sample spun through the Sephadex in a bench 
centrifuge at 2000rpm, to remove any remaining sodium borohydride. The 
eluant was collected in small plastic tubes. Duplicate 200ul samples were 
then plated out on the m icro titra tion  plates for each antiserum dilution point 
and taken through the procedures described in section 6.23 .2 .
6.2.6. Western Blot analysis of glycated and non-qlycated proteins
6.2.6.1 SDS polyacrylamide gel electrophoresis
This method is based on that of Laemmeli (1970). A clean set of 
glass gel plates (10x10 cm) and spacer arms (washed and acetone cleaned) were 
set up and sealed w ith  2.3% (w/v) agar solution around the edges. Water was 
temporarily added between the plates to check fo r any leakage. The water 
was removed and 25ml o f 10% (w/v) acrylamide running gel added and le ft to 
set w ith approximately 2 cm of water on top of the gel. Once set, the water 
was poured o ff and 0.8% (w/v) acrylamide stacking gel was then added on top 
of the running gel, a well template inserted and the gel le ft to set. The
template was then removed and the wells filled  w ith electrode buffer. 
Samples were added to each well w ith  a 50iil Hamilton syringe, the samples 
having firs t been boiled for 3 minutes in sample buffer at the required sample 
concentration. The bottom spacer bar was removed along with the sealing 
agar the gel placed in an electrophoresis tank, the upper and lower chambers 
being filled  w ith electrode buffer. Any air bubbles at the bottom of the gel 
were removed and the gel was run at a constant current o f 20mA un til the 
Coomassie blue bands reached the lower running gel when the current was 
increased to a constant 40mA.
When the Coomassie blue band reached the bottom o f the gel, the 
gel plate was removed and the lower running gel was either stained fo r protein 
or the separated proteins transferred to nitrocellulase for Western blot 
analysis. I f  protein staining was required, then the gel was transferred to a 
tank containing staining solution and le ft overnight at room temperature. The 
gel was then destained w ith several changes of destaining solution un til a clear 
background was obtained. A photographic record of the gel was then made.
6.2.6.2. Western blot analysis
This procedure relies on the electrophoretic transfer o f proteins to 
nitrocellulose paper which is then subject to immunological analysis. The 
techniques employed are based on those of TowMn et al. (1979) and Burnette et 
al., (1981).
SDS-PAGE of the sample to be analysed was carried out as described 
in section 6.2.6.1. The resulting gels were soaked for 43 minutes in transfer 
buffer, so as to allow any changes in gel size due to swelling or shrinking to 
occur before, and not during, the transfer stage to nitrocellulose. The transfer
apparatus was set up as follows: a sheet o f nitrocellulose slightly larger than 
the gel was wetted with transfer buffer and laid on top of 2 sheets of 
Whatmann 3MM paper lying on top o f a Scotch Brite scouring pad. The gel was 
then placed on the nitrocellulose sheet followed by a further 2 sheets of 
Whatmann 3MM f ilte r  paper. The completed sandwich was held together by a 
• plastic grid. It was important to ensure that no air bubbles were caught in 
the sandwich, as this would lower transfer e ffic iency and cause possible band 
distortion. The assembly was then inserted into an electrophoretic tank w ith 
the nitrocellulose paper facing the anode and the tank filled  w ith  transfer 
buffer. E lectrophoretic transfer was achieved by running the system for more 
than 5 hours at a constant 20V. A fte r transfer, the nitrocellulose paper was 
removed and subjected to immuno-staining.
The immunostaining procedure was carried out as follows
i) 3 x 15 minute washes at room temperature w ith 50ml
blocking buffer.
ii) 3 hours at room temperature w ith 50ml blocking buffer
containing 50]il o f specific antibody.
iii)  A further 3 x 15 minutes washes in 50ml blocking buffer.
iv) 1 hour a t R T  w ith 50ml of blocking buffer containing
500ul 0.2% (w/v) donkey anti-sheep IgG used as a bridging 
antibody.
v) 3 x 15 minutes washes in 50ml blocking buffer at room
temperature.
vi) Another 1 hour at room temperature w ith 50ml blocking
buffer containing 100]il o f peroxidase-anti-peroxidase
sheep IgG.
vii) Finally, the nitrocellulose paper was washed 3 times w ith
50ml blocking buffer for 15 minutes, each tim e at room 
temperature, and then rinsed once w ith 50ml of PBS for 15 
minutes.
v iii) The nitrocellulose paper was stained with 5% (w/v) 
diaminobenzidine in 100ml of 0.1M tris/hydrochloric acid 
buffer, pH 7.5 containing 20yl o f 30% (v/v) hydrogen 
peroxide solution and washing the nitrocellulose paper in 
d istilled water. A photographic record was then made.
6.3. RESULTS
6.3.1. Antiserum screening and immunisation profiles.
Serum from sheep immunised against the monofructosyl-derivative of 
glycated 6-aminohexanoic acid were screened for antibodies to the hapten 
w ith system (a) diagramatically represented as follows:-
1
Solid | 2pg/m l Sheep DAS-HRP OPD
Phase ^ BSA-Hapten Serum Substrate1 Sample
(Hapten = l-am ino-l-deoxy-D-fructose-6-am inohexanoic acid)
Figure 6.1 shows the immunisation titre  pro file  fo r a sheep (No. 915) 
immunised w ith a fructosyl-6-aminohexanoic acid-ovalbumIn conjugate. A t 30 
weeks post immunisation, the t itre  had risen to a peak ofl-98,000 before fa lling  
back to a t itre  of 1**8,000 a fte r 55 weeks. A fte r boosting, at 80 weeks post 
prime, a sharp rise in titre  was observed, up to i;120,000 which fe ll back to 
1:80,000 at the last recorded data point.
A second sheep (No. 80) immunised w ith fructosyl-6-aminohexanoic 
KLH conjugate also produced antibodies against the fructosyl derivative of 
glycated 6-aminohexanoic acid. Figure 6.2 shows this immune reponse. In this
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Figure 6.1 Immunisation profile fo r ovine antibodies to a 1-am ino-l- 
deoxy-D-fructose residue produced by sheep 915 a fte r immunisation w ith a 
monofructosyl-6-aminohexanoic acid-ovalbumin conjugate.
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Figure 6.2 Immunisation profile for ovine antibodies to a 1-am ino-l- 
deoxy-D-fructose residue producecj by sheep 80 a fter immunisation with a 
monofructosyl-6-aminohexanoic acid-KLH conjugate.
animal, the titre  rose to l:115,000 only 16 weeks a fte r immunisation, before 
fa lling slowly to aV-42000 t itre  a fte r 51 weeks. As can be seen, no boosting was 
carried out as the t itre  had not stopped fa lling and stabilised before the end of 
the experimental part of these studies. .
A th ird  sheep (No.A40) was immunised w ith a fructosyl-lysyllysine-
KLH conjugate and ini ta lly  screened for antibodies to fructosyl lysyllysine 
w ith the following system (b), again shown diagram atically:-
1
Solid ^ 5yg/m l Sheep DAS-HRP OPD
Phase ^ globulin-Hapten Serum Substrate1 Sample
(Hapten = fructosyl-lysyllysine)
Although antiserum dilution curves were obtained w ith  this system,
an immunisation titre  profile is not shown as the t itre  value appeared to 
fluctuate between 500 to 2000 before fa lling to zero in a random fashion. 
However, in case this was due to a fau lt in Ag conjugate, an alternative 
system was set up to screen for these antibodies to fructosyl-lysyllysine. The 
above system was used, but a d iffe ren t coating Ag was substituted, this being 
a glycated -iyramine-BSA conjugate at a 2ug/m l concentration. Figure 6.3 
shows the t itre  profile  when using this alternative coating Ag fo r antibody 
screening. T itre  levels reached a maximum of!:39,000 a fte r only 2 weeks post- 
immunisation. T itre  levels then gradually fe ll back to zero by 14 weeks post 
immunisation.
A further sheep (No. A27) was immunised w ith an fructosyl-L-valine 
ovalbulin conjugate and screened for antibodies to the fructosyl residue using a 
fructosyl-tyramineHBSA conjugate as a coating Ag as s im ilarly outlined above 
for sheep No. A40. Unfortunately, no antiserum dilution curves were produced 
w ith any of the serum samples collected when compared to pre-immune serum.
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j Figure 6.3 Immunisation profile of ovine antibodies to a 1-am ino-l- 
deoxy-D-fructose residue produced by A40 a fte r immunisation with a 
j glycated lysyllysine-KLH conjugate. The coating Ag used fo r screening 
; was a fructosyl-tyram ine-BSA conjugate.
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Figure 6.4 Immunisation profile fo r ovine antibodies to a fructosyl- 
lysyllysine residue produced by sheep 1651,' a fter immunisation with a 
glycated poly-L-lysine-ovalbumin conjugate. The coating Ag used for 
screening was a fructosyl-lysyllysine chicken-Y-globulin conjugate.
Two other sheep, namely numbers 1640 and 1207, which were 
immunised w ith a fructosyl-tyram ine-ovalbum in conjugate and a fructosyl-4- 
aminobutyric acid-ovalbumin conjugate respectively also appeared to show a 
negative immune respone when screened for antibodies using the following 
system (c):-
Solid ^ 
Phase ^ BSA-Hapten
Sheep
Serum
Sample
DAS-HRP OPD
Substrate
(Hapten = l-am ino-l-deoxy-D-fructose-6-am inohexanoic acid)
However, a seventh sheep (no. 1651) was immunised w ith a glycated 
po ly-L-lysine-ovalbum in conjugate and was shown to have antibodies to a 
fructosyl-lysyllysine residue. This was concluded a fte r using 10pg/ml 
fructosyl-lysyllysine-chicken-$-globulin  conjugate as coating Ag fo r screening 
in system (c), diagramatically represented above. Figure 6.4. shows the 
immunisation profile  fo r this sheep. A fte r only 8 weeks post-immunisation, 
the t itre  had reached a level o f 1:4000 and remained at this level fo r 16 weeks
before startingjddecline, in the 24th week a fte r immunisation.
6.3.2. Sensitivity analysis fo r the antibody screening assay.
Figure 6.5 shows the result fo r the e ffec t of incubation time on OPD 
substrate to product formation using the following detection system fo r sheep 
antibodies:-
iSolid |  
Phase ^
I
Sheep
Serum
Sample
BSA-Hapten
(Hapten = l-am ino-l-deoxy-D-fructose-6-am inohexanoic acid)
DAS-HRP OPD
Substrate
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Figure 6.5 The e ffect of incubation tim e on the colour intensity produced 
w ith orthophenylenediamine substrate used in the screening of anti- 
fructosyl ovine antibodies from sheep immunised w ith A  = fructosyl-4- 
aminobutyric acid-ovalbumin conjugate (sheep 1207); □  = fructosyl- 
tyramine-ovalbumin conjugate (sheep 1640); +  = glycated poly-L-lysins- 
ovalbumin conjugate (sheep 1651).
The results for three sheep No. 1207, 1640 and 1651 are shown in 
figure 6.5. It can be seen that as the substrate incubation time increased, the 
signal-to-noise ratio became greater, especially for sheep 1207, but less so for 
the other sheep, 1640 or 1651. However, at the 30 minute incubation time 
interval normally used for all substrate incubations when assessing antiserum 
titre , there was no appreciable signal present.
6.3.3 The effect of bridge recognition on antiqen-antibody binding
In section 6.3.1. when screening for an ti—fruc tosy l antibodies from 
sheep A40, the assay procedure adopted circumvented the problems of bridge 
recognition by using a d iffe ren t fructosamine derivative and chem ica l'link in 
the hapten-carrier protein conjugate as the coating Ag. This is best illustrated 
in figure 6.6. Moreover, figure 6.3 clearly shows that anti-fructosyl (or anti-1- 
1 amino-1-deoxy-D-fructose) antibodies were detected a fte r overcoming the 
problems o f bridge recognition.
Figure 6.7a illustrates the presence of an antiserum dilution curve fo r 
anti-fructosyl antibodies from sheep No. 915 using the screening system ig 
illustrated in section 6.3.2 except that the hapten was fructosyl-tyram ine, 
j to overcome any bridge recognition effects.
Figure 6.7b also shows an antiserum dilution curve for anti-fructosyl 
antibodies, using the above screening system, fo r sheep No. 80. The antiserum 
titre  in figure 6.7b is only 1-4700 at 16 weeks post immunisation. The anti- 
fructosyl serum titre  for sheep 915 at 66 weeks post immunisation is greater 
than 112800 as further antiserum dilution points were not included. However, 
fo r sheep No. 80 when screening fo r anti-fructosyl antibodies as opposed to 
anti-fructosyl-6-aminohexanoic acid antibodies, the titre  is a facto r o f 22 
smaller at a sim ilar time point a fte r immunisation.
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Figure 6.6. The chemical and structural difference between two hapten- 
protein conjugates for overcoming Bridge e ffect when screening fo r 
antibodies recognising the fructosyl hapten, (a) Immunogen, protein = KLH or 
ovalbumin; (b) coating Ag, protein = 3SA.
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Figure 6.7 (a) An antiserum dilution curve fo r anti-fructosyl antibodies
from sheep 915 immunised with a monofructosyl-6-aminohexanoic acid- 
ovalbumin conjugate using 2yg/ml BSA-fructosyl-6-aminohexanoic acid as 
coating Ag. (b) Antiserum dilution curve for anti-fructosyl antibodies from 
sheep 80 using the same coating Ag as in (a).
6.3.4. The assessment of antiserum avidity and specificity for various
antigens
Antiserum dilution and displacement curves were constructed to 
assess the avid ity and specficity of antisera from sheep A40 and 913 to various 
antigens. Displacement curves were constructed with the following system 
initially using the methodology as outlined in section 6.2.3.3.
1
Solid ^ BSA-Hapten Antiserum DAS-HRP OPD
Phase ^ + substrate
1 Ag
(Hapten = l-am ino-l-deoxy-D -fructose-6-am ino hexanoic acid)
Figures 6.8a and 6.8b show antiseurm displacement curves for 
sheep antisera from sheep A40 and 913 respectively. A concentration of 
4 iig /m l in vivo glycated HSA was used as a displacing Ag, but this resulted in 
very l it t le  displacement of the antiserum dilution curves w ith antisera from 
both sheep. Further antiserum displacement curves w ith  sheep 913 antiserum 
using l-am ino-l-deoxy-D-fructose-6-am inohexanoic acid as a displacing Ag 
and 1-deoxy-morpholino-D-fructose along w ith methyl ester or methyl amine 
derivatives of fructosyl-6-aminohexanoic acid gave very l it t le  or no 
displacement at a 4ug/m l concentration o f displacing Ag. Moreover, when a 
d iffe ren t coating Ag was used, a 1-am ino-l-deoxy-D-fructase-tyram ine-BSA 
conjugate, to construct antiserum dilution curves w ith antisera from sheep 913 
and A40, no significant displacement was observed when challenged w ith 
4yg/m l in vivo glycated HSA. Sim ilarly, no displacement was seen when 
challenged w ith 4yg/m l o f either 1-deoxy-morpholino-D-fructose or the methyl 
ester or methyl amide derivatives of l-am ino-l-deoxy-D -fructose-6- 
aminohexanoic acid. On the other hand, when a fructosyl-6-amino-hexanoic 
acid-KLH conjugate was used as a displacing Ag, a displacement curve was 
obtained (figure 6.9).
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Figure 6.8 (a) Antiserum dilution and displacement curves for antibodies
from  sheep A40 immunised with a glycated lysyilysine-KLH conjugate. 
Coating Ag (A ) = 2yg/ml fructosyl-6-aminohexanoic acod-BSA; Displacing 
Ag (□ ) = 4yg/m l glycated HSA. (b) Antiserim  dilution and displacement 
curves for sheep 915 immunised w ith  a mono-fructosyl-6-aminohexanoic 
acid-ovalbumin conjugate. Coating Ag (A)= 2pg/ml fructosyl-6-am ino- 
hexanoic acid-BSA; Displacing Ag (□ ) = 8yg/m l glycated HSA.
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Figure 6.9 Antiserum displacment curves for antibodies from sheep 915
immunised with a mono-fructosyl-6-aminohexanoic acid-ovalbumin 
conjugate. Coating Ag (A ) = 2yg/m l fructosyl-6-aminohexanoic acid-BSA 
conjugate; Displacing Ag are 8yg/m l fructosyl-6-aminohexanoic acid-KLH 
(4), 8yg/ml K L H (D ) and 8yg/ml fructosyl-6-aminohexanoic acid (O).
6.3.5. The use of plasma and haemoglobin as displacing antigens for
antiserum dilution curves using sheep 913 an ti-l-am ino-l-deoxy-D - 
fructose-6-aminohexanoic acid antiserum ~
The results reported in this secton used the following 
immunoassay system to obtain antiserum displacement curves w ith normal 
human plasma or haemoglobin as displacing Ag.
iSolid ^  
Phase ^
I
BSA-Hapten Antiserum
+
Displacing
Ag
DAS-HRP OPD
substrate
(Hapten = l-am ino-l-deoxy-D -fructose-6-am ino hexanoic acid)
Antiserum = Sheep 915, 27 days post boost (batch No. 915/IE)
Displacing Antigen = Plasma or haemolysate. The Antiserum and 
displacing Ag were pre-incubated for 2 hours at 37°C before plating out 
into the m ic ro titra tion  plate wells.
Figure 6.10a shows a series of antiserum displacement curves w ith 
varying concentrations o f normal human plasma as competing Ag. A t a 1:50 
d ilution o f the plasma, there is very l it t le  displacement from the antiserum 
dilution curve. However, at a low antiserum dilution of 1:4000, there is a 
noticeable displacement which is, probably due to the Hook e ffe c t (Canteraro 
et al. 1980) where the more antibody present sterica lly inhibits other antibody 
from binding to the solid phase, thereby giving rise to  a decreased signal. 
Without the displacing Ag being present, the Hook e ffec t for the antiserum 
dilution curves is not present at the dilutions shown, but w ill occur at a lower 
antiserum dilution. Figure 6.10b shows the construction of a sample d ilution 
curve from the antiserum displacement curves shown in figure 6.10a. 
Although this data shows that a standard curves is feasable for measuring 
glycated proteins, as normal plasma contains approximately 5% glycated 
proteins, i t  is necessary to determine which glycated proteins are responsible 
for the large displacements seen.
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Figure 6.10 (a) Antiserum displacement curves using normal human
plasma at varying dilutions as displacing Ag with anti-fructosyl-6- 
aminohexanoic acid antiserum from sheep bleed 915/IE (27 days post 
boost). A  = 2yg/m l fructosyl-6-aminohexanoic acid-BSA conjugate as 
coating Ag; □  = 1:50 dilution, - f  = 1:10 dilu tion, O  = d ilution, X = 1:2 
dilution of normal plasma, (b) Sample dilution curve with normal human 
plasma at a 1:294000 dilution of the same sheep 915 antiserum.
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Figure 6.11 Antiserum displacement Curves using normal human 
haemoglobin as displacing Ag with the same sheep 915 antiserum as used in 
Figure 6.10. A =  2pg/m l fructosyl-6-aminohexanoic acid-BSA conjugate as 
coating Ag; □ = 1:20 dilution, 4- = 1:2 dilution of normal human 
haemolysate; <>= displacement w ith  8yg/ml fructosyl-6-aminohexanoic 
acid-KLH conjugate.
Figure 6.11 also shows a series o f displacement curves, but w ith 
normal haemolysed red blood cells at specific dilutions. Unfortunately, there 
may be a flaw  in the experimental design here as red cell membranes were 
also present in the pre-incubate of antigen and antibody. Therefore, antibody 
may become trapped by cell membrane inhibiting binding of antibody to solid 
phase Ag and this would lead to an a rtif ic ia lly  reduced signal, sim ilar to that 
which would be seen for a true displacement signal for a particular antibody 
dilution. Several possible solutions can be used to overcome this problem and 
show that the red cell membrane is not responsible for the observed 
displacement. These Will be considered la ter in the discussion (section 6.4).
Figure 6.12, shows the effects of sodium borohydride-reduced normal 
human plasma samples on antiserum displacement curves. Essentially, sodium 
borohydride, which w ill reduce the fructosyl residues to the straight chain 
g lucito l form, has affected the amount o f displacement acheived at equivalent 
human plasma dilutions. This therefore indicates that there are glycated 
protein components in normal plasma which are responsible fo r the 
displacement curves obtained in figure 6.10a. However, i t  can be seen that 
there is s till some slight displacement present. This displacement may be due 
to non-specific binding effects at low antiserum dilutions w ith respect to the 
antiserum dilution curve, as the antiserum dilution curve was not constructed 
in Ag free m atrix, but PBSGT buffer. Moreover, one cannot tru ly  compare the 
antiserum dilution curve constructed in PBSGT buffer, as shown in figure 6.12, 
w ith the antiserum displacement curves, where all glycated protein antigen 
has been removed by sodium boroy.dride reduction, leaving essentially antigen- 
free m atrix. Therefore all displacement curves using glycated moieties as 
antigen should only be compared against antiserum dilution curves where only
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Figure 6.12 The e ffec t of sodium borohyride reduction on normal human 
plasma as a displacement Ag. □  = 1/10 d ilution of sodium borohydride 
treated plasma, - f-  = 1/4 dilution of sodium borohydride treated plasma,<> = 
1/10 d ilution plasma, x  = 1/4 dilution plasma, A  = antiserum dilu tion curve.
A ll antiserum dilution curves used anti-fructosyl-6-aminohexanoic 
antibodies from sheep bleed 915/IE.
antigen has been removed and the m atrix le ft intact. In this case, Ag-free 
m atrix is the antiserum displacement curve where normal human plasma has 
been reduced by sodium borohydride and all specific displacements due to 
glycated components in human plasma are referred to this curve and not the 
antiserum dilution curve constructed only in PBSGT buffer.
6.3.6. Western blot analysis of glycated and non-qlycated proteins
Figure 6.13 is a photograph o f a Western blot. Nine tacks were 
loaded w ith protein samples, but only four tracks have been immunostained fo r 
glycated protein. These tracks correspond to fructosyl-tyram ine-BSA, 
fructosyl-6-aminohexanoic acid BSA conjugates and two tracks containing in 
vivo glycated HSA at d iffe ren t protein loadings. Unfortunatley, the la tte r two 
tracks did not give an intense immunostain. However, a fa in t band can be 
observed in these two tracks at a position level w ith the more intensely 
stained band in track 2 corresponding to BSA, which has a sim ilar molecular 
weight as HSA of 68000 daltons.
Figure 6.14 shows an additional Western blot where three tracks 2, 4 
and 6 have been immunostained. These tracks were loaded w ith a fructosyl-6- 
aminohexanoic acid-BSA conjugate, human plasma and purified in vivo 
glycated HSA respectively. The stain in track 6 is diffuse as well as fa in t and 
is marked by an arrow. This can be compared to adjacent tracks of equivalent 
protein loadings, using either sodium borohydride or sodium periodate-treated 
glycated HSA, where no immunostain is seen. No immunostain is seen in track 
3 corresponding the fructosyl-tyram ine BSA conjugate. However, the prim ary 
antibody used for immunostaining in this blot was an immunosorbent-purified 
anti-glycated epitope antibody from sheep 915-IE antiserum, 27 days post 
boost. Therefore, secondary steric effects may have inhibited Ag-Ab binding,
T rack  number
Figure 6.13 An immunostained Western blot using ovine anti-fructosyl-6- 
aminohexanoic acid antiserum from sheep 915 (27 days post boost). Track 
Nos; (1) 20yg BSA; (2) 20yg fructosyl-tyramine-BSA; (3) 20yg fructosyl-6- 
aminohexanoic acid-BSA; (4) 20yg unglycated Hb; (5) 20yg in vivo glycated 
Hb; (6) 50yg in vivo glycated Hb; (7) lOyg unglycated HSA;7"8) 10yg in vivo 
glycated HSA; (9) 25yg in vivo glycated HSA.
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Figure 6.14 An immunostained Western blot using ovine IgG from sheep 
915 antiserum affinity purified with glycated HSA. Track Nos; (1) ly g  
BSA; (2) lyg  fructosyl-6-aminohexanoic acid-BSA; (3) lyg  fructosyl- 
tyramine-BSA; (4) lOpg plasma; (5) lOyg sodium borohydride-treated 
plasma; (6) 10pg in vivo glycated HSA; (7) lOyg sodium borohydride-treated 
HSA; (8) lOyg sodium periodate-treated HSA.
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Figure 6.15 SDS-Polyacryiamide gel stained for protein with cooimassie 
biue. Track No. (1) lp g  BSA; (2) lu g  BSA-fructosyi-6-aminohexanoic acid; (3) 
lug  BSA-fructosyl-tyramine; (4) 10ug plasma; (3) 10ug sodium borohydride 
treated plasma; (6) 10ug in vivo glycated HSA; (7) 10ug sodium borohydride 
treated HSA; (8) 10ug sodium periodate-treated HSA; (10) Molecular weight 
markers: ovotrandbrrin (78kD), bovine serum albumin (66.2 kD), ovalbumin (43 
kD), carbonic anhydrase (30 kD), myoglobin (17.2 kD), cytochrome C (12.3 
kD)..
even although a fructosyl residue was present. Figure 6.15 is essentially an 
identical track loading to that fo r figure 6.14, except that track 9 was loaded 
w ith  molecular weight markers and the SDS-polyacrylamide gel stained for 
protein w ith  Comassie blue. Figure 6.15 essentially confirms tha t those tracks 
immunostained in Figure 6.14 correspond to protein having a molecular weight 
of 68000 daltons.
This is particu larly important for the immunostain in track 4, where 
this band corresponds to that fo r serum albumin, thereby confirming that the 
main immunoreactive constituent in human plasma, as was seen w ith  the 
antiserum displacement curves in section 6.3.5., is glycated human serum 
albumin.
6.4 DISCUSSION
Several d iffe rent immunogens were injected into sheep in order to 
produce antisera that could recognise glycated epitopes on proteins. Three 
sheep, namely A27, 1640 and 1207 immunised w ith fructosyl-valine-ovalbumin, 
fructosyl-tyramine-ovalbumin and fructosyl-4-am ino-butyric acid-ovalbumin 
conjugate respectively, did not appear to e lic it an immune response when the 
sera were screened fo r antibodies to fructosyl residues. However, as was seen 
in Figure 6.5, antibodies were defected when the substrate was le f t  to 
incubate for a longer period in the ELISA system, more so for sheep 1207. 
This suggested that the screening assay in use was not sensitive enough and 
that the problem could be overcome by using a suitable am plification system. 
Several possibilites exist which involve the use of systems such as substrate 
cycling, biotin-streptavidin matrices or fluorogenic substrates as reviewed by 
Jackman (1988) and Gould (1988). Time, on the other hand, did not allow the 
development and optim isation of a suitable am plification system fo r detecting 
anti-fructosyl antibodies. The antisera from sheep A27, 1640 and 1207 were 
therefore considered to be of no further practical use at the tim e, and all
effo rts  were diverted to the more promising antiserum from sheep A40, 915,
80 and 1651, immunised with a fructosyl-lysyllysine-KLH, fructosyl-6-aminohexanoic 
acid-ovalbumin, fructosyl-6-aminohexanoic acid-KLH and glycated poly-L- 
lysine-ovalbumin conjugate respectively..
Both sheep 915 and 80 exhibited the presence of anti-fructosyl 
antibodies, as were evident from the results shown in figure 6.1 and 6.2. 
However, the Ag used for screening possessed the same chemical attachment 
between hapten and carrier protein as that used for the original immunogens in 
both sheep. Therefore, to avoid the likelihood of bridge recognition (Van 
Weemen and Schuurs, 1975; Gilby and Jeffcoate, 1973; Cameron et al., 1973) a 
screening Ag possessing a different hapten carrier protein chemical 
attachment was used.
Unfortunately, glycated 6-aminohexanoic acid contained only one 
functional group, namely a carboxyl group, fo r linking to a carrier protein.
This carboxyl group could undergo two possible reactions, without a ffecting 
the rest of the hapten. These were (i) amidation and (ii) esterification.
The la tte r reaction, however, would not produce a stable irrevesible 
crosslink and was therefore not used. The firs t reaction had already been used 
for preparation of the immunogens in sheep 915, 80 and A40 and could 
therefore not be used to circumvent the problem of bridge recognition. A 
a lternative glycated amine, such as fructosyl-tyram ine, was chosen since the 
Mannich reaction could be used to  link the hapten to the protein. Therefore, 
as well as forming a d iffe rent chemical attachment, a structura lly d iffe rent 
amine was also used in the coating Ag. Figure 6.7(a) and (b) demonstrated the 
presence of anti-fructosyl antibodies from sheep 915 and 80 respectively. It 
should be noted that the antiserum titre , w ith the alternative coating Ag, is 
much lower than that shown in figure 6.2 at a sim ilar tim e period w ith  sheep 
915. On the other hand, when screening fo r anti-fructosyl antibodies in sheep
A40 and 1651 ^  the coating Ag used in itia lly , circumvented the problem of
bridge recognition from the start unlike that w ith sheep 915 and 80. Although
the post-immunisation screening had not progressed as far as that seen with
6*3 an<^
sheep 915 and 80, figures|6.4 demonstrated that for sheep A40 and 1651 
respectively, low antiserum titres  for specific anti-fructosyl antibodies were 
present.
In itia l displacement studies were carried out w ith antisera from 
sheep 915 and 80. Figures 6.8 (a) and (b) showed that l it t le  or no displacement 
had occurred w ith glycated HSA as a displacing Ag. Similar results were seen 
w ith other serum samples from the same sheep (not shown). Four possible 
conclusions were drawn from this experiment:
i) The antiserum binds w ith greater avid ity to the coating Ag
due to bridge recognition, in this case fructosyl-6-am ino- 
hexanoic acid-BSA, rather than to the glycated HSA 
molecules which contain fructosyl residues on the £ -amino 
groups of lysine side chains 
(ii) A second possibility could be due to steric hinderance of
Ag-Ab binding. The fructosyl residue on the ^-amino group 
of a lysine may exist in a recess or pocket on the surface 
o f the protein molecule thereby being inaccessable fo r Ag- 
Ab binding. Other research groups who have raised
antibodies to glycated proteins, as outlined in section 1.3, 
produced antibodies to the straight chain reduced g lucito l 
form which is more like ly to protrude out o f a c le ft. 
Problems due to steric hinderance should not arise i f  the 
glycated protein were denatured, then the fructosyl residue 
would no longer be masked and could be recognised by the
anti-fructosyl antibodies .j Such a technique could be 
carried out by using Western blot analysis.
A th ird consideration is that the preferential site of 
glycation in vivo for HSA is a lysyl lysine sequence (Garlick 
and Mazer, 1983). The second unglycated lysine residue 
may inhib it Ab binding by possessing a net positive charge 
when the £-amino group is in its undissociated form. The 
positive charge could therefore a ffe c t the interaction of 
Ab to Ag especially as the anti-fructosyl Ab was raised 
against an immunogen where there was no additional 
charges in close proxim ity to the fructosyT residue.
Finally, an alternative explanation may be due to the 
re lative number of fructosyl groups which are contributed 
to the ELISA system between the coating Ag and the 
displacing Ag. This w ill a ffec t the amount o f displacement 
detected. In the present system there were 5.9 pmoles of 
coating Ag, equivilant to 2yg/m l BSA-hapten conjugate, as 
opposed to a maximum. 23.5 pmoles of displacing Ag 
(glycated HSA) in each ELISA well. However, the results 
in chapter 5 (table 5.1) showed that there were 17 fructosyl 
residues per BSA molecule fo r the coating Ag used, 
fructosyl-6-aminohexandb acid-BSA conjugate. Whereas,, i f  
in vivo glycated HSA can be assumed to have only 1 
fructosyl residue per HSA molecule (Olufemi et a l., 1987) 
then the relative amounts of fructosyl residues between 
the coating Ag and displacing Ag are 100.3 pmoles and 23.5 
pmoles respectively. Hence the antibodies more like ly  to 
bind to the coating Ag rather than the displacing Ag 
causing very l it t le  displacement.
To test whether bridge recognition may have an e ffec t on the role of 
glycated HSA as a displacing Ag, several small molecules were used as 
alternative displacing Ag,including a derivative of fructosyl-6-amino-hexanoic 
acid possessing an amide bond to simulate the ’bridge' between the hapten and 
carrier protein in the original immunogen. Unfortunately, the results proved 
negative indicating that deoxy-morpholino-D-fructose, fructosyl-6- 
aminohexanoic acid and the ester and amide derivatives did not give any 
substantial displacement. To determine the strength of the bridge e ffec t, the 
experiment was repeated using fructosyl-tyram ine-BSA as the coating Ag w ith 
antiserum from sheep 915. Again, sim ilar results to these just described were 
observed. In addition, an antiserum dilution curve usmg sheep A40. Ab <and 
fructosyl-tyram ine-BSA as a coating Ag could not be displaced by in vivo 
glycated HSA. This data suggested that neither bridge recognition nor steric 
hinderance to Ag-Ab binding was a problem. The e ffec t o f an increased 
relative concentration of displacing Ag was then investigated as Lew (1984) 
reported that epitope density could a ffec t Ag-Ab complex form ation. The 
correctness of this possible solution was indicated by the results shown in 
figure 6.9. Substantial displacement was achieved when using 0.3 pmoles of 
fructosyl-6-amino-hexanoic acid-KLH as displacing Ag against 5.9pmoles of 
fructosyl-6-amino-hexanoic acid - BSA as coating Ag in the m ic ro titra tion  
plate well. However, the displacing Ag; fructosyl-6-aminohexanoic acid - KLH^ 
contained an equivalent o f 1200 pmoles of fructosyl groups (see table 5.1) as 
opposed to only 100.3 pmoles of fructosyl groups fo r the coating Ag, fructosyl- 
6-aminohexanoic acid - BSA. Therefore, Ab w ill more like ly  bind to displacing 
Ag, as opposed to coating Ag, thereby giving rise to the appreciable amount of 
displacement observed in figure 6.9.
According to Olufemi et al. (1987) p there are 0.37 moles 
fructosamine/mole of to ta l HSA in plasma. There are therefore approximately
200 nmoles/ml of fructosyl residues in plasma assuming a HSA concentration 
of 40mg/ml. Therefore,as plasma dilution is increased,one would expect to 
observe a series of d ilution curves w ith decreasing displacement, re lative to an 
antiserum dilution curve. This e ffec t was observed (figure 6.10). In addition, 
this displacement w ith human plasma was removed by pretreatment w ith 
sodium borohydride as shown in figure 6.12. As sodium borohydirde reduces 
the fructosyl residue to its stra ight chain g lucito l form , this demonstrates that 
it  is glycated plasma proteins which are responsible for the displacement seen 
in figure 6.10. Similar results were also observed w ith human haemoglobin , 
shown in figure 6.11. However, the presence o f cell membrane could give rise 
to a rtif ic ia l displacement curves as Ab may become trapped by the cell 
membrane and be unable to bind to coating Ag. This problem could have been 
overcome by removal at the red cell membrane a fte r lysis by centrifugation. 
Supernatant, containing almost 100% haemoglobin protein could then be used 
as displacing Ag.
HSA, were used to immunostain a Western blot. An intense band was observed 
in track 4 corresponding to a molecular weight of 68000 daltons. The adjacent 
track 5, did not give an immunostain which was loaded w ith  sodium 
borohydride-treated human plasma. Therefore, the displacement curves seen 
in figure 6.10 were due to glycated HSA in plasma which has a molecular 
weight of 68000 daltions. In addition, a fa in t band corresponding to glycated 
HSA was seen in track 6, but not in tracks 7 or 8 where the fructosyl residue 
had been destroyed by either sodium borohydride or periodate treatm ent. 
Similar results were seen in figure 6.13, but no tracks were loaded w ith  
plasma. It w ill be seen that glycated haemoglobin gave no immunostained 
band. However, protein loadings were low as there was a lim it to the size of 
sample
■ anti-fructosyl-6-aminohexanoic acid
In figure 6.14 Ddies from sheep 915,-purified against glycated
that could be added w ithout causing diffusion problems w ith the SDS 
polyacrylamide gel. This low protein loading could account for the very fa in t 
bands seen w ith pure glycated HSA in tracks 7 and 8 in figure ‘6.13.
In conclusion, serum from sheep 913 immunised 
against fructosyl-6- aminohexanoic acid ' contained antibodies that could
recognise in vivo glycated HSA in human plasma. However, the number of
competing fructosyl residues in the displacing Ag had to be an order of
magnitude greater than those in the coating Ag to produce useful
displacement. This experimental data suggests that an ELISA could be
developed to measure glycated HSA, although there is some doubt as to
whether a sim ilar ELISA may be obtained for glycated haemoglobin. Time,
unfortunately, did not perm it fu rther assessment of serum from sheep 80 and
A40 and therefore no comparison could be made as to which immunogen would
produce the best antiserum fo r an ELISA measuring glycated proteins.
CHAPTER 7
THE DEVELOPMENT OF AN ELISA 
FOR GLYCATED HUMAN SERUM ALBUMIN
7.1 INTRODUCTION
Several research groups, as outlined earlier in section 1.2.4.7, have 
raised antisera to glycated proteins and developed an immunoassay for the ir 
measurement. However, only two of these groups (Javid et al., 1978 and 
Knowles et al., 1987) have developed an immunoassay for the measurement of 
unreduced in vivo glycated protein. Both assays were of a competitive nature 
for the measurement o f glycated haemoglobin, more specifically HbA The 
remaining immunoassays measured the reduced g lucito l derivative of glycated 
proteins. Three o f these assays were based on a RIA while the other two were 
ELISAs. The radioimmunoassays measured the soclium borohydride-reduced 
drivative of glycated human serum albumin or glycated LDL (Curtiss and 
Witzum, 1983). For glycated human serum albumin, the radioimmunoassays 
were based on a competitive form at (Nakayama et al., 1986) or a non­
com petitive immunoradiometric assay (Ohe et al., 1987). Sim ilarly, one ELISA 
measured reduced glycated proteins by a com petitive based system (Go et al., 
1987), while the other assay of Zeuthen et al., (1986) measured sodium 
borohydride-reduced HbA^c by an immunoenzymometric assay. A common 
feature of a ll these assays was that they were based on a heterogeneous 
form at.
When measuring small molecules, which may contain only one 
epitope, constraints on assay design usually necessitate the use of . a 
competitive immunoassay format. However, glycated proteins w ill contain 
several epitopes, one of which being the attached fructosyl residue itse lf. 
Therefore, as is evident from the work of others mentioned above, both 
competitive and non-competitive assay systems could be developed. 
Moreover, the la tte r system allows the possibility of specifica lly measuring 
any glycated protein using an anti-frucfosyl Ab and an appropriate anti-prote in 
Ab to form the sandwich. The competitive system, on the other hand, only 
allows the measurement o f glycated proteins as a whole.
This chapter w ill describe the development of two approaches for the 
measurement of glycated HSA. The two approaches utilised both the 
competitive and non-competitive systems. Both assay formats initially 
involved the use of an enzyme-labelled second Ab for the indirect 
quantification of the glycated protein.
7.2 MATERIALS AND METHODS
7.2.1 Materials
Whatman pre-swollen DE 52 DEAE cellulose anionic exchange resin 
and te tram ethyl benzidine (TMB) were puchased from Sigma Chemicals Co 
Ltd (UK). Am ine-activated, controlled pore glass m atrix, CPG 2000A was a 
g if t from C lifm ar Associates, University o f Surrey. Rabbit anti-human 
haemoglobin(igG) and rabbit anti-human serum a lbum in(lgG )w ^ obtained from 
Dako Immunochemicals Ltd. Horseradish peroxidase-labelled sheep an ti­
human serum albumin (igG ) was bought from Binding Site. Horseradish 
peroxidase-labelled sheep anti-rabbit IgG, donkey anti-sheep IgG and normal 
sheep serum (igG) were all obtained from Guildhay Antisera Ltd., Guildford. A ll 
other reagents and immunochemicals were obtainined as described in section 
6.2.1.
7.2.2 The purification of IgG antibodies from whole serum
To 10ml sheep serum, 5ml saturated ammonium sulphate solution
were slowly added dropwise w ith stirring to precipitate the IgG and IgM 
immunoglobulins. The precipitate was sedimented by centrifugation at 2000g 
for 10 minutes and a fte r discarding the supernatant was then redissolved in 
10ml o f d istilled water. The immunoglobulins were reprecipitated by the 
further addition of 5ml saturated ammonium sulphate solution and then 
centrifuged at 2000g for 10 minutes. .The precipitate was again redissolved in 
a small amount o f d istilled water and dialysed against d istilled water fo r 24 
hours at 4°C, to remove the ammonium sulphate.
A DEAE anion exchange column (2 x 2cm, VD= 65ml) was pre-D
equilibrated with lOmM sodium phosphate buffer, pH 6.4. The dialysate was 
diluted tenfold w ith lOmM sodium phosphate buffer, pH 6.4 prior to loading on 
to the DEAE column. The column was eluted with lOmM sodium phosphate 
buffer, pH 6.4, at a flow rate of lm l/m in . Fractions (5ml) were collected and 
the ir absorbance measured at 280nm. Those fractions having absorbance at 
280mm >0.007 units were pooled. A 1:10 dilution was taken and the 
absorbance at 280nm read to calculate the IgG protein concentration, using 
the follow ing expression (Hurn and Chantler, 1980):-
concentration (mg/ml) = (OD2qqX10)/1.34
The IgG preparation was then stored in a clean, sterile glass bottle  at 
4°C to which was added 10yl of 10% (w/v) sodium azide solution per 1ml of 
IgG solution.
7.2.3 The purification of sheep anti-glycated epitope antibodies.
7.2.3.1 The production of a glycated human serum albumin a ffin ity  column.
From a stock solution of in vivo glycated HSA, the equivalent of 
45mg protein was diluted to 20ml w ith lOOmM sodium phosphate buffer, pH 
6.8. To this protein solution was added lg  amine-activated CPG 2000A glass 
m atrix , followed by 200yl of 25% (v/tv) glutaraldehyde solution and the m ixture 
gently mixed for 2 hours at room temperature. 2M glycine solution (1ml) was 
added and the slurry mixed fo r a further 2 hours at room temperature. The 
resulting a ffin ity  resin was packed into a column and washed through with 
40ml of distilled water. The column was then pre-equilibrated w ith  PBS, 
pH7.4, prior to use.
7.2.3.2 A f f in ity  p u rifica tion  o f sheep anti-g lyca ted  epitope antibodies.
Into 10ml PBS was added 10ml IgG solution prepared from ovine
antiTructosyl-6-amino-hexanoic acid antiserum (batch G/S/915/Ic) prepared as
described in section 7.2.2 and applied to the glycated HSA a ffin ity  column.
The column was washed through w ith a further 20ml PBS, collecting the eluate
in one container. Bound IgG was then eluted stepwise w ith  6ml 0.1M
glyc ine /H C l, pH 3.0, followed by 6ml 0.1M glycine/HCl, pH 2.0, collecting 
double strength
lm l fractions into lmI|PBS, pH 7.4. The absorbance of each fraction at 280nm 
was measured and the resulting absorbance peaks pooled using Hurn and 
Chantler's (1980) formula (see section 7.2.2). The concentration of the eluted 
bound IgG was determined as well as the percentage recovery from  the 
column. The two pooled bound IgG fractions were stored at 4°C in clean 
sterile glass bottles also containing 10yl 10% (w/v) sodium azide per lm l of 
IgG solution.
7.2.4 General ELISA procedure
A ll m icro titra tion  plate wells were prewashed w ith 40mM sodium 
bicarbonate buffer, pH 9.6,prior to coating. The wells were then coated w ith  a 
known concentration of Ag or Ab and le f t to incubate at 37°C fo r 2 hours in a 
humid environment. A ll wells were subsequently washed four times w ith 
PBSGT a fte r each incubation period. The wells were then blocked w ith  0.2% 
casein (w/v) in PBSGT fo r one hour at 37°C. Further stages which involved 
either incubating plates w ith  Ab or Ag were carried out at 37°C fo r 2 hours in 
a humid environment. A fte r the addition of enzyme-labelled Ab, OPD 
substrate (prepared as described in section 6.2.2.2) or TMB substrate, 150yl 
per well, was used to detect any bound enzyme-labelled Ab present. This 
involved incubation of substrate for 30 minutes at 37°C in a humid 
environment and a fte r stopping w ith 50yl of 2.5M sulphuric acid, measuring 
the absorbance at 490nm or 450nm respectively w ith  a Flow Laboratories 
Multiscan Plus Autoreader. TMB substrate was prepared as follows: In 800ml
of industrial methylated sp irit were dissolved 2g of tetramethylbenzidine 
(TMB), followed by the addition of 200ml distilled water. A second solution of 
0.2M trisodium c itra te /ace tic  acid buffer, pH 5.0, was prepared and both 
solutions kept at 4°C prior to use. Active TMB substrate was prepared by 
mixing 10ml of TMB solution w ith 90ml of 0.2M trisodium c itra te /ace tic  acid 
buffer, pH 5.0, solution along w ith 40yl of 30% (v/v) hydrogen peroxide 
solution.
7.2.5 The development o f a com petitive ELISA
7.2.5.1 In itia l assay protocol fo r glycated HSA
M icro titra tion  plate wells were coated w ith 200yl of 2yg/m l 
fructosyl-6-amino-hexanoic acid-BSA conjugate dissolved in 40mM sodium 
bicarbonate coating buffer pH 9.6. A fte r incubation, washing and blocking 
w ith casein as described in section 7.2.4, duplicate 200yl aliquots of sample 
preincubation mixtures were added to each well and le ft to incubate for 2 
hours at 37°C. The sample preincubation mixtures were prepared as follows: 
Into a to ta l volume of 500yl were added a 1:100 000 dilution of sheep an ti­
glycated epitope antiserum (batch number G/S/915/IE, 27 days post boost) or 
normal sheep serum along w ith  various concentrations of glycated HSA ranging 
from 0 to 2mg/ml diluted in PBSGT. These pre-incubation mixtures were le ft 
to incubate for 2 hours at 37°C prior to plating out. 200yl aliquots o f 1:20000 
diluted horse radish peroxidase-labelled donkey anti-sheep IgG in PBSGT were 
used to detect sheep anti-glycated epitope Ab bound to the Ag coated wells. 
OPD substrate, 150yl per well, was used to  visualise bound enzyme-labelled Ab, 
as described in section 7.2.4.
7.2.5.2 Optim isation of the competitive ELISA for glycated HSA
Four experiments were carried out to optimise the basic assay system 
described in section 7.2.5.1.
Experiment I: To show the e ffec t of using a ffin ity -purified  sheep anti-glycated 
epitipe antibody on NSB, as opposed to crude sheep anti-serum as used in 
section 7.2.5.1, the m icro titra tion  plates were coated with antigen and blocked 
w ith casein as described in section 7.2.5.1. However, the pre-incubation 
mixtures contained 248ng/ml of a ffin ity -p u rified  sheep anti-glycated epitope 
IgG (Batch G/S/915/IE) or normal sheep serum IgG along with 0 to 2.8 mg/ml 
of either glycated HSA, sodium borohydride treated- or sodium periodate 
treated-glycated HSA. The remaining protocol was as described in section
7.2.5.1,except TMB substrate was used instead of OPD substrate.
Experiment II: In this second experiment the e ffec t of varying coating Ag
concentration on NSB was investigated. The plate was coated w ith  various 
concentrations of fructosyl-6-aminohexanoic acid-BSA conjugate ranging from 
10 to 2000 ng/m ljfo llwed by incubation w ith  0.2% (w/v) casein, as described in
7.2.5.1. In the pre-incubation m ixture, 248 ng/ml of anti-glycated HSA 
antibodies or normal sheep serum IgG were incubated w ith  either 0, 0.9 or 1.7 
mg/ml of glycated HSA. Again TMB substrate was used and the remaining 
protocol was as described in section 7.2.5.1.
Experiment III: In an attem pt to investigate the e ffec t o f varying the dynamic 
range of the competitve ELISA for glycated HSA, the residual sheep an ti­
glycated epitope IgG concentration aliquoted into each well a fte r pre- 
incubation w ith standard was varied.
M ic ro titra tion  plates were coated w ith  5ng/ml fructosyl-6- 
aminohexanoic acid-BSA conjugate. Various concentrations of glycated HSA 
ranging from 0 to 0.8 mg/ml were then preincubated w ith 248ng/ml of sheep 
anti-glycated epitope IgG. Varying sample aliquots of these preincubation 
mixtures ranging from 17 to 200yl were then pipetted in duplicate into the
wells and made up to 200yl w ith PBSGT. Again TMB substrate was used as 
described in section 7.2.4.
Experiment IV: The e ffec t of enzyme-labelled donkey anti-sheep IgG
concentration on signal levels,as detected by the measurement of absorbance 
at 450nm , was investigated. A fte r coating w ith 5ng/ml fructosyl-6- 
aminohexanoic acid-BSA conjugate and then blocking w ith casein, duplicate 
200yl aliquots of preincubate mixtures were pipetted out. These mixtures 
contained 24.8ng/ml a ffin ity -p u rifie d  sheep anti-glycated epitope antibodies 
(Batch G/S/915/IE) or normal sheep serum IgG w ith  glycated HSA ranging from 
0 to 60yg/m l. Horseradish peroxidase-labelled donkey anti-sheep IgG was 
added at d iffe rent dilutions to each standard curve. The dilutions used were 
1:2500, 1:5000, 1:7500 and 1:10000. TMB substrate was again used as 
described in section 7.2.4.
7.2.5.3 An optimised assay fo r Glycated HSA.
M icro titra tion  plate wells were coated w ith 5ng/ml fructosyl-6-
amino-hexanoic acid-BSA conjugate. Pre-incubation mixtures were prepared
using 62ng/ml a ffin ity -pu rified  sheep anti-glycated epitope antibodies (Batch
G/S/915/IE) or normal sheep serum IgG w ith 0 to 200 yg/m l concentrations of 
diluted in PBSGT
glycated HS/^_ Duplicate 200yl aliquots were pipetted out and the plate 
incubated as described in section 7.2.4. A 1:5000 dilution of horseradish 
peroxidase-labelled donkey anti-sheep IgG, 200yl aliquots per well, was added 
and TMB substrate used to detect any signal present by measuring absorbance 
at 450nm.
7.2.5.4 The e ffec t of human plasma on the standard curve of glycated HSA 
The methodology was essentially as described in section 7.2.5.3.
However, the preincubation mixtures contained an additional component of a
1:40 d ilution of pooled normal human plasma. The plasma was separated from 
blood by centrifugation at 2000g fo r 15 minutes, having been collected in 
Lithium  heparin coated vials.
7.2.5.5 A cross reac tiv ity  assessment of a ffin ity -pu rified  sheep anti-glycated
epitope IgG
The methodology described in section 7.2.5.3 was used to determine 
the specific ity  of the anti-gl>cated epitope IgG (Batch G/S/915/IE). Several 
d iffe rent preincubation mixtures were prepared incorporating various d iffe ren t 
antigens so asto qualita tive ly assess specific ity  of the assay to glycated HSA. 
In all cases 62ng/ml sheep anti-glycated epitope IgG (Batch G/S/915/IE) or 
normal sheep serum IgG was used in the pre-incubation mixtures. The 
concentrations over which the antigens were tested are shown below:-
(i) Glycated HSA 0-1.5ymoles/l
(ii) Sodium periodate- 0-294 ymoles/1
treated glycated HSA
(iii) Sodium borohydride- 0-294 ymoles/l
treated glycated HSA
(iv) 6-aminohexanoic acid 0-200 mmoles/1
(vi) D-glucose 0-200 mmoles/1
(vi) D-fructose 0-200 mmoles/1
(vii) Fructosyl-6-amino-hexanoic acid 0-200 ymoles/1
7.2.6 The development of a non-competitive ELISA
7.2.6.1 The use of donkey anti-sheep IgG as capture antibody
M icro titra tion  plate wells were coated w ith  200yil lO yg/m l donkey 
anti-sheep IgG diluted in 40mM sodium bicarbonate buffer pH 9.6 and le f t  to 
incubate as described in section 7.2.4. A fte r blocking w ith 0.2% (w/v) casein 
solution, 200yl aliquots of ly g /m l sheep anti-glycated epitope IgG or normal 
sheep serum IgG diluted in PBSGT were added to the wells. Following the 
incubation and washing stages, duplicate 200yl aliquots of glycated HSA,
sodium periodate-or sodium borohydride-treated HSA at concentrations ranging 
from 0.1 to lOOOyg/ml diluted in PBSGT were added to the wells. A fte r a 
further incubation and washing cycle,200yl aliquots per well of 1:500 diluted 
rabbit anti-HSA antibodies were added followed by another incubation and 
washing cycle. 200yl aliquots of 1:10000 diluted horse-radish peroxidase- 
labelled donkey anti-rabbit IgG in PBSGT were added to each well. Following 
a final incubation and washing cycle, TMB substrate was added to each well 
and the absorbance at 450nm measured as described in section 7.2.4.
7.2.6.2 The use of sheep anti-glycated epitope IgG as capture antibody.
H alf the wells on a m icro titra tion  plate were coated w ith  ly g /m l o f 
sheep anti-glycated epitope IgG in 40mM sodium bicarbonate buffer pH 9.6. 
The remaining wells were coated w ith  ly g /m l normal sheep serum under sim ilar 
conditions and le f t to incubate as described in section 7.2.4. Following 
blocking w ith 0.2% (w/v) casein along w ith a further incubation and washing 
cycle, duplicate 200yl aliquots of glycated HSA were added at various 
concentrations ranging from 0 to lOOOyg/ml to the wells. To detect bound 
glycated HSA two d iffe ren t systems were investigated. The firs t system used 
rabbit anti-HSA(lgG)follwed by horseradish peroxidase-labelled donkey anti- 
rabbit IgG as described in section 7.2.6.I. The second system involved the use 
of 2yg/m l horseradish peroxidase-labelled sheep anti-HSA (igG ) dissolved in 
PBSGT and 200yl aliquots dispensed into each well. TMB substrate was then 
used to detect the completed sandwich by measuring absorbance at 450nm as 
described in section 7.2.4.
7.3 RESULTS
7.3.1 The development o f a com petitive ELISA fo r glycated HSA
7.3.1.1 An un-optimised competive immunoassay fo r glycated HSA.
In figure 7.1a is shown a standard curve fo r g lycated HSA using the
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Figure 7.1 Standard curves for glycated HSA using (a) crude sheep 915/IE antiserum, 
(b) a ffin ity  purified sheep 915/IE anti-glycated epitope IgG. A  = in vivo 
glycated HSA; □= sodium borohydride-treated HSA; # =  sodium perlodate- 
treated HSA.
following system:-
Glycated HSA H R P -
$ BSA-Hapten 0.2% (w/v) + labelled
! casein Sheep anti­glycated epitope antiserum
donkey anti­
sheep IgG
OPD
substrate
N.B. (a) Sheep anti-glycated epitope (G/S/915/IE) antiserum is the bleed
collected 27 days a fte r boosting.
(b) Hapten = fructosyl-6-aminohexanoic acid
It can be seen that a very high NSB level was present. Also 
apparent, was the small change in absorbance at 490nm between the high and 
low concentrations of glycated HSA. On the other hand, this figure illustrated 
the feasib ility  of developing a competitive ELISA for glycated HSA, i f  the high 
background NSB could be eliminated.
7.3.1.2 The e ffec t o f using anti-glycated epitope a ffin ity  purified IgG.
The assay system irvsection 7.3.1.1 was essentially used to compare 
the e ffec t of using a ffin ity -p u rif ie d  primary antibodies, instead of crude 
antiserum. The modifications are shown below. In addition this modified 
system was used in all further optim isation experiments as well as the fina l 
developed competitive ELISA system:
Ay
y  BSA-Hapten 0.2% (w/v) Glycated HSA HRP-labelled
casein +
A ffin ity -P u rified  
Sheep a n ti-  
glycated epitope 
IgG
donkey anti -  
sheep IgG
TMB
substrate
N.B. Hapten = fructosyl-6-aminohexanoic acid
Figure 7.1b shows that although the use of a ffin ity -p u rifie d  anti- 
glycated epitope antibodies considerably reduced the level of NSB, the la tte r
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Figure 7.2 A histogram illustra ting  the e ffec t of coating 
concentration on signal levels as detected by absorbance at 450nm. §§ 
mg/m l glycated HSA as competing Ag; [|§ = 0.9 mg/ml glycated HSA; 
Omg/ml glycated HSA.
was s till unacceptably high. Further analysis, however, shows that the rate of 
change in absorbance at 450nm between the high and low glycated HSA 
concentrations was greater than previously observed in figure 7.1a. Two 
additional curves illustrated in figure 7.1b representing sodium borohydride 
and sodium periodate-treated HSA do not show any decrease in absorbance at 
450nm w ith  increasing concentration. This therefore suggests that the a ffin ity  
purified anti-glycated epitope antibodies recognise only glycated HSA in this 
experiment.
7.3.1.3. The e ffec t of varying coating antigen concentration on signal levels
as detected by absorbance at 450nm.
Figure 7.2 demonstrates the e ffec t of coating Ag concentration on 
signal levels at three d iffe ren t glycated HSA concentrations. Above a 
lOOOng/ml coating Ag concentration, signal levels were very high as was also 
evident in figures 7.1a and 7.1b when a 2000ng/ml coating Ag concentration 
was used. However, as coating Ag concentration was decreased to lOng/ml 
the e ffec t on signal levels due to specific Ag-Ab binding was very noticable. 
This can be seen by observing that fu ll displacement w ith 1.7mg/ml of 
glycated HSA gave low NSB levels at a lOng/m l coating Ag concentration as 
opposed to a very high NSB level when a lOOOng/ml coating Ag concentration 
was used. However, the intensity o f the specific signal was also reduced at 
low coating Ag concentrations and must therefore be amplified.
7.3.1.4. The e ffec t of residual sheep anti-glycated epitope IgG concentration
a fte r preincubation w ith standard on the assay dynamic range.
Figure 7.3 illustrates the e ffec t of varying the residual sheep an ti­
glycated epitope IgG concentration a fte r pre-incubation w ith standard on the 
dynamic range of the competetive ELISA for glycated HSA. As the 
concentration of sheep anti-glycated epitope concentration fe ll, so the
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Figure 7.3 The e ffec t of residual concentration of ovine anti-glycated 
j epitope IgG a ffin ity -purified  from sheep bleed 915/IE after preincubation 
w ith  standard on the dynamic range of the ELISA for glycated HSA. A =  no 
dilution; □ =  1:2 dilution; - f  = 1:4 dilution; <C>= 1:8 dilution and X = 1:12 
dilution of the preincubation mixture.
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Figure 7.4 The e ffec t of enzyme-labelled anti-sheep IgG concentration on 
specific signal levels as detected by absorbance at 450nm. A  = 1/10000 
dilution; □ =  1/7500 dilution; - f  = 1/5000 d ilution; <> = 1/2500 d ilu tion 
enzyme labelled donkey anti-sheep IgGJPrimary antibody = anti-glycated 
epitope IgG from sheep bleed 915/IE.
dynamic range of the ELISA shifted towards a lower concentration range of 
glycated HSA. In addition , it  is also apparent that the standard curve began 
to fla tten  out as the sheep anti-glycated epitope concentration fe ll. This is 
essentially due to less antibody being present to bind to immobilised coating 
antigen. I t  is important to note that as the concentration of anti-glycated 
epitope antibody was progressively reduced in the well, so the glycated HSA 
concentration fe ll by a sim ilar amount. However, the ratios of antibody to 
glycated HSA remained constant at each analyte concentration. Therefore, as 
the d ilution of antibody and glycated HSA antigen in the preincubation m ixture 
was increased, less antibody per well is used as well as shifting the dynamic 
range of the ELISA towards a lower concentration of glycated HSA analyte.
7.3.1.5. The e ffect of varying enzyme-labelled donkey anti-sheep IgG on
specific signal levels as dectected by absorbance at 450nm.
In-figure 7.4 the e ffec t of increasing enzyme-labelled donkey an ti­
sheep IgG concentration on the signal levels is clearly demonstrated. As the 
concentration of enzyme-labelled Ab was increased,there was a corresponding 
increase in signal levels. This was due to more enzyme labelled donkey an ti­
sheep IgG being present to bind to sheep anti-glycated epitope IgG which in 
turn had bound to the immobilised coating Ag.
7.3.1.6. A standard curve for glycated HSA ____
diluted in PBSGT
The optimised standard curve fo r glycated HSAjusing the competitive 
ELISA form at is shown in figure 7.5. The curve was constructed over the 
range 0 to 200 ]ig /m l glycated HSA. Although, the most precise range would 
appear to lie between 0 to lOOpg/ml, only a precision dose profile  would 
determine the operating range of this standard curve fo r accurate 
measurement of sample containing unknown amounts of glycated HSA.
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Figure 7.5 A standard curve fo r glycated HSA diluted in PBSGT buffer- 
using a ffin ity  purified sheep anti-glycated epitope IgG. A ll points are the 
mean of two determinations, error bars only shown i f  qreater than the point 
marker. Anti-glycated epitope IgG antibodies were purified from  sheep 
bleed 915/IE.
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Figure 7.6 The e ffec t of plasma m atrix on a standard curve for glycated 
HSA. A  = standard curve in PBSGT buffer; □  = standard curve in a 1/40 
dilution of plasma. Assay conditions as fo r Figure 7.5
7.3.1.7. The e ffe c t of normal human plasma on the standard curve fo r
glycated HSA.
Figure 7.6 illustrates the e ffect of human plasma on the standard 
curve for glycated HSA. Human plasma was added to one set of standards at a 
1:40 dilution, representing an initial approximate dilution for the measurement 
of glycated HSA in plasma. Both curves appear sim ilar down to a glycated
HSA concentration of 25pg/ml. Below this value,a m atrix e ffec t reduces the
\
Ag-Ab binding and the curves began to differ and by 0 iig/m l glycated HSA the 
curves differed by approximately 0.5 absorbance units.
7.3.1.8’ Determination of the specific ity  of sheep anti-glycated epitope IgG
The cross rea c tiv ity  of sheep anti-glycated epitope IgG was defined 
as the molar quantitiy o f antigen, re la tive to that of glycated HSA, needed to 
reduce the binding of antibody to coating Ag at zero analyte concentration by 
50%. Figure 7.7 shows the cross rea c tiv ity  curves for various compounds 
which might cross react w ith  these antibodies and is accompanied by table 7.1 
which numerically ills tra tes.the  various degress of cross reac tiv ity  of sheep 
anti-glycted epitope IgG. There was hardly any cross re ac tiv ity  w ith  both 
sodium borohydride or sodium periodate treated HSA, and
surprisingly, very little cross reac tiv ity  w ith  fructosyl-6-amino-hexanoic acid, 
the hapten used in the preparation of the immunogen. Although the results are 
not shown here fo r the fructosyl-6-am ino-l-am ino—r-methyl-hexanamide 
derivative, i t  did show sim ilar cross reaction values to fructosyl-6- 
aminohexanoic acid in this ELISA system. D-fructose, which has considerable 
structura l homology w ith the fructosamine residue, except that i t  lacks the 
secondary amine attached to the methylene group in D-fructose, only showed 
negligib le cross reac tiv ity  of 0.00015%. However, D-fructose w ill tend to 
adopt the furanose ring form where as the fructosamine w ill mainly adopt the 
pyranose form as observed by Neglia et al. (1985) and this may account fo r the
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Figure 7.7 Cross reac tiv ity  curves for-a competitive ELISA for glycated 
HSA. A  = glycated HSA; □  = sodium borohyride treated HSA;4* = sodium 
periodate treated HSA; O  = D-glucose; X  = D-fructose; = 6-
aminohexanoic acid; 9  = l-am ino-l-deoxy-D-fructose-6-am ino-hexanoic 
acid.
Table 7.1
A cross reac tiv ity  table for the specific ity  of 
a ffin ity  purified anti glycated epitope 
antibodies to various competing antigens 
from sheep bleed 915/IE
Antigen
Glycated H5A
Sodium borohydride -  
treated H SA
Sodium peroidate- 
treated H S
Fructosyl-6-amino- 
hexanoic acid
D-fructose
D-glucose
6-aminohexanoic acid
Specificity
100%
<0.15%
<0.15%
<0.03%
0.00015%
<0.0003%
<0.0003%
lack of cross re ac tiv ity . D-glucose, on the other hand,showed no cross 
rea c tiv ity  at a value greater than 0.0003%
7.3.2 The in itia l studies on the development o f a non-competitive ELISA for 
glycated H5A.
7.3.2.1 The use of donkey anti-sheep IqG as capture antibody in a two-site 
sandwich ELISA for glycated H5A.
Figure 7.8 show the results obtained fo r three d iffe rent types of HSA 
sample when assayed using the following ELISA form at:
A/ Donkey 0.2% (w/v) A ff in ity - Glycated Rabbit HRP-labelled
f  anti-sheep casein purified HSA anti- donkey
IgG
A
sheep anti­
glycated 
epitope IgG
HSA IgG anti-rabb it
IgG
TMB
substrate
Neither sodium borohydride-or sodium periodate-treated HSA 
gave any significant curve. However, w ith  sodium borohydride-treated HSA, 
as the protein concentration was decreased,there was an incrase in absorbance 
at 430nm indicating an apparent increase in binding. For glycated HSA, on the 
other hand, a curve was obtained which rose to a peak value at lOOyg/ml 
sample and started to fa ll at a lOOOyg/ml concentration, exhibiting a prozone 
e ffec t (Cantarero et al., 1980). In all three HSA samples, however, i t  can be 
seen that a very high NSB level occured which i t  was necessary to remove in 
order to improve specific signal levels, as detected by the increase in 
absorbance at 450nm above background.
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Figure 7.8 An immunometric ELISA for glycated HSA using a donkey anti- 
I sheep IgG, sheep anti-glycated epitope antibodies as a capture system and 1 
HRP-labelled sheep anti-HSA as detecting Ab. A  = glycated HSA; □  = 
sodium periodate-treated HSA; -f-= sodium borohydride-treated HSA.
7.3.2.2 The e ffe c t of using a f f in ity  purified  sheep an ti-g lyca ted  epitope IgG
as capture antibody on N5B levels in a two site sandwich ELI5A fo r 
glycated HSA.
The results shown in figure 7.9a and 7.9b were obtained using the 
follow ing assay form at:
TMB
substrate
Figure 7.9a and 7.9b show that by using sheep anti-glycated
epitope or normal sheep serum IgG respectively as capture antibody, although
NSB levels were s till high, the NSB levels were reduced by more than 50% of
the levels shown in figure 7.8. Whereas, figure 7.9a illustrates, a crude
uncnrrfintpd fn r NSB 
standard curve fo r glycated H S /^w ithou t a prozone, the results in figure 7.9b
show that NSB levels for normal sheep serum were unfortunately greater than
those for sheep anti-glycated epitope as capture antibody.
7.3.2.3 The e ffec t of sequentially om itting various stages of a tw o -s ite  
sandwich ELISA fo r glycated HSA on NSB levels.
The assay form at displayed in section 7.3.2.2. was used and the 
e ffec t on NSB levels by om itting various stages of the form at investigated. 
Table 7.2a and 7.2b show the result of om itting various stages when using 
either sheep anti-glycated epitope or normal sheep serum IgG respectively. In 
table 7.2a when glycated HSA sample was either present or not present, a 
strong signal was observed. This was repeated in table 7.2b for normal sheep
/y A ff in ity - 0.2% (w/v) Glycated Rabbit HRP-labelled
^ purifed casein HSA anti - donkey an ti-
 ^ sheep anti- HSA IgG rabbit IgG
/ glycated
^ epitope IgG
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Figure 7.9 (a) The use of sheep anti-giycated epitope IgG as capture
antibody. A  = glycated HSA present; □  = no HSA present, (b) The use of 
normal sheep serum IgG as capture antibody: A  = glycated HSA present; □  = 
no HSA present.
Table 7.2
The e ffect of om itting various stages of an 
immunometric assay on NSB levels.
(a) Using sheep anti-glycated epitope IgG as capture Ab.
Coat
Ag
Casein
Block
Sample
(glycated HSA)
Rabbit
anti-HSA
HRP-labelled 
Donkey 
anti-rabbit 
IgG
TMB
substrate
Signal
level
(A450mm)
- - - - - - 1.62
- - NONE - - - 0.83
- - - NONE - - 0.09
NONE 0.11
(b) Using Normal Sheep serum IgG as capture Ab.
Coat
Ag
Casein
Block
Sample
(glycated HSA)
Rabbit
anti-HSA
HRP-labelled 
Donkey 
anti-rabbit 
IgG
TMB
substrate
Signal
level
(A450mm)
- - - - - - 1.55
- - NONE - - - 1.14
- - - NONE - - 0.12
. NONE — 0.10
^
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serum IgG as capture antibody, indicating that one of the later stages of the 
assay was possibly responsible for the high NSB seen, as no signal should have 
been obtained when the sample was absent. In both tables 7.2a and 7.2b when 
rabbit anti-HSA IgG was omited no signal was obtained indicating that HRP 
labelled donkey anti-rabbit IgG did not cross react w ith any previous stages in 
the assay form at used. This set o f results suggested that rabbit anti-HSA was 
binding non-specificially w ith  other components in the assay form at other than 
glycated HSA.‘
7.3.2.4 The use of horse-radish peroxidase-labelled sheep anti-HSA IgG in a
two-site sandwich ELISA for glycated HSA.
Figure 7.10 shows a standard curve for glycated HSA using the 
following assay form at:
A f f in i ty -
purified 0.2% (w/v) Glycated HRP-labelled
sheep an ti­ casein HSA sheep a n ti-
glycated HSA IgG
epitope IgG
TMB
substrate
It can be seen that the curve extends over a concentration 
range of 0 to 100 yg/m l glycated HSA. However, as w ith  the standard curve 
obtained in section 7.3.1.6 only a precision dose profile  w ill determine over 
what dynamic range the greatest precision w ill be obtained fo r this standard 
curve. It is also apparent that the NSB levels using this slightly modified assay 
form at have been significantly reduced to an acceptable level, although 
further reduction in NSB would be welcome i f  specific signal levels were to be 
amplified. A further advantage of using HRP-labelled sheep anti-HSA IgG as 
detection antibody has been the reduction in assay tim e due to the elim ination 
of one stage so that a direct assessment rather than an indirect assessment of 
bound glycated HSA, as used previously, becomes attainable.
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Figure 7.10 A standard curve fo r glycated HSA in PBSGT buffer using a 2 
site sandwich ELISA. NSB not subtracted
7.4 DISCUSSION
7.4.1 A com petitive ELISA fo r glycated HSA
In chapter 6, it  was shown that at least one of the antisera 
raised proved promising for the development of an immunoassay for the 
quantitative assessment of glycated HSA. The rationale behind in itia lly  
developing a competitive, as opposed to a non-competitive ELISA,wd.4 two 
fold. Due to the lim ited  amount of time remaining^the competitive ELISA 
would prove easier to develop, as the assay form at used in chapter 6 to screen 
for antibodies to glycated epitope (fructosamine) would only have to be 
optimised. Whereas, to develop a non-competitive, two site sandwich, ELISA 
may have proved more time consuming. Problems associated w ith  the la tte r 
form at might arise in selecting antibodies that recognised epitopes w ithout 
any steric hinderance between them, as well as encountering possible problems 
w ith  high NSB levels. In  addition, although OPD substrate was used in itia lly , 
this was subsituted by TMB substrate in all subsequent EIAs as i t  was shown to 
be a better substate by Bos et al. (1981).
Figure 7.1a demonstrated that a crude standard curve for 
glycated HSA, using sheep anti-glycated epitope antiserum, could be obtained. 
Unfortunately, high background NSB levels were present in this system, even 
though casein was used as a blocking agent to reduce NSB (Kenna et al., 1985). 
Shields and Turner (1986) conclusively demonstrated the importance of using 
a ffin ity -p u rif ie d  antibody, as opposed to neat antiserum or IgG purified 
antibodies,- in lowering NSB levels in a non-competitive sandwich ELISA 
system. Figure 7.1b, on the other hand, clearly showed the benefit of using 
a ffin ity -p u rifie d  antibodies in a competitive ELISA for lowering NSB levels. 
However, as the resulting NSB levels was s till too high, fu rther measures were 
taken to reduce it.
Variations in coating Ag concentration were found to 
substantially a ffec t signal levels, as shown in figure 7.2. More im portantly, 
however, residual NSB levels, a fte r displacing w ith 1.7mg/ml glycated HSA, 
were reduced from 1.12 to 0.3 absorbance units at 450nm when coating Ag 
concentration was reduced from 2000 to lOng/ml glycated HSA as displacing 
Ag. Subsequently, a 5ng/ml coating Ag concentration was chosen fo r all 
further competitive ELIS As using this batch of antiserum as any residual NSB 
levels would be kept to a minimum.
Earlier in chapter 1, assay sensitiv ity was shown not be an 
important factor when the analyte concentration was very high. Excessive 
analyte dilution would therefore be required to bring the sample concentration 
w ithin the dynamic range of the assay and this could be a potential source of 
error. Therefore, the dynamic range of the assay should be set so as to allow 
minimal dilution of sample. In the case of glycated HSA, analyte levels are 
very high, as discussed earlier in chapter 1 and therefore the dynamic range of 
the assay should be chosen to take account of this. However, large amounts of 
glycated HSA standard would be needed to produce a standard curve and this 
would prove impracticable. Therefore, the assay dynamic range could be 
lowered so to allow the use of smaller amounts of glycated HSA standard, but 
not to lower i t  too fa r so that large sample dilutions would be required. Figure
7.3 illustra ted the e ffec t of varying the amount of residual sheep anti-glycated 
epitope IgG applied to m icro titra tion  plate wells on assay dynamic range. In 
conjunction w ith the data observed in figure 7.4 showing the e ffec t of HRP- 
labelled donkey anti-sheep IgG concentration on specific signal levels, a 
standard curve w ith a dynamic range of 0 to lOOyg/ml glycated HSA was 
produced (figure 7.3). This required the use of a 62ng/ml concentration of 
a ffin ity -pu rified  sheep anti-glycated epitope IgG and a 1:3000 d ilu tion of HRP- 
labelled donkey anti-sheep IgG.
Nakayama et al. and Go et al. (1987) both developed a 
competitive immunoassay fo r the measurement of reduced glycated HSA. 
Both these assays used a dynamic range of between 0 to lOOpg/ml and could 
easily discrim inate between the glycated HSA levels of normal and diabetics. 
However, no direct comparison can be made between the competitive assay 
system described here and those of Nakayama et al. (1986) and Go et al. 
(1987) because this assay measures native, unreduced glycated HSA. 
Nevertheless, the dynamic range for this competitive assay is comparable, 
more so to that of the assay reported by Go et al. (1987). Another major 
difference between the ELISA described here and those reported by Nakayama 
et al. (1986) and Go et ah (1987) was the use in this assay of purified in vivo 
glycated HSA as opposed to in v itro  glycated HSA as a standard. Moreover, 
Go et al. (1987) showed that the extent of in v itro  glycation affected the 
degree of Ag-Ab binding. This observation however, is not surprising as the 
sites of glycation in v itro  and in vivo do d iffe r (Garlick and Mazer, 1983; Iberg 
and Fluckinger, 1986) and is more extensive in the former case as incubation 
tim e w ith  glucose is increased.
Figure 7.6 shows the e ffec t of whole plasma on the standard
curve for glycated HSA. The resulting shallower curve was due to endogenous
antigen present in the plasma, demonstrating the necessity fo r using antigen
free plasma m atrix to dilute the standard. Therefore, in order to measure
of the
glycated HSA in plasma, w ithout the need fo r purificationjfanalyte as used by 
Go et al. (1987) fo r example, i t  is necessary to construct the Standard curve 
for in vivo glycated HSA in antigen-free plasma m atrix, rather than in the 
PBSGT assay buffer as shown in figure 7.6.
m atrix:
Two possible methods exist fo r producing the an tig e n -fre e
i) The removal of glycated HSA by Glycogel B a ffin ity  chromatography
ii) The reduction of all fructoysl residues present to the g luc itio l form 
w ith sodium borohydride. However, both methods have the ir 
drawback.
It  is uncertain whether a 100% effic iency can be attained in e ffec tive ly  
removing all glycated HSA from human plasma by Glycogel B a ffin ity  
chromatography, w ithout the repeated use of rechromatography. In addition, 
as large amounts of plasma m atrix would be required, a large a ffin ity  column 
would be needed necessitating a large captial outlay as Glycogel B a ff in ity  
m atrix  at present costs around £700 fo r 100ml of resin.
The second method for preparing antigan -r free m atrix  on the 
other hand, may prove more sucessful and cheaper. By the addition of excess 
sodium borohydride, 100% reduction of fructo$yl residues should be 
accomplished. It  is however, necessary to remove any unreacted borohydride. 
This may be achieved by the slow dropwise addition of acetone form ing 
propanol as it  reacted with : sodium borohydride. It should be mentioned at
this stage that although sodium periodate can also remove fructosyl residues, 
it  would be d iff ic u lt to remove any excess unreacted sodium periodate w ithout 
using dialysis. This in turn would therefore a lter the composition of the 
plasma m atrix.
Cross reactiv ity  curves (figure 7.7) indicated that sheep an ti­
glycated epitope IgG was highly specific fo r glycated HSA, as both sodium 
periodate-or sodium borohydride-treated ' . HSA exhibited less than
0.15% cross reactiv ity . Fructosyl-6-aminohexanoic acid, on the other hand, 
the hapten used in the preparation of the immunogen cross reacted by only 
0.03%. These results at f irs t would appear to be misleading as one would
expect the anti-glycated epitope antibodies to have a higher degree of cross- 
reac tiv ity  fo r fructosyl-6-aminohexanoic acid than that observed here. 
However, a sim ilar observation was reported by Morris et al. (1975) during the 
development of an RIA for morphine. The antibody exhibited very l it t le  cross 
reac tiv ity  towards the orginal hapten, non-morphine, used as antigen, but cross 
reacted twenty fold greater w ith morphine.
Unfortunately, tim e did not allow the competitive ELISA to be 
further developed in Ag-free plasma m atrix so as to allow the measurement of 
glycated plasma protein levels. One major disadvantage w ith this competitive 
ELISA was that unless more glycated plasma proteins were studied for cross- 
reac tiv ity , w ith  the antiserum used here, the assay cannot be regarded as
to ta lly  specific fo r glycated HSA in plasma. However, a non-competitive, two 
site sandwich, ELISA would overcome this problem by allowing the specific 
measurement of glycated HSA.
7.4.2 An immunometric ELISA for glycated HSA.
In order to try  and lim it the possible sources of high NSB that m ight 
be encountered in developing a tw o-s ite  sandwich ELISA, a ffin ity -p u rifie d  
sheep anti-glycated epitope capture antibody was used. This strategy was 
undertaken as shown by the work of Shields and Turner (1986) on the 
importance of antibody qua litity  in sandwich ELISA systems. The work of 
Vaidya et al. (1985), reported the e ffec t of solid phase on the distortion of the 
protein te rtia ry  structure. Later, Kilshaw at al. (1986) showed the e ffec t of 
solid phase on antibody binding site distortion of capture antibody in lowering 
specific signal levels. To overcome this problem Kilshaw et al. (1986) 
recommended the use of a primary capture antibody on solid phase which 
would bind the anti-analyte antibody without causing any antibody binding site 
distortion of this secondary capture antibody. Therefore, the in itia l two site
ELISA for glycated HSA used donkey anti-sheep IgG as a primary capture- 
antibody. The results in figure 7.8 showed that it  should be possible to derive 
a standard curve for glycated HSA, if the conditions could be optimised to 
elim inate the prozone e ffect (Cantarero et al., 1980). High NSB levels, 
however, were also present and posed a serious problem as this would greatly 
a ffec t the signalrnoise ratios.
It  was thought that the donkey anti-sheep IgG primary capture 
antibody was binding non-specifically w ith  other stages in the sandwich ELISA. 
So as to discount this possibility, sheep anti-glycated epitope IgG was used 
d irectly  as primary capture antibody. However, in order to maximum specific 
signal levels, optimal coating of solid phase w ith  capture antibody was 
necessary. Cantarero et a l., (1980) and la ter Wilson et al., (1986) found that 
optimum coating of polystyrene m icro tita tion  plate wells was achieved w ith  
3ng IgG per square m illim etre  of solid phase. Protein concentrations in excess 
of this went beyond the lim it of independance of protein binding to solid phase 
and could result in protein-protein binding, giving rise to a possible reduction 
in observed signal levels.
On removing donkey anti-sheep IgG coating Ab, from  the 
sandwich, NSB levels were reduced as was shown in figures 7.9a and 7.9b. This' 
suggested that donkey anti-sheep IgG was indeed reponsible fo r some of the 
NSB. However, plates coated with normal sheep serum IgG had higher NSB 
levels than those coated w ith  the specific sheep anti-glycated epitope IgG. 
Why this should be was not clear, but one possibility may be tha t sheep 
albumin is weakly associated w ith the normal sheep serum IgG preparation 
used (Clayton, Groves and Morris, personnel communication). A fte r 
completing further studies involving the sequential removal of various layers 
from the ELISA sandwich in the immumometric assay (see Table 7.2a and b).
i t  appeared that rabbit anti-HSA IgG was responsible fo r the high NSB values 
obtained in figure 7.9 by binding non-specifically to sheep serum IgG.
To try  and elim inate this problem, both rabbit anti-HSA and 
HRP labelled donkey anti-rabbit IgG antibodies were subsfctited by a single 
HRP-labelled sheep anti-HSA IgG antibody. This course of action was 
completely vindicated as i t  led to a drastic reduction in NSB levels and the 
production of a standard curve to glycated HSA, as is shown in figure 7.10. 
The standard curve exhibited a dynamic range of 0 to 50pg/ml glycated HSA, 
and appeared linear up to 25yg/m l, which was : ->less than that fo r the 
competitive ELISA (section 7.4.1.). However, the standard curve was fa r from 
optimised as i t  would have to be constructed in Ag-free plasma m atrix fo r the 
measurement of glycated HSA in plasma samples. Further more, cross 
reac tiv ity  analysis would have to be undertaken as well as possibly increasing 
specific signal levels. Assay precision, sensitiv ity and parallelism studies 
would also need to be investigated. Only then could any correlation between 
this assay and other methods fo r measuring glycated HSA be investigated. 
Ohe et al. (1987), on the other hand, produced an immunoradiometric assay fo r 
reduced glycated HSA which exhibited a linear standard curve over a dynamic 
range of 5 to 500yg/ml glycated HSA. In addition, HSA was purified from  the 
plasma sample prior to analysis,thereby elim inating any need fo r Ag-free 
plasma m atrix in the immunoassay.
To conclude, both a competitive and non-competitive ELISA for 
glycated HSA have been developed. The la tte r form at, however, should prove 
more promising in the long term as the assay design would allow greater 
specific ity and less susceptibility to interference factors once a fu lly  
optimised assay has been developed. The clin ica l benefits of such an assay are 
large as an immunoassay to glycated HSA should prove to be better than 
present methods fo r measuring glycated proteins.
CHAPTER 8
GENERAL DISCUSSION 
AND CONCLUSIONS
8.1 GENERAL DISCUSSION AND CONCLUSIONS
Glycated proteins have been of increasing research and clin ica l 
interest over the past decade. Indeed, the extent of glycation of d iffe ren t 
proteins in vivo has been linked to the long-term complications associated w ith 
diabetes mellitus (see chapter 1). Furthermore, the measurement o f glycated 
protein levels, in particular haemoglobin, has allowed the clin ician to 
retrospectively monitor glycaemic control in diabetic patients. Currently, 
there are several methods for measuring glycated proteins. However, each 
method is standardised d iffe ren tly  and as a result the reference range o f 
protein glycation and the units used to express the result are method 
dependant. These methods also suffer from a variety o f disadvantages, in tha t 
they are tim e consuming, expensive or susceptibile to interference from other 
factors. Johnson et. al. (1988), fo r example, concluded that both 
th iobarbituric acid colorim etry aiid. boronate a ffin ity  chromatography were 
inaccurate for measuring glycated HSA levels. Recently, research has been 
directed towards the measurement o f glycated HSA or plasma protein as a 
short term  index fo r the assessment o f glycaemic control (Hayashi and Makino, 
1985; Shima et al., 1988). Drexel et al. (1987) proposed that the measurement 
o f glycated ' serum proteins would provide a better index of glycaemic status 
due to the location o f these proteins w ith in the plasma. Glycated haemoglobin 
levels, on the other hand, would only re fle c t intra-erythrocyte glucose 
concentrations. Moreover, Davie et al. (1989) have substantiated this, by 
finding that intra-erythrocyte glucose levels were affected by various 
factors. These in turn, would lead to a variation in intra-erythrocyte glycated 
haemoglobin levels when compared to plasma glucose and glycated plasma 
protein levels. Therefore, although present c lin ica l assessment o f glycaemic 
control utilises the measurement o f glycated haemoglobin levels, it  would 
perhaps be more accurate, in view of these findings, to determine the 
glycation of a specific plasma protein.
Since the advent of ELISA, firs t introduced by Engvall and Perlmann 
(1971) along with other colleagues, it  has become a powerful and widely used 
analytical technique. A major advantage of using an immunoassay for 
measuring analyte concentration is the specific ity which can be achieved w ith 
antibodies (Voller, 1979). In addition, the use of a rugged ELISA system can 
allow the rapid determination of analyte concentration in large numbers of 
samples w ith re la tive ly low cost as it  can be semi-automated. U n til very 
recently (Cohen and Hud, 1989), there were no immunoassays reported that 
would measure in vivo glycated HSA. Several groups, however, had reported 
the development of an immunoassay to reduced glycated proteins and two 
groups in particular (Javid et al., 1978; Knowles et al., 1987) had produced 
antibodies that recognised native glycated haemoglobin.
In order to develop an immunoassay that could measure, in vivo 
glycated proteins, it  was essential to raise antibodies that only recognised the 
glycated epitope. This would allow fle x ib ility  in being able to measure any 
glycated protein, providing a two-site sandwich ELISA was used. To try  to 
achieve this goal, several d iffe ren t glycated amines were synthesised and 
purified. A fte r conjugation to either KLH or ovalbumin as carrie r proteins 
(see chapter 5), the subsequent immunogens were injected into sheep to raise 
antisera against the glycated amines. Unlike previous workers such as Zeuthen 
et al. (1986) and Nakayama et al. (1986) who used purifed glycated proteins or 
reduced glycated protein as immunogens, the novel method described in this 
study resulted in several antisera recognising glycated amines. One of these 
antisera appeared to recognise both glycated HSA and haemoglobin as was 
evident from the antiserum displacement studies described in chapter 6. 
However, Western blot analysis confirmed that the antiserum from sheep No. 
915 only recognised glycated HSA. Using this antiserum, both com petitive and 
non-competitive curves for glycated HSA were constructed (Chapter 7). Cross
reactiv ity  curves using the com petitive assay form at (chapter 7) indicated that 
the antiserum specifically recognised glycated HSA,as opposed to non-glycated 
HSA. However, o f particular interest was the greater specific ity of the 
antiserum for glycated HSA rather than the hapten used for immunisation, 1- 
amino-l-deoxy-D-frutose-6-aminohexanoic acid (fructosyl-6-aminohexanoic 
acid). A simple explanation for this would be that a polyclonal antiserum w ill 
contain a population o f antibodies w ith varying specificities and a ffin ity . 
Therefore,the antibodies whichjimmunosorbent-purified against glycated HSA 
w ill have greater cross rea c tiv ity  w ith  that m ateria l than the original hapten.
Unfortunately, a c r itica l evaluation of the non-competitive EIA fo r 
glycated HSA described here was not made against other published methods as 
described in chapter 1. However, an EIA fo r glycated HSA has only recently 
been reported (Cohen and Hud, 1989). Two major differences occur between 
the EIA of Cohen and Hud and that reported here. F irs tly , the method of 
Cohen and Hud was able to measure both in v itro  and in vivo glycated HSA, in 
both the unreduced and sodium borohydride reduced forms. Whereas, this was 
not the case for this EIA as was evident by the Western blot analysis (Chapter 
6) and cross-reactivity assessment (Chapter 7). The explanation put forward 
by Cohen and Hud (1989) did not explain this anomaly as sodium borohydride is 
known to destroy the furanose or pyranose ring form o f the fructosyl residue 
(Ketoamine) to leave the straight chain g lucito l derivative, which is vastly 
d iffe ren t in its stereochemistry (Watkins et al., 1985). However, when Cohen 
and Hud’s methodology was examined more closely, i t  was apparent that heat- 
treated glycated HSA was used for boosting, in order to impart greater 
immunogenic properties. Although, in most cases this can be advantageous, 
heat treatm ent of the glyated residue can accelerate the formation o f AGE, as 
discussed in chapter 1. This, in turn, would mean the animal would be boosted 
against AGE. • Therefore, i t  is possible that Cohen and Hud may have
inadvertently developed an EIA for AGE. Nevertheless, a note of caution is 
necessary as the chemistry of AGE is currently not fu lly  understood and 
sodium borohydride may a ffec t some AGE. This last statement could have 
relevance to the EIA developed in this study because, although unlikely, there 
may have been a population of antibodies recognising early AGE which were 
isolated in the a ffin ity  purification step. Even though the hapten was well 
characterised prior to conjugation and immunisation, there is nothing to stop 
the fructosyl residue from Ageing once injected into the host animal, 
especially a t a temperature of 37°C. Therefore, antibodies to early AGE 
could be produced.
The second difference between the EIA reported here and that o f
Cohen and Hud was that they developed and then used mouse monoclonal
antibodies, as opposed to the polyclonal antiserum used here. This can o ffe r
several d istinct advantages. Monoclonal antibodies are specific fo r only one
epitope and allow reproducible antibody quality in unlim ited amounts provided
the immortalised cell lines are properly maintained. In addition,they enable
the one step purification of antigen with very high purity from an impure
source (Kohler, 1986). However, by raising a polyclonal antiserum in sheep,
the possibility of developing monoclonal antibodies does, s til l exist using
m 3
heterohybridoma technology (Teng, et al.,^and Tucker et al., 1984). Groves et 
al., (1987) reported the production of an ovine mouse heterohybridoma which 
secreted bovine monoclonal antibodies to testosterone.This was acheived by 
fusing a mouse myeloma cell line w ith ovine lymphocytes isolated from  venous 
blood. A sim ilar technique could therefore be undertaken to immortalise those 
ovine plasma cells secreting anti-fructosyl antibodies.
Time was unfortunately, the lim iting  factor in this study and, as a 
result, the final goal o f producing a rugged EIA fo r measuring glycated
proteins, in this case for glycated HSA, for routine use in the diabetic c lin ic 
was not achieved. Nevertheless, a standard curve for glycated HSA using 
either a competitive or non-competitive system was developed. To conclude, 
therefore, this data, in association with the Western blot analysis in chapter 6, 
clearly demonstrates that the antiserum from sheep No. 915 has significant 
potential fo r the development of a rugged EIA fo r glycated proteins. 
Furthermore, several other antisera which were produced were not fu lly  
evaluated fo r potential use in an EIA and may equally be as good, i f  not better, 
than the antiserum from sheep No. 915.
8.2 PROPOSAL FOR FURTHER WORK
Considerable additional work is required to optimise and validate the 
crude ELISA for glycated HSA developed here. The identification of a suitable 
Ag-free m atrix (as outlined in chapter 7) and its e ffe c t on the tw o-site, non­
com petitive ELISA described in this study w ill need to be investigated. 
Parallelism studies using plasma from a poorly controlled diabetic w ill 
ascertain whether or not there are other components w ithin diabetic plasma 
which are giving rise to additional m atrix effects. Furthermore, precision 
dose profiles (Ekins, 1981) w ill determine over what range the assay has the 
greatest precision. Considering this la tte r point in greater deta il, i t  is 
important to achieve the greatest precision in assessing glycated HSA levels in 
the range between those glycated HSA levels o f diabetic and those of normals. 
Indeed, Hall et al., (1984) found that the results for the measurement o f 
glycated plasma protein by boronate a ffin ity  chromatography could be placed
r
into one of three d iffe ren t groups. These groups corresponded to normal, 
impaired glucose tolerance and diabetic when catagorised according to the 
WHO (1980) c rite ria  for blood glucose levels. Therefore, by precisely defining 
the EIA parameters, it  should be possible to distinguish accurately between
normals, diabetics and individuals w ith impaired blood glucose tolerance, as 
well as monitoring the decrease in glycated HSA levels in well-controlled 
diabetics. However, adequate quality control w ill be required.
An evaluation to the c lin ica l usefulness of this EIA by comparison 
w ith other published methodologies for measuring glycated HSA and glycated 
haemoglobin should be undertaken.
This would involve correlation studies w ith other methods along w ith 
the investigation as to whether this EIA would discrim inate between well 
controlled and poorly controlled diabetics. I f  successful, this EIA would serve 
as a suitable indicator, along w ith  plasma glucose levels, in assessing and 
monitoring glycaemic control, as well as a possible routine screening assay fo r 
diagnosing diabetes.
Although there has only been time to investigate one of the antisera 
produced to a glycated epitope, the remaining antisera should be studied as to 
their potential, fo r use in an EIA to glycated HSA or other glycated proteins. 
In the case of the former, this would allow an evaluation as to which antiserum 
is preferable fo r use in an EIA to glycated HSA. With regards to the la tte r 
point, however, other proteins are known to be glycated in vivo as discussed 
earlier in chapter 1, such as collagen, apo-lipoprotein B, myelin and 
immunoglobulins. Therefore,by developing an EIA to those glycated proteins a 
comparison could be made against the EIA fo r glycated HSA as an indicator 
fo r glycaemic control. A lternative ly, certain c lin ica l complications are 
believed to be associated w ith the glycation of individual proteins. Lopes 
V irella et a l. (1988), for example, were able to show an association between 
high glycated LDL levels and atherosclerosis. Therefore, a fu rther study could 
also be undertaken to investigate the correlation of measuring other glycated 
proteins by EIA and their association with diabetic complications.
With the possible development of several EIAs to d iffe rent glycated 
proteins, the feasib ility  of simultaneously measuring two or more glycated 
proteins in the same m icro titre  plate becomes apparent. This was a technique 
investigated by Blake (1982) and could enable the simultaneous measurement 
of glycated HSA and haemoglobin or even glycated LDL, fo r example.
Finally, as mentioned earlier, the possibility o f producing ovine
donor
monoclonal antifructosyl antibodies exists, w ithout k illing thejsheep. This has 
important consequences i f  EIAs fo r glycated proteins were to be available on a 
commerical. basis. Monoclonal antibodies would allow an infin ia te  source of 
well defined and characterised immunoreagents to be made available. 
Whereas, an EIA using polyclonal antiserum, even i f  the antibodies have been 
a ffin ity  purifed, w ill require standardisation of each batch o f purified 
antibodies so as to maintain reproducibility. Together w ith the lim ited supply 
of polyclonal antibody, monoclonal antibodies clearly o ffe r a d is tinct 
advantage. Furthermore, the possibility that the ELISA developed here may 
recognise AGE could easily be discounted i f  a monoclonal antibody to fructosyl 
residues was used. Despite the problems encountered in developing an ELISA 
for glycated proteins in this study, i t  is probable that an EIA fo r glycated HSA 
using antibodies developed in this work w ill be used in monitoring diabetic 
control in the future.
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